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ABSTRACT

Alzheimer’s disease is characterized by the presence of amyloid plaques, made up
primarily of Aβ peptides, and neurofibrillary tangles, containing hyperphosphorylated
tau. Aβ is generated by sequential proteolysis of the amyloid precursor protein (APP) by
β- and γ-secretases. The leading hypothesis of Alzheimer’s disease pathogenesis is the
amyloid cascade hypothesis, which suggests that amyloid is central to the disease
process. However, tau pathology correlates more closely with cognitive dysfunction and
follows a predictable anatomical course through the brain. We hypothesize that if Aβ is
upstream of tau pathology and tau pathology follows this predictable course through the
brain, Aβ production may also propagate through the brain in an anatomical fashion. In
order to investigate this possibility, we examined two broad cellular processes induced in
cells when exposed to Aβ, p53-dependent apoptosis and cell cycle activation. We report
that p53-dependent apoptosis is associated with a decrease in the Aβ and sAPPα and an
increase in an alternative, caspase-cleaved fragment of APP, resulting from an apparent
cleavage in the near extracellular domain of APP.

Mitosis is associated with the

phosphorylation of both tau and APP, and increased production of Aβ. Our results
indicate that while p53-dependent apoptosis is not associated with increased
amyloidogenesis, cell cycle activation increases Aβ production and may play a role in
disease propagation. Together, these findings suggest various treatment approaches,
including cell cycle inhibition and disruption of APP endocytosis, which may decrease
x

amyloidogenic processing. Continued research into these potential approaches, coupled
with earlier detection of the disease process, could lead to promising treatments for
Alzheimer’s disease.

xi

CHAPTER 1: INTRODUCTION TO ALZHEIMER’S DISEASE

1.1. Chapter Synopsis
Here, we briefly discuss the long history of age-related dementia, from its early
descriptions in the Greco-Roman period to the modern era. A persisting theme in the
history of dementia has been a debate as to whether dementia should be considered part
of normal aging or a pathological state. The initial description of the neuropathology of
what would come to be known as Alzheimer’s disease (AD) began to set this disease
apart from normal aging, and a further understanding of the specific pathology as well as
the genetics of AD helped to solidify this distinction.

Today, much of what we

understand about the pathological progression of AD still centers upon the pathological
hallmarks first described by Alois Alzheimer [1], namely the extracellular plaques and
neurofibrillary tangles. As the genetics of AD came to be better understood, amyloid-β
(Aβ), the primary constituent of these extracellular plaques, emerged as a major player in
the pathogenesis of AD. Aβ is produced via proteolysis of the amyloid precursor protein
(APP). Therefore, a complete understanding of the proteolysis of APP is central to our
understanding of AD pathogenesis. The studies in the chapters that follow aim to further
this understanding through an investigation of how various pathological cellular states
alter APP proteolysis. In the course of these studies, we will discuss the identification of
a novel proteolytic site, examine more closely the way in which this proteolytic event
occurs, and examine the function of the fragments generated by this proteolytic cleavage.
1

1.2. A Brief History of Dementia from the Greco-Roman Period to the 19th
Century
The conceptualization of AD as it is currently understood has historical roots
extending as early as the Greco-Roman period. These early scholars, not unlike scholars
of more recent times, appear divided in their opinion as to whether dementia can be
considered pathological as opposed to a normal part of aging. For example, Pythagoras
described the end stage of life as the time when “the scene of mortal existence closes,
after a great length of time, to which, very fortunately, few of the human species arrives.
The system returns to the imbecility of the first epoch of the infancy [3].”

Here,

Pythagoras implies that “imbecility” with advanced age is a natural facet of life’s
progress, a view that seems to be shared by Aristotle, who suggests that elderly
individuals be excluded from high administrative positions because
There is not much left of the acumen of the mind which
helped them in their youth, not of the faculties which served
the intellect, and which some call judgment, imagination,
power of reasoning and memory. They see them gradually
blunted by deterioration and see that they can hardly fulfill
their function [3].
The view that dementia is a natural part of aging, shared by Aristotle and
Pythagoras, stands in contrast to that of Cicero, who in his essay De senectute states
As wantonness and licentiousness are faults of the young
rather than of the old, yet not of all young men but only the
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depraved, so the senile folly called dotage is characteristic
nor of all old men but only of the frivolous [4].
Galen, who in his “On Anatomical Procedures” (c. 200) described atrophy of the
brain in very old animals such that “the brain is much too small to fill the cavity of the
skull,” also shared Cicero’s view, describing patients
In whom the knowledge of letters and other arts are totally
obliterated; indeed they can’t even remember their own
names … Even now it is seen, that on account of extreme
debility in old age, some are afflicted with similar
symptoms [4].
While it’s clear from these early writings that age-related cognitive decline was
recognized even before the Common Era, it is also apparent that a conflict in thought
exists, one side believing dementia to be a normal part of aging, and the other side
recognizing it as a pathological state. This conflict continued for centuries, and can be
found in the writings of Chaucer and Shakespeare, with the latter making distinctions
between “senile decay” and “plain madness” [3]. Progress in the conceptualization of
dementia in the Middle Ages, the Renaissance, and in the centuries that followed was
greatly hampered by a lack of understanding of the function of the brain – the
predominant thought of most of this period was that mental functions were seated in the
heart, not the brain. It was not until the end of the 18th century that neuropathology was
connected to disease, and with it the first description, made by William Cullen in 1776, of
senile dementia as a medical entity involving “decay of perception and memory, in old
age” [as quoted in 3].

In the following century, French psychiatrist Jean-Étienne
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Dominique Esquirol, a student of Phillipe Pinel, established a formal distinction between
“dementia” and “amentia”, the former being associated with disease and the latter being
developmental in origin [3].
The classification of dementia as a disease paved the way for pathologists to take
an interest in the brain and begin to assess the physiological changes associated with
dementia. With the vast advances in microscopy made during the 19th century and the
concomitant development of several new staining methods, including the silver stain
discovered by Camillo Golgi in 1873 and later improved by Max Bielschowsky in 1903
[3], the stage was set for Alois Alzheimer’s landmark work identifying a new disease of
the cerebral cortex.
1.3. Initial Description of Alzheimer’s Disease Neuropathology: The Case of
Auguste D
On November 4, 1906, Alois Alzheimer presented a case study in a lecture at the
37th Conference of South-West German Psychiatrists in Tübingen [1].

In 1907, an

original case report entitled “Über eine eigenartige Erkrankung der Hirnrinde”
(translation: “A peculiar Disease of the Cerebral Cortex”), authored by Alois Alzheimer,
was published in the Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche
Medizin, a German journal for psychiatric and psychological medicine [See 5 for original
German, 6 for translation to English]. This landmark case study marks the starting point
in our understanding of the specific type of dementia which would later come to be
known as “Alzheimer’s disease.”
The case study presents the case of 51 year old Auguste D, who in 1901 was
admitted to an insane asylum in Frankfurt after presenting with “ideas of jealousy toward
4

her husband” and “memory weakness” which rapidly progressed to the point that she
could “no longer negotiate her way around her dwelling” [6]. The report proceeds to
describe a woman “entirely disoriented to time and place,” occasionally mistrustful of
doctors fearing they would assault her physically or sexually, apparently suffering from
auditory hallucinations, and often loudly yelling [6].
Physically, Frau D was largely normal, able to walk with a normal gait, use both
hands well and had normal papillary and patellar reflexes. However, she often spoke
awkwardly, evidently unable to name common objects and often forgetting their purpose.
As she deteriorated over the four and a half years of her illness, she ultimately became
“completely dull, lying in bed with legs pulled up,” suffering from incontinence and
ultimately succumbing to septicemia due to decubitus on April 8, 1906 [1, 6].
The medical file of Auguste D, lost for nearly 90 years, was finally located in an
archive in Frankfurt on December 21, 1995, 2 days after the 80th anniversary of Alois
Alzheimer’s death. As Alzheimer had left Frankfurt in 1903, the later stages of disease
progression and her ultimate demise were not directly observed by Alzheimer. Her file
notes a “Tendency to develop a decubitus since the beginning of 1906. Ulcerations at the
sacral and left trochanteric area with a size of about 5 cm. Very weak, high fever up to
40°C within the last days. Pneumonia in both inferior lobes” [1]. Upon her autopsy in
Frankfurt, it was noted that she had moderate hydrocephalus, cerebral atrophy,
arteriosclerosis of the small cerebral vessels, pneumonia in both inferior lobes, and
nephritis [1]. Following her death and initial autopsy, Alois Alzheimer requested that her
brain and medical records be sent to the Royal Psychiatric Clinic in Munich, where
Alzheimer worked under the clinic’s director Emil Kraepelin.

5

Alzheimer’s description of the histopathology found in the brain of Auguste D,
included in his 1907 paper, marks some of the most seminal writings on the subject of
AD. Alzheimer described an “evenly atrophic brain” with evidence of atherosclerosis,
consistent with the changes observed at autopsy. Sections of Frau D’s brain were silver
stained using Bielschowsky’s method, leading to the first descriptions of the
neurofibrillary tangles now deemed characteristic of the disease. Alzheimer’s description
states:
Initially, through their particular thickness and particular
stainability, a single one or a few fibrils come to prominent
on the inside of an otherwise still “normal” appearing cell.
Then, during further progression, many such fibrils
running next to each other show changes in the same way.
They subsequently fold together into dense bundles and
move toward the cell surface. Eventually, the nucleus and
the cell disintegrate, and only a tangled bundle of fibrils
indicates the place which had formerly been occupied by a
ganglion cell [6].
This description defines multiple facets of what we now understand to be tau
pathology, initial changes to the neuropil and formation of paired helical filaments, which
ultimately accumulate into neurofibrillary tangles. Upon the ultimate death of the cell,
these tangles may remain as “ghost” or “tombstone” tangles, marking the site where the
neuron had been. Tau pathology was more recently and further described by Heiko
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Braak, and, as the progression of this pathology follows a distinct anatomical path
through the brain, is used today for neuropathological staging of disease progression [7]. 1
Alzheimer also noted that “since these fibrils are stainable with other dyes than
normal neurofibrils, a chemical transformation must have taken place; which appears to
be the cause for the fibrils’ persistence after the demise of the cell [6],” reflecting on the
changes to tau, now understood to be hyperphosphorylation and misfolding, that cause it
to become stable and accumulate in sufficient quantity and conformation for silver
staining. 2
In addition to his description of neurofibrillary tangles, Alzheimer also described
“dispersed over the entire cortex and especially numerous in the upper layers … miliary
foci; which are due to storage of a peculiar matter into the cortex. It can be detected even
without staining, but remains very refractory to dyes [6].” This is consistent with the
characteristic amyloid plaques, now considered central to the pathology of AD.
It is worth noting that Alois Alzheimer was not the only individual to study the
histopathology of dementia cases including Auguste D. In addition to Alzheimer,
Gaetano

Perusini,

Oskar

Fischer,

and

Francesco

Bonfiglio

also

described

histopathological changes in dementia. The eponym “Alzheimer’s disease” was coined
by Emil Kraepelin and first published in the 8th edition of his Handbook of Psychiatry in
1910, four years after Alzheimer’s initial description at the conference in Tübingen [1].
The conferring by Kraepelin, the most influential psychiatrist of the time and considered
the father of modern scientific psychiatry, and his inclusion of “Alzheimer’s disease” in
this important text ensured the longevity of the moniker.
1

For further discussion of tau pathology, see section 1.4.2.

2

For further discussion of amyloid pathology, see section 1.4.1.
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Following the description by Alois Alzheimer in 1906 and inclusion of
“Alzheimer’s disease” in the Handbook of Psychiatry in 1910, AD gained recognition as
a psychiatric disease with an organic basis, but it would be nearly three-quarters of a
century before the composition of the “miliary foci” described by Alzheimer would be
understood, enabling further study into AD pathogenesis.
1.4. The Neuropathology of Alzheimer’s Disease
As is often the case in science, the initial observation of the pathological
hallmarks of AD came long before the technology was available to further understand
them. Technological advances in proteomics and genomics of the mid-twentieth century
enabled determination of the amino acid sequence of individual proteins, as well as
mapping these proteins to specific genes. Application of these technologies during the
1980s and 1990s has resulted in vast progress in understanding AD neuropathology, and
consequently AD pathogenesis.
1.4.1. Amyloid Plaques
In 1984, the constitutive protein of senile plaques was isolated using high
performance liquid chromatography, and the protein sequenced for the first time [8]. The
sequence obtained from this initial sequencing was:
NH2-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln 3-ValHis-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val--COOH [8]

3

The sequence published by Glenner and Wong in the paper cited here identifies the eleventh amino
acid of Aβ as Gln. Subsequent work from the same lab and others has resulted in a consensus of
Glu at this position.
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This sequence is now appreciated to be the first 24 amino-acids of the amyloid-β
peptide (Aβ), a proteolytic fragment of the amyloid precursor protein (APP) which varies
in length but is most commonly 40 or 42 amino acids long. Upon its sequencing, there
was no homology found with any of the proteins that had been sequenced up until that
point. The discovery of this novel protein as specifically aggregated in AD brain raised
the hope that antibodies might be generated against it, potentially enabling detection of
the disease state by the presence of these proteins in the patients sera by
radioimmunoassay [8]. This, however, did not prove to be a viable approach, as it was
not appreciated at the time that the peptide isolated and sequenced as the constituent of
amyloid plaques was in fact a proteolytic fragment of a larger protein expressed
throughout the body. 4
In addition to Aβ, the primary component of plaques, many proteins have been
observed to be associated with Aβ plaques. Aβ is notoriously “sticky”, and deposits of
Aβ proteins tend to also contain a variety of other proteins. A 2004 study utilizing laser
capture microdissection of postmortem AD brain tissue found 26 proteins enriched
specifically in amyloid plaques. These included collagen, tau, glial fibrillary acidic
protein, vimentin, 14-3-3, dynein, phosphofructokinase, and Ubiquitin-activating enzyme
E1, among others [9]. It is not clear from this study, however, whether these proteins are
aggregated extracellularly along with Aβ within the plaque, or if these protein are in fact
contained within the surrounding cells and represent a cellular response to the presence of
the plaque. Indeed, dystrophic neurites and activated astrocytes are often found in the
vicinity of these plaques, and plaques are often decorated with microglia [10].

4

The proteolysis of the amyloid precursor protein will be discussed further in section 1.7.
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1.4.1.1.

Factors that Promote Amyloid Deposition

Of particular interest in understanding the formation of amyloid plaques are
factors that promote oligomerization of Aβ peptides to form fibrils and ultimately deposit
into amyloid plaques. The fibrillization of Aβ is controlled by many factors in the local
microenvironment including pH, temperature, and the presence of metal ions.
Immunoreactivity of Aβ to certain antibodies, specifically antibodies that recognize Aβ914

or Aβ17-21 (6F/3D and 4G8, respectively) are less able to detect Aβ at lower pHs,

suggesting that the accessibility of the antibody to its epitope on the Aβ peptide is
reduced due to changes in Aβ conformation. Susceptibility to degradation by proteinase
K is also reduced at lower pHs, suggesting that low pHs are associated with an
oligomeric state [11]. The immunoreactivity of Aβ using these same antibodies is also
sensitive to temperature – they are most reactive at normal body temperatures and
reactivity tends to decrease at febrile temperatures [12], suggesting that Aβ may have an
increased propensity for aggregation at higher body temperatures.
1.4.1.1.1.

Metal Ions

The contribution of metal ions to the oligomerization of Aβ has been well
established, but its importance in the disease process has been somewhat controversial.
Copper ions have been shown to bind with high affinity to histidine and tyrosine residues
(potentially involved residues from the Aβ peptide include H6, H13, H14, and Y10) [13].
This facilitates crosslinking of Aβ peptides via their tyrosine residues and promotes
oligomer formation [14]. Interestingly, Aβ also is capable of catalyzing the reduction of
Cu(II) and Fe(III), which results in the production of H2O2 and potentially contributes to
oxidative stress [15, 16]. While copper appears to be capable of cross-linking peptides
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into oligomers, it also, somewhat incongruously, has been shown to prevent the
formation of thioflavin T positive, β-sheet rich aggregates of Aβ, but enhances
neurotoxicity. This suggests that copper promotes the formation of small oligomers of
Aβ, but not plaque deposition. These small oligomers, however, seem to be particularly
toxic [17, 18].
In addition to copper, zinc has been shown to promote the aggregation of Aβ,
which has been hypothesized to result in a localized disruption in zinc homeostasis [19,
20]. Indeed, levels of zinc present in the cortices and hippocampi of Tg2576 transgenic
mice are elevated as compared to controls. Aβ plaques may effectively sequester zinc
extracellularly, reducing intraneuronal zinc and impairing microtubule stability.
The role of aluminum in AD has also been a subject of some controversy, which
has garnered some attention from the media and worked its way into mainstream culture,
leading to concerns regarding exposure due to use of deodorants, anti-perspirants,
aluminum cookware, and aluminum cans. A potential connection between aluminum and
AD first became apparent in the 1960s, when Igor Klatzo described the induction of
cerebral neurofibrillary degeneration, similar to that seen in AD, by aluminum [21].
Aluminum has been shown to induce conformational changes in Aβ that reduce the αhelical content of the peptide and may enhance its aggregation [22]. Aluminum has also
been shown to cause apoptotic cell death in neurons and glia as well as inhibit LTP in
vitro. A lack of a significant difference in aluminum levels between AD patients and
controls, among other problems, resulted in significant debate over the importance of
aluminum in AD [23]. In support of aluminum as a potential disease modifier, studies in
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transgenic mice overexpressing APP (Tg2576) suggest that there is increased plaque
deposition in mice who are fed an aluminum-enriched diet as compared to controls [24].
1.4.1.1.2.

Aβ Associated Proteins

In addition to metal ions, deposition of amyloid can also be affected by proteinprotein interactions. Proteins that bind Aβ and stabilize a β-pleated sheet conformation
can facilitate its aggregation into plaques [25].

Such proteins include α1-

antichymotrypsin, ApoE, C1q complement factor, and GM-1 gangliosides. α1Antichymotrypsin is an acute-phase serine protease inhibitor secreted by activated
astrocytes in response to stimulation by IL-1β [26]. It has been shown to be associated
with amyloid plaques in AD [27], but is not found in other amyloidoses that do not
involve the Aβ peptide [28].

α1-Antichymotrypsin has been shown to promote

fibrillization of Aβ [29], as well as promote deposition of Aβ into plaques, as transgenic
mice that express both human APP(V717F) and α1-antichymotrypsin have increased
plaque load as compared to transgenic mice that express APP(V717F) without α1antichymotrypsin [30]. ApoE4 acts similarly to α1-antichymotrypsin in that it also binds
to and promotes the fibrillization of Aβ in vitro [29] and is associated with higher plaque
loads in older mice, with synaptic deficits occurring even in younger mice. ApoE4 is
also the most common and significant genetic risk factor for sporadic AD, which will be
discussed later in this chapter. 5
Another protein which has been shown to localize to amyloid plaques is the
complement factor C1q [31]. This protein is part of the C1 complex, and the C1q subunit
itself binds to a ligand and, provided there are no inhibitors of the process also present,

5

Genetic risk factors for sporadic AD are discussed in section 1.6.4.
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activate the complement cascade [32]. C1q can bind to amyloid, activating an immune
response to the aggregated peptides. It has also been show to promote the aggregation of
Aβ both in vivo and in vitro. Incubation of amyloid in the presence of C1q results in 7x
more aggregation than amyloid incubated alone. Further, injection of C1q into the brains
of APP+PS1 transgenic mice leads to an increase in Congo red-positive fibrillar amyloid
deposits in vivo [33].
GM-1 gangliosides are also elevated in AD and have been shown to both bind Aβ
and localize to Aβ plaques in AD. The binding of GM1 gangliosides to Aβ results in the
conversion from a predominately random-coil tertiary structure to a structure rich in βsheet, which facilitates oligomerization. GM1 gangliosides are generally appreciated for
their neuroprotective functions; while they are not neurotrophic in and of themselves,
they do appear to potentiate neurotrophic effects [34]. The binding of GM1 gangliosides
in amyloid plaques may result in the sequestration of these molecules in plaques,
preventing them from mediating neurotrophism. GM1 gangliosides are also associated
with certain immune responses – cholera toxin binds specifically to GM1 gangliosides,
and antibodies against GM1 gangliosides are upregulated in the autoimmune disease
Guillain-Barré syndrome.
1.4.1.2.

Factors that Impair Aβ Clearance

In addition to factors that affect its deposition, the amount of Aβ present in the
brain is also modulated by Aβ clearance. Aβ clearance is modulated predominately by
microglia, phagocytic cells capable of phagocytosing and degrading Aβ. Aβ can be taken
up into cells through scavenger receptors such as SRA, CD36, and RAGE, and degraded
by Aβ degrading enzymes such as insulysin, neprilysin, and MMP9. This is thought to
13

be more efficient in unaffected individuals, but as the disease progresses these microglia
enter a more pro-inflammatory state associated with increased production of IL-1β and
TNF-α, and the expression of genes associated with Aβ clearance decreases, while
expression of genes associated with aggregation increases. This state of “malactivation”
results in impaired amyloid clearance and shifts the balance of amyloid dynamics toward
plaque deposition [35].
Plaque load is ultimately determined by the balance of factors affecting Aβ
production via proteolysis, oligomerization and deposition, and clearance. When factors
that increase Aβ production or oligomerization outweigh those mediating degradation and
clearance, amyloid plaques form. The formation of plaques, however, may not correlate
directly with toxicity – the plaques may actually serve to sequester more toxic forms of
amyloid. The dichotomy apparent in data regarding Aβ toxicity in the presence of copper,
for example, illustrates this phenomenon. Copper can cross-link peptides into oligomers
and confer neurotoxicity, but the formation of thioflavin T positive, β-sheet rich
aggregates is actually decreased. This suggests that it is the small oligomers that confer
this copper-mediated toxicity [17, 18].
Further support for the notion that small oligomers, and not plaques per se, are
responsible for the deficits seen in AD comes from the observation that the addition of
clusterin, another protein that can bind Aβ and associate with amyloid plaques, to PC12
pheocromocytoma cells in culture reduces amyloidogenesis while, seemingly conversely,
increasing cell toxicity [36, 37]. The case for small oligomers as toxic agents also
extends to in vivo models, as synapse loss in transgenic mice expressing human APP in
the absence of amyloid deposits [38], and memory loss in transgenic mice can be
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reversed even when amyloid is not removed [39, 40]. This evidence has led to the
oligomer hypothesis, which suggest that memory loss early in the disease process can be
attributed to oligomer-induced destruction of synapses, with later stages of the disease
associated with oligomer-induced cellular degeneration and death [For review, see 41].
This places small oligomers of Aβ at the center of disease pathogenesis, with plaques
acting, potentially, as a means of sequestration of these toxic oligomers. The hypothesis
that amyloid is central to the disease process of AD will be discussed further in section
1.5.
1.4.2. Neurofibrillary Tangles
The other major histopathological hallmark of AD are neurofibrillary tangles, the
“tangled bundles of fibers” [5] that appear, eventually overtaking the neurons until only
“ghost” or “tombstone” tangles remain. The formation of neurofibrillary tangles (NFTs)
involves the hyperphosphorylation of the microtubule associated protein tau. When tau
becomes hyperphosphorylated, it falls off of microtubules and forms fibrils – a
conformation referred to as a paired helical filament (PHF) [42]. PHF accumulates
intracellularly, forming neurofibrillary tangles.

The dissociation of tau from

microtubules and subsequent formation of NFTs may ultimately result in destabilizing
changes to the microtubules that can impair axonal transport, leading to synaptic
dysfunction and ultimately to neurodegeneration [43].
The normal physiological function of tau is the stabilization of microtubules. The
ability of tau to bind to microtubules is regulated by serine/threonine directed
phosphorylation [44], though it may also be affected by glycosylation and other posttranslational modifications [45-47]. The phosphorylation of tau is typically higher during
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development, and is generally low in the differentiated cells of the adult brain. However,
in the case of some tauopathies, including AD, the tight regulation suppressing tau
phosphorylation is lost, and tau becomes aberrantly hyperphosphorylated.
Factors that directly affect the phosporylation of tau may include, naturally, the
upregulation or aberrant activation of kinases responsible for phosphorylation of tau as
well as the downregulation of phosphatases responsible for dephosphorylation. At least
30 different serine/threonine residues on tau may be phosphorylated by a number of
different kinases, including proline directed kinases such as mitogen activated protein
kinase (MAPK), glycogen synthase kinase 3 (GSK3), cyclin dependent kinase 5 (cdk5),
Jun N-terminal kinases /stress-activated protein kinase (JNK/SAPK), and p38 mitogenactivated protein kinase (p38 MAPK), and non-proline directed kinases such as cyclic
AMP-dependent protein kinase, protein kinase C (PKC), microtubule affinity regulating
kinase (MARK) and calcium/calmodulin-dependent protein kinase (CaMK) [43]. The
phosphatases implicated in regulating the phosphorylation state of tau include protein
phosphatases 1, 2A, 2B, and 2C [43, 48].
In addition to phosphorylation, other covalent modifications to tau also occur,
though their relevance to the pathological state of tau is not clear. These modifications
include gycosylation, glycation, ubiquitinylation, sumoylation, and nitration [49].
Furthermore, tau may also undergo proteolysis by calpain, cathepsin-L, or caspase-3, and
the cleaved forms of tau generated seem to be particularly toxic to cells [50, 51].
Cleavage of tau by calpains generates a 17 kD species that in some studies seems to be
associated with toxicity, but is not prone to aggregation. Tau cleaved by caspase-3 or
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degraded by lysosomal proteases, however, does show a greater propensity towards
aggregation [52-55].
The specific mechanism of tau-mediated neurotoxicity has not been fully
established. Some mechanisms that have been proposed and garnered support include the
hypothesis that an increase in bound tau can inhibit the attachment of motor proteins
resulting in a slowing of axonal transport and ultimately impeding cellular function.
Further, cleavage of tau by caspases and lysosomal proteases result in the generation of a
fragment in which the repeat domain of tau is exposed [51]. This fragment is particularly
prone to aggregation, and may result in the formation of toxic neurofibrils [51]. The
accumulation of tau is also dependent on a failure of cytosolic chaperones to facilitate tau
clearance [56]. Of course, there may also be other, as-yet-unidentified mechanisms
contributing to tau toxicity.
The complex interactions between phosphorylation, ubiquitinylation, and tau
proteolysis are still being elucidated. It does appear that the phosphorylation of tau at
specific sites, such as S262/S356, impedes proteasomal degradation, as the CHIP/Hsp90
complex does not recognize and ubiquitinylate this form [57]. The failure of tau turnover
can lead to an increase in the accumulation of phospho-tau species, which ultimately
aggregate within the cell.
1.5. The Amyloid Cascade Hypothesis
The relative importance of Aβ and tau, historically, has been the focus of much
debate within the field. The most widely accepted hypothesis regarding AD pathogenesis
is the amyloid cascade hypothesis, and this hypothesis has dominated AD research for the
past 20 years [58, 59]. According to this hypothesis, the production and/or accumulation
17

of Aβ is central to disease pathogenesis. The major support for the amyloid cascade
hypothesis is in the genetics of familial AD, which will be discussed in detail in section
1.6.

Mutations in APP and the presenilins (the catalytic portion of the γ-secretase

enzyme complex, one of the enzymes responsible for the cleavage of APP into Aβ, as
discussed in section 1.7) result in an increase in the production of Aβ42 throughout life.
In individuals without familial disease-causing mutations, failures in Aβ clearance lead to
elevated levels of Aβ. This results in the accumulation of oligomerized Aβ throughout the
parenchyma, which has delirious effects on synaptic function. The Aβ aggregates into
plaques, resulting in microglial activation and astrocytosis. The ensuing inflammatory
responses lead to oxidative injury. This oxidative stress is also associated with altered
kinase and phosphatase activity that leads to the hyperphosphorylation of tau, eventually
causing the formation of neurofibrillary tangles and ultimately cell death. [60]
1.5.1. In Vivo Evidence in Support of the Amyloid Cascade Hypothesis
Central to the amyloid cascade hypothesis is the notion that amyloid production
precedes tangle formation. This notion has been difficult to show conclusively, as most
models of AD utilize overexpression of amyloid, tau, or both in order to induce diseaselike conditions. One important study addressing the question of whether amyloid does
indeed precede tau deposition utilized triple transgenic mice (carrying mutations in PS1,
APP, and tau) and carefully assessed the mice at different ages, finding that amyloid
deposits in the cortex were visible before the first evidence of tau pathology [61].
Further, while mutant tau expressing animals develop tau pathology in the absence of Aβ
overexpression, when these mice are crossed with APP transgenic mice pathology is
enhanced [62]. Injection of Aβ42 fibrils into the brains of mutant tau transgenic mice also
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induces enhanced tau pathology, with five times more amygdalar neurons containing
neurofibrillary tangles in Aβ42-injected mutant tau mice as compared to those not injected
with Aβ [63]. Finally, clearing Aβ using passive immunotherapy in triple transgenic
mice results in first a decrease in Aβ followed by a decrease in early phospho-tau species
[64]. Taken together, the evidence from these transgenic mouse models suggests that Aβ
can indeed induce changes in tau pathology, with increased levels of Aβ enhancing
pathology and decreased levels of Aβ associated with a decrease in some species of
phospho-tau [65].
While the evidence from these in vitro models offers significant support for the
amyloid cascade hypothesis, the major limitation is that the models utilize gross
overexpression of wild type human or mutant human protein in the brains of transgenic
mice.

While they are particularly useful for examining the downstream effects of

increased levels of these proteins on other systems, they do not address many aspects of
the human condition, especially anything that may be upstream of Aβ pathology.
Further, in the case of doubly or triply transgenic mice expressing both tau and APP, each
pathology would develop in the absence of the other gene. While use of these models
allow us to study the interaction between the two pathologies to some extent, because
these pathologies are essentially driven by the overexpression or mutation present the
external validity of the models are somewhat questionable. Finally, with the exception of
the htau mice developed by Karen Duff and Peter Davies [66], most models of tau
pathology used in AD research utilize mutations in tau, such as those seen in tauopathies
like frontotemporal dementia. These mutations are not found in AD patients, so the
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specific mechanisms of aggregation of tau may be very different in these transgenic
models than in the human condition.
1.5.2. In Vitro Evidence in Support of the Amyloid Cascade Hypothesis
While they do not completely solve the problem of external validity and
applicability to the human condition, in vitro models are often more appropriate for
working out specific intracellular mechanisms with regard to how Aβ may induce tau
pathology. In vitro studies have been seminal in showing that tau is essential for Aβinduced neurotoxicity – neurons expressing either human or mouse tau are susceptible to
Aβ induced degeneration, while neurons from tau-knockout mice are not [67]. Two
proposed mechanisms by which Aβ may mediate its toxicity are via oxidative stress
and/or via receptors on the neuronal membrane [48]. As discussed earlier in section
1.4.1.1.1, Aβ oligomerization, when stabilized by binding to metals such as copper and
zinc, can result in the formation of H2O2. H2O2 and other reactive oxygen species induce
oxidative stress on cells, including peroxidation of lipids, oxidation of amino acids in
proteins, DNA damage, and disruption of mitochondrial respiration [48]. Mitochondrial
disruption starves cells of energy and results in internal generation of additional free
radicals, which can also ultimately result in the induction of apoptosis.
While the oxidative stress pathway places Aβ clearly upstream of cell death, the
connection to hyperphosphorylated tau is less clear. Reactive oxygen species may induce
activation of JNK and p38 MAPK, which may be involved in the phosphorylation of tau,
though the specific pathway by which oxidative stress results in increased tau
phosphorylation requires further investigation.
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In addition to oxidative stress related pathways, some evidence exists that the
effect of Aβ on tau phosphorylation may occur via a receptor-mediated transduction
pathway. Aβ can bind receptors on the cell surface and induce signaling via multiple
cellular pathways. For example, binding of Aβ to amylin receptor 3 can induce activation
of PKA, MAPK, Akt, and cFos pathways [68]. APP can also bind to death receptor 6,
triggering cell death during trophic factor deprivation (which also induces proteolysis via
an amyloidogenic pathway) [69]. Further, Aβ exposure can induce the activation of
GSK-3. GSK-3 inhibition prevents Aβ induced cell death, and GSK-3 is a known tau
kinase [70]. Though the specific pathways involved in this activation have not yet been
entirely mapped out, Aβ does seem to be effective in inducing both cell death and
activating tau kinases. Therefore, both the in vivo work presented in the previous section
and the in vitro work presented here strongly support the notion that Aβ may indeed be
the instigator of further disease pathology, as suggested by the amyloid cascade
hypothesis.
1.6. The Genetics of Alzheimer’s Disease
While the in vitro and in vivo evidence presented above provides strong support
for this hypothesis, the longest standing and perhaps strongest support for the amyloid
cascade hypothesis comes from the evidence that suggested the hypothesis in the first
place – the genetics of familial AD. Familial AD (FAD) is an early-onset form of AD
that accounts for about 10% of cases. FAD involves the presence of at least one of
several genetic mutations that result in the development of AD. Importantly, all FAD
cases result from either mutation or duplication of the APP gene, or gain of function
mutations in one of the enzymes responsible for the generation of Aβ from APP,
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specifically presenilin 1 or presenilin 2 [71]. The fact that no mutations have been
identified in the NFT-associated protein tau in the brains of AD patients, while mutations
in APP that confer both increased and decreased risk, as will be discussed in this section,
have been identified, stands in strong support of the amyloid cascade hypothesis.
1.6.1. Trisomy 21 and APP Duplication
The gene for APP is located on chromosome 21. Down’s syndrome (DS) arises
from missegregation of chromosome 21 in the fertilized ovum, resulting in trisomy 21 in
every cell of the body. This results in a duplication and consequent overexpression of
APP and an increase in the proteolytic fragment Aβ, leading to plaque formation and
development of AD pathology. All adults with trisomy 21 over the age of 40 years
develop neuropathology similar to AD [72], thought to be primarily due to the extra
“gene dosage” and consequent overexpression of APP.
It should be noted, that while individuals with complete trisomy 21 always
present with AD like pathology, there are individuals with most major clinical features of
DS without trisomy of the entire chromosome but rather a duplication of a small part of
the chromosome. The smallest region thus far identified that results in clinical features
reminiscent of DS is a 4.3 Mb region spanning 21q22.13-21q22.2 [73], a region which
does not include APP (located at 21q21.2) but does include the kinase Dyrk1A, which is
known to phosphorylate APP and tau.

This family, thus far mother and daughter,

presents with facial features reminiscent of DS, speech deficits, and mild intellectual
disability [73]. Due to the rarity of the genetic anomaly and the young age of the patients
identified as carriers, it is not yet clear if individuals with partial trisomy present with
progressive neurodegeneration, though cognitive dysfunction is evident.
22

A large genetic screening of a UK population found that APP duplication was
significantly associated with early onset dementia as well as an increased risk of seizures.
This screen did identify one family in which two individuals were identified as affected
or probably affected with early onset dementia where the region duplicated included the
APP gene but not the so-called “DS critical region” identified in individuals presenting
with DS-like phenotype due to partial trisomy 21 [74]. Another screening of a Swedish
population identified an individual with AD who also had a duplication of a very small
portion of chromosome 21 that included the APP gene but not the DS critical region [75].
Though duplication of such a small locus is very rare, the type of early onset dementia
seen in patients with APP duplication in the absence of DS critical region strongly
suggest that APP is central to the pathogenesis of individuals with AD as well as the
progressive neurodegeneration observed in DS individuals.
1.6.2. Mutations in APP that Increase Risk for AD
In addition to duplication of the APP gene, various pathogenic mutations which
result in early onset AD have been identified along the APP gene. These include 25
mutations, shown in Table 1.1 [2], which are mostly aggregated in two regions along the
peptide – in the vicinity of amino acid 671 or in the vicinity of amino acid 717 (according
to the 770 isoform). Importantly, as will be discussed later in this chapter (section 1.7),
these locations are the points at which APP is cleaved in order to form the Aβ peptide.
These mutations increase the propensity for APP to be cleaved to form Aβ or, as is the
case for many of the mutations at amino acid 717 (the γ-secretase site mutations) increase
the ratio of the more toxic form Aβ42 to the less toxic Aβ40. Particularly notable is the
Austrian mutation, T714I, which results in an 11-fold increase in the Aβ42:Aβ40 ratio [76].
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Table 1.1. Mutations in APP resulting in early onset AD.
Mutation
KM670/671NL
D678N
E682K
A692G
E693K
E693Q
E693Δ
E693G
D694N
L705V
A713T
T714A
T714I
V715A
V715M
I716T
I716V
I716F
V717F
V717G
V717I
V717L
T719P
L723P
K724N

Name

First Reported

Swedish
Mullan et al., 1992
Tottori
Wakutani et al., 2004
Leuven
Browers et al., 2008
Flemish
Hendriks et al., 1992
Italian
Tagliavini et al., 1999
Dutch
Levy et al., 1990 and Van Broeckhoven et al., 1990
Tomiyama et al., 2008
Arctic
Kamino et al., 1992
Iowa
Grabowski et al., 2001
Obici et al., 2005
Giaccone et al., 2002
Iranian
Pasaler et al., 2002
Austrian
Kumar-Singh et al., 2000
German
De Jonghe et al., 2001
French
Ancolio et al., 1999
Terrini et al., 2002
Florida
Eckman et al., 1997
Clarimón et al., 2008
Indiana
Murrell et al., 1991
Chartier-Harlin et al., 1991
London
Goate et al., 1991
Murrell et al., 2000
Ghidoni et al., 2009
Australian
Kwok et al., 2000
Belgian
Theuns et al., 2006

Twenty-five mutations, listed here, have been identified as resulting in early onset
AD. Importantly, these mutations are located predominately in the vicinity of amino
acid 671 and amino acid 717, the two sites at which APP is cleaved in order to form the
Aβ peptide. This list has been compiled from the AD Mutations database accessible at
http://www.molgen.vib-ua.be/ADMutations [2].
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The plaques in the brains of these individuals are diffuse, predominately consist of Aβ42,
and do not contain detectable levels of Aβ40. As diffuse, non-fibrillar, small oligomeric
Aβ is thought to be the most toxic form; this strongly implicates Aβ42 as a particularly
pathogenic species, and places considerable focus on the enzyme responsible for its
production, γ-secretase.
1.6.3. Mutations in Presenilins that Increase Risk for AD
The γ-secretase complex is made up of four proteins:

presenilin, nicastrin,

anterior pharynx defective 1 (Aph1), and presenilin enhancer 2 (Pen2) [77]. The catalytic
subunit of the γ-secretase complex is presenilin. Vertebrates have two presenilin genes
encoding two different presenilins, PS1 and PS2, either of which may be incorporated
into the γ-secretase complex [78]. A total of 185 mutations have been identified in PS1
and 13 in PS2, making presenilin mutations far and away the most common mutations
seen in early onset familial AD.

The mutations tend to cluster in exon 8, which forms

the long acidic loop between the sixth and seventh transmembrane domains, suggesting
that this structural feature is likely important in the enzyme’s function [79].
Other notable mutations in presenilin include the delta 9 mutation, a mutation that
affects mRNA splicing such that exon 9 is deleted [80]. This mutation results in a unique
phenotype similar in some ways to the Austrian mutation in APP described above, in
which there is an increase in the Aβ42:Aβ40 ratio, resulting in diffuse plaques [81].
1.6.4. Mutation in APP that Decreases Risk for AD
To date, only one genetic mutation has been identified which renders protection
against AD. This very rare mutation, APP(A673T) was identified from a population of
1,795 Icelanders and is located adjacent to the β-secretase cleavage site, which is
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involved in Aβ production. This mutation decreases the production of Aβ by 40% in
vitro, and confers decreased risk for developing AD. This strongly supports both the
amyloid cascade hypothesis as well as the notion that inhibition of β-secretase activity
should prevent disease progression [82].
1.6.5. Genetic Mutations in Tauopathy
Importantly, there are known genetic mutations in tau that yield an AD
phenotype.

However, transgenic mice overexpressing APP or mutant APP is not

generally sufficient to produce tau pathology in mice. While hyperphosphorylation of tau
is sometimes seen, formation of neurofibrillary tangles and neurodegeneration is rare,
most likely due to differences in tau between mice and humans. Mice tend to produce
more 3R tau than 4R tau in adulthood, while in humans the pattern is reversed. 4R tau
has a higher propensity for aggregation as compared to 3R tau, making human tau more
prone to forming neurofibrillary tangles when phosphorylated as compared to mouse tau.
Mutations in tau, while not associated with AD in humans, have been associated
with frontotemporal dementia, which, like AD, features hyperphosphorylated tau,
neurofibrillary tangles, and progressive neurodegeneration. Because the tau pathology
observed in frontotemporal dementia is similar to that observed in AD and AD mice do
not develop tau pathology with expression of human wild-type or mutant APP, mutations
in tau have been “borrowed” from frontotemporal dementia for use in AD mouse models.
The tau mutation most commonly used in animals for the study of AD is the P301L
mutation. This mutation results in the formation of neurofibrillary tangles as well as
significant neuron loss in the hippocampus, gross atrophy of the forebrain, and decreased
brain weight [83].
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1.6.6. Genetic Risk Factors for Sporadic AD
Importantly, 90% of AD cases are not associated with known genetic mutations.
This is intriguing as it suggests that mechanisms other than those directly related to APP
and its proteolysis may contribute to the production, deposition, or impaired clearance of
Aβ in the majority of AD cases. There have been many genetic polymorphisms which,
through genome wide association studies, have been shown to result a modestly increased
risk of AD.

These include the genes encoding bridging integrator 1, clusterin,

complement receptor 1, ABCA7, phosphatidylinositol binding clathrin assembly protein,
and CD33, among others. Together these implicate mechanisms including endocytosis
and complement system, which likely influence Aβ generation 6 and clearance,
respectively.
The most important genetic risk factor for late onset AD, however, is the
apolipoprotein E4 allele, which confers a three times greater risk of developing AD. The
specific mechanism by which ApoE4 increases the risk is still not entirely clear.

Some

candidate mechanisms include inflammation-induced vascular damage [84], increased Aβ
levels [85, 86], changes in Aβ fibrilization [87], brain hypometabolism independent of
Aβ [88], and impaired Aβ clearance [89].
1.7. Understanding APP Proteolysis
1.7.1. Classical Processing of APP: Amyloidogenic and Non-Amyloidogenic
Pathways
Altered proteolysis of APP is a central event in AD pathogenesis. APP is cleaved
sequentially by β- and γ-secretases to generate Aβ fragments that are 38-43 amino acids
6

The role of endocytosis in Aβ generation is further discussed in section 1.7.1.2.
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in length. These fragments, as described in section 1.4.1., are the primary component of
amyloid plaques and the initiators of the amyloid cascade [90, 91]. β-secretase cleaves
APP between amino acids 671 and 672, while γ-secretase cleaves in the vicinity of amino
acids 711-714 (based on APP770). It is the γ-secretase cleavage that determines the length
of the Aβ fragment and thus its propensity for aggregation. Cleavage of APP by β- and
γ-secretases is referred to as amyloidogenic processing because it results in the formation
of amyloid-β (Figure 1.1, amyloidogenic pathway). The major β-secretase in the brain is
β-site APP cleaving enzyme 1 (BACE) [92], while γ-secretase, as described above in
section 1.6.3, is comprised of a multiprotein complex including presenilin 1 or 2,
presenilin enhancer 2, nicastrin and anterior pharynx defective 1, with the catalytic
subunit being the presenilin [77]. The initial cleavage is thought to be performed by
BACE, generating the APP C-terminal fragment C99 as well as the N-terminal fragment
sAPPβ. C99 is then cleaved by γ-secretase to generate Aβ and the APP intracellular
domain (AICD).
APP can also be cleaved by α-secretases between amino acids 687 and 688. This
cleavage occurs at the extracellular surface of the plasma membrane and is within the Aβ
domain, thereby precluding the formation of Aβ. Because this cleavage precludes the
formation of Aβ, it is known as non-amyloidogenic processing (Figure 1, nonamyloidogenic pathway). α-Secretases are members of the ADAM (a disintegrin and
metalloprotease domain) family of proteins, ADAM-10, ADAM-17 (also known as
TACE), ADAM9, and ADAM19 have all been shown to have α-secretase activity [93].
In this pathway, full length APP is cleaved by α-secretase to generate the C-terminal
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Figure 1.1.
Classical processing of APP via the non-amyloidogenic and
amyloidogenic pathways. Aβ is produced through sequential cleavage of the APP
peptide by β- and γ-secretases via the amyloidogenic pathway. Aβ can aggregate to
form amyloid plaques, one of the histopathological hallmarks of AD. Alternatively,
APP may be cleaved by α-secretase to form sAPPα, a neuroprotective proteolytic
fragment.
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fragment C83 as well as the N-terminal fragment sAPPα. C83 can also be cleaved by γsecretase to generate the small peptide p3 as well as AICD.
Importantly, sAPPα has been shown to have neuroprotective properties. sAPPα
can inhibit calcium currents and increase potassium currents, stabilizing membrane
potentials and protecting cells against excitotocity [94-96]. It has also been shown to
have neurotropic properties, promoting neurite outgrowth, synaptogenesis, and cell
adhesion [97, 98]. Intracerebroventricular sAPPα administration in rats results in
enhanced learning and memory performance, increased long-term potentiation, and
enhanced N-methyl D-aspartate receptor mediated currents [99]. Further, sAPPα can
increase the proliferation rates of neural stem cells [100]. Taken together, this indicates
that sAPPα can be considered to have both neurotropic and neurotrophic properties [101].
1.7.1.1.

Phosphorylation Dependent Changes in Processing

APP can be phosphorylated at T654, S655, and T668, with the phosphorylation at
T668 resulting in the most pronounced conformational change to the C-terminus [102].
In neurons, this phosphorylation is primarily performed by cyclin-dependent kinase 5
(cdk5) [103]. Increased expression of the cofactors that regulate cdk5 activity, namely
p25 and p35, results in increased APP phosphorylation as well as increased production of
various proteolytic fragments of APP, including Aβ, sAPPβ, and sAPPα [104]. The
phosphorylation of APP at T668 has been associated with an increase in the translocation
of AICD to the nucleus, localization of APP to the centrosome, and enhancement of
neurodegeneration [105, 106].
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1.7.1.2.

Effect of Trafficking on APP Proteolysis

Trafficking of APP also seems to be important for Aβ production.

The

cytoplasmic domain of APP contains an endocytosis signal (YENP740), and mutating or
deleting this region results in decreased production of Aβ [107]. When APP at the
surface of the cell is labeled, endocytosis can be observed and labeled Aβ is produced
[108-110]. Depletion of cellular potassium prevents clathrin-mediated endocytosis and
effectively lowers Aβ production [109, 110]. Taken together, these data illustrate that
endocytosis is important for the production of Aβ.
Depleting proteins important in the early multivesicular body pathway result in
accumulation of APP in the early endosomes, but reduce Aβ production. Depleting
proteins that act later in this pathway result in an accumulation of APP in the trans-Golgi
network and enhanced APP processing and production of Aβ, suggesting that APP
processed into Aβ is first endocytosed then routed to the trans-Golgi network. APP
recycled from the early endosomes into the trans-Golgi network creates a pool of APP
from which Aβ is produced [111].
1.7.2. Alternative Processing of APP by Other Proteases
In addition, other proteases such as calpains and caspases are also known to
cleave APP [112-117]. For example, APP is cleaved by caspase-3 at three distinct sites in
apoptotic cells [113, 118]. Two of these sites, DNVD*S198 and DYAD*G220 are located
near the N-terminus of APP, while a third site, VEVD*A740, is located near the Cterminus. Since the cleavage at VEVD*A740 could be prevented with the small peptide
inhibitor DEVD-FMK, this cleavage of APP has been attributed to caspase-3 [113].
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Caspase activation, DNA fragmentation, and apoptosis are associated with
neurodegeneration in AD brains [112, 119-121]. Studies in post mortem AD brain tissues
have shown increased levels of caspases, specifically caspase-1 and -7, prior to exhibition
of other signs of apoptosis [122]. Induction of caspases in AD brain, along with the
observation that caspases can cleave APP, suggests that caspase-mediated processing of
APP may contribute to pathology development in AD. Caspase-3, -6, and -8 have all
been implicated in APP cleavage [113, 123]. The studies presented in later chapters here
will also provide evidence for caspase-7 mediated cleavage of APP [124].
1.8. Closing Remarks
In this chapter, we have discussed the history of age-related dementia and the
earliest descriptions of AD, first described by Alois Alzheimer in 1906. A certain
dichotomy has existed throughout history, with some believing memory impairment and
cognitive dysfunction to be a normal part of aging, while others recognizing that, at least
in some cases, there appears to be something more at work. The case of Auguste D, who,
at 51 years of age, was relatively young for the degree of impairment she experienced,
marks the first investigation into the neuropathology of what would come to be known as
AD.
Since the very beginning, our understanding of AD has been driven by its
neuropathology. Understanding what these histopathologically characteristic plaques and
tangles are made of, how they form, why they persist, how they may be removed, and
what affect they have on the brain have been the major questions the AD field has faced
for the last 40, if not 100, years. The discovery of the Aβ peptide, its parent protein, and
the genetic work that followed provided the foundation for the amyloid cascade
32

hypothesis, which has largely driven AD research for nearly 25 years. The notion that
Aβ is at the center of the disease process is well supported, through genetics, in vitro, and
in vivo work. However, the specific mechanisms underlying its production, beyond
which secretases cleave the parent protein at which locations, is still under investigation.
Only recently have we begun to appreciate the importance of endocytosis in the
production of Aβ.
Many facets of the AD brain contribute to its dysfunction. There are impairments
in the blood brain barrier, impaired circulation, inflammation, the presence of protein
aggregates both inside and outside of cells, and cell death. In the chapters that follow,
we will discuss cellular processes that are activated in the AD brain, namely cell cycle
activation and activation of apoptotic pathways, and the effect these processes have on
both classical and alternative processing of APP.
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CHAPTER 2: THE ANATOMICAL CASCADE, CELL CYCLE ACTIVATION,
AND CELL DEATH 1

2.1. Chapter Synopsis
Our understanding of the pathogenesis of AD has been largely driven by the
amyloid cascade hypothesis for nearly 20 years. Given the strong genetic evidence and
the large body of in vitro and in vivo evidence presented in chapter 1, the fixation the AD
field has had on Aβ seems quite appropriate. However, somewhat of a dichotomy exists
between disease severity as determined by cognitive function and amyloid load. While
tau pathology can be rather closely correlated to cognitive function, amyloid pathology
correlates only weakly. This can be explained by the identification of small oligomers as
the toxic species. However, this leads to an interesting question – if small oligomers of
Aβ are upstream of tau pathology, and tau pathology follows a predictable, anatomical
progression through the brain which correlates with disease severity, do the production of
Aβ and its small oligomers may also follow a predictable pattern through the brain? This
question led to the hypothesis that certain facets of microenvironment present in the AD
brain may in fact beget Aβ production, allowing pathology to propogate through the
brain. Here, we present evidence of cell cycle dysregulation in the AD brain, and
describe how this dysregulation ultimately leads to cell death. We also present the

1

Portions of this chapter have been previously published (Fiorelli and Padmanabhan, 2010, 2011)
and are utilized with the permission of the publishers. See Appendices B and C.

49

hypothesis and supporting evidence from the literature that these aberrant cell cycle
related events and the cell death that follows may in fact lead to altered proteolytic
processing of amyloid precursor protein, and that this altered proteolytic processing may
set off the anatomical progression of disease-related pathology in the AD brain. In the
chapters that follow, we will present our experiments designed and performed to address
the hypothesis that aberrant cell cycle related events and apoptosis alter APP processing
and promote AD pathogenesis.
2.2. The Alzheimer’s Disease Dichotomy
While the evidence discussed in chapter 1 presents a strong case for the
importance of Aβ in AD pathogenesis, the fact that Aβ-related plaque pathology does not
correlate well with disease severity has historically been somewhat of a “thorn in the
side” of the amyloid cascade hypothesis. Plaque pathology seems to develop over the
decades-long preclinical phase of AD, and is likely present long before cognitive
dysfunction is severe [1]. Some individuals with moderate to advanced plaque pathology
never show cognitive dysfunction [2, 3]. Further, plaque pathology is observed broadly
throughout cortical regions of the brain, with no apparent specificity for regions
functionally associated with spatial or associative memory. The severity of amyloid
plaque pathology in the brain has very little to no predictive value in determining the
degree of cognitive dysfunction in the AD patient.
2.2.1.

Anatomical Progression of Tau Pathology

Tau pathology, on the other hand, is much more tightly correlated with cognitive
dysfunction. Tau pathology progresses in a distinctive, predictable, anatomical pattern
through regions of the brain specifically associated with memory. In fact, the correlation
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between tau pathology and AD severity is so well established that staging of tau
pathology is perhaps the most widely recognized neuroanatomical measure of disease
severity. The formation of argyrophilic NFTs in AD follows a predictable, nonrandom
course throughout the hippocampus, neocortex and subcortical nuclei [4]. This
predictable anatomical pattern of progression was first defined by Heiko Braak in 1991,
and its use has become common practice in staging the progression of AD.
2.2.1.1.

Braak Staging of Alzheimer’s Disease

According to Braak’s method of neuropathological staging, six distinct stages of
disease progression can be distinguished based on the localization and severity of tau
pathology [4, 5].

In Braak stage I, very slight pathology may be seen in the

transentorhinal cortex, specifically in layer Pre-α. As the disease progresses into stage II,
pathology in the transentorhinal cortex becomes somewhat more severe. Pathology is
largely confined to the transentorhinal cortex, but some mild pathology may be detected
in the CA1 region of the hippocampus, the entorhinal cortex, and the temporal isocortex
in stage II. Because the pathology of Braak stages I and II is largely isolated in the
transentorhinal cortex, these are sometimes referred to collectively as the transentorhinal
stages.
In Braak stage III, the transentorhinal cortex is heavily burdened with tangle
bearing neurons, and increasing pathology can be seen in the hippocampus, entorhinal
cortex, and temporal isocortex, though pathology of the neocortex is minimal at this
point. In addition, mild pathology may be seen in the other layers of the transentorhinal
and entorhinal cortices; in addition to layer Pre-α pathology is seen in layers Pri-α and
Pre-β as well. Stage IV is the first stage in which pathology is pronounced in layers
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outside of Pre-α, as pathology in Pri-α and Pre-β advances. In stage IV, there is marked
destruction of the transentorhinal and entorhinal cortices, as well as marked damage in
the CA1 region of the hippocampus, and increasing damage throughout the hippocampal
formation. There is still little involvement of the neocortex at this point. The losses seen
in stage III and IV within the external and internal principle strata result in significant
impairments in the transfer of information between the hippocampus and the neocortex,
thereby disrupting the limbic circuits. Because of this disruption, stages III and IV
together are referred to as the limbic stages.
In the most advanced pathological stages of AD, Braak stages V and VI,
extensive damage can be seen throughout the hippocampal formation, entorhinal and
transentorhinal cortices, and the temporal isocortex.

The significant damage in the

temporal isocortex gives stages V and VI their collective name – the isocortical stages.
There is also significant pathology in the neocortical association areas. Interestingly, the
conventionally used criteria for the diagnosis of AD require extensive pathology in the
neocortical regions. Therefore, only pathology of at least Braak stage V or VI would be
definitively diagnosed as AD based on conventional neuropathological criteria [4].
2.2.1.2.

Correlation of Tau Pathology with Cognitive Function

Overall, the correlation between Braak stage and clinical dementia rating (CDR)
of individuals with probable AD is high (ρ=0.66, P<0.01) according to Gold et al. [6]),
though the Braak stages are not particularly useful for distinguishing individuals with
normal (CDR score of 0 on a scale of 0 to 3) cognition from those with mild cognitive
changes (CDR score of 0.5) [6].
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According to Braak and Braak [4], the transentorhinal stages of the disorder are
considered cognitively silent. However, some studies have found that these stages are
often associated with clinical pathology: 71% of individuals in Braak stage I and 75% of
individuals in Braak stage II showed at least mild cognitive changes according to CDR
score [6], and 22% of individuals in Braak stage I or II were considered clinically
demented according to the CAMDEX criteria [7].
While a thorough analysis of the types of neuropsychological testing involved in
these studies is beyond the scope of this text, it must be noted that both the CDR and
CAMDEX assessments address global cognitive function. It is, therefore, not surprising
that such a gross approach to neuropsychological analysis results in significant overlap
across different neuropathological stages.

When individual modalities of cognitive

functions are examined independently, it appears that the transentorhinal stages are
associated with deficits in episodic memory [8]. Neuroanatomically, the transentorhinal
cortex receives inputs from the isocortical association areas, and project to the
hippocampal formation via the entorhinal cortex [4]. Based on these neuroanatomical
substrates, damage to the transentorhinal cortex characteristic of Braak stage I and II
would result in the deficits in episodic memory observed in these early stages. This is
also consistent with the observation that episodic memory is typically impaired very
early, during the preclinical course of the disease [8].
The limbic stages, Braak stages III and IV, are particularly interesting. While
stage III is quite ambiguous, with 43% of individuals in stage III clinically demented
according to CAMDEX criteria [7] and CDR scores covering the full range of possible
scores [6], conversion to stage IV is quite significant. On the basis of CDR scores, all the
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individuals reaching stage IV neuropathology were at least mildly demented [6], while on
the basis of the CAMDEX criteria 67% of individuals at stage IV were considered
clinically demented, the first stage at which significantly more individuals were demented
than not (χ2=6.31, P=0.01) [7].
The limbic stages, as described above, are associated with severe pathology in the
transentorhinal cortex, moderate pathology in the hippocampal formation, and only very
slight pathology in the temporal isocortex. The increasing severity of neuropathology is
also associated with progressions in clinical pathology, including deficits in verbal
abilities, visiospatial function, attention, and executive functions [8]. Interestingly, the
neuroanatomical regions associated with these cognitive functions are largely neocortical,
including association, frontal, and prefrontal cortices. While the loss of connections
between the association cortex and the hippocampal formation due to destruction of the
transentorhinal and entorhinal regions may partially account for these clinical
manifestations, the clinical pathology suggests more neocortical involvement than is seen
in the limbic stages.
Considering the statistically significant conversion from stage III to stage IV, and
the vast extent of neuropathology seen at these advanced stages, it is not surprising that
progression into the neocortical stages is associated with severe dementia. On the basis
of CDR score, 88% of individuals at stage V were severely demented [6], and on the
basis of CAMBREX score 70% of individuals at Braak stage V or higher were
considered clinically demented [7].

Clinically, these stages are associated with

increasing severity in the same types of deficits seen in the previous stages. In addition,
deficits are also seen in primary memory – the fluid, working memory required for
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performance of everyday tasks. Such deficits are associated with intermediate and late
stages of AD [8].
Even in individuals with deficits in primary memory, as is associated with Braak
stage V and VI, little deficit is observed in tasks that require sensory-motor performance
[8]. The end stages of AD can involve aphasia, loss of the ability to control movement,
inability to perform activities of daily living, and unresponsiveness. These are somewhat
beyond the scope of the Braak staging classifications, as stage VI can be associated with
advancing intermediate clinical stages of the disorder and are not specific to end stage
disease [8]. The spatiotemporal progression of neuropathological changes proposed by
Braak and Braak [5] are, therefore, more useful in setting forth the progression of the
early stages of the disease, which are dominated by allocortical pathology. As the
progression continues and neocortical pathology dominates, the Braak stages are less
indicative of clinical manifestations.
2.2.2.

Oligomeric Amyloid and the Anatomical Cascade

The apparent dichotomy between the vital importance of amyloid in the disease
pathogenesis, so strongly supported by genetic evidence, and the lack of correlation
between amyloid plaque pathology and disease severity (while tau pathology, which is
thought to be downstream of amyloid pathology, correlates rather well with disease
severity especially in the intermediate phase of the disease) can be largely explained by
the recent evidence that small oligomers of Aβ act as the toxic species. These small
oligomers are not evident in gross neuropathological assessments aimed at examining
amyloid pathology, such as thioflavin-S and Congo Red staining, as these dyes
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specifically stain β-pleated sheet structures and therefore require much larger Aβ
aggregates for detection.
Biochemical analysis, however, does suggest that Aβ42 levels in the brain do
indeed correlate with disease severity, so while plaque load is not well correlated the
cognitive function the total levels, inclusive of both Aβ contained in plaques and more
soluble forms, including small oligomers, does correlate well with cognitive function,
with individuals with higher levels of soluble Aβ having significantly poorer cognitive
function [9, 10].
If the presence of small oligomers of amyloid is indeed upstream of tau
pathology, and tau pathology follows a predictable anatomical course through the brain, it
stands to reason that the presence of small amyloid oligomers may also follow a similar
anatomical progression through the brain, despite our inability to detect with anatomical
specificity the presence of small, soluble peptides secreted into the parenchyma. The
anatomical progression of tau pathology may serve as a roadmap, heralding the presence,
or, given the longevity of neurofibrillary tangles, the former presence, of small oligomers
of amyloid in the extracellular space.
This hypothesis suggests that amyloid, like tau, follows an anatomical progression
through the brain, whereby Aβ in the cellular microenvironment causes some change in
the surrounding cells which result in changes in the processing of amyloid precursor
protein. A schematic of this hypothesis is presented in Figure 2.1. This may ultimately
result in the production of more Aβ, allowing Aβ production to propogate through the
brain in a fashion similar to tau pathology. Aβ has been shown to induce both cell cycle
activation and apoptosis in cells, both of which are candidates for processes which may
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Figure 2.1. Schematic of the anatomical cascade hypothesis. Aβ has been shown to
induce phosphorylation of tau and has also been proposed to act as a mitogenic
signal. Furthermore, the phosphorylation of tau can occur in a cell cycle dependent
manner. Tau pathology is also known to propagate through the brain in a predictable
manner. If amyloid is upstream of tau and tau propagates through the brain, it stands
to reason that Aβ production may also propagate through the brain in a similar
fashion. In this schematic, Aβ elicits cell cycle activation in the cell on the left,
which may lead to p53-dependent apoptosis. Alternatively, the cell may progress
further into the cell cycle, resulting in the phosphorylation of tau. This research is
aimed to address the hypothesis that cell cycle activation and/or p53-dependent
apoptosis may be associated with altered APP processing, including an increase in
the production of Aβ. This Aβ can then affect surrounding cells, allowing pathology
to propagate through the brain.
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alter APP proteolysis.

Cell cycle activation is associated with posttranslational

modifications to APP which may alter its trafficking and processing throughout the cell.
Apoptosis is associated with the activation of caspases, some of which have been
shown to directly cleave APP, though the contribution of these alternative proteolytic
events to the production of Aβ is not clear. In the rest of this chapter, we discuss the
evidence for cell cycle activation and apoptosis occurring in the AD brain, as well as the
evidence that cell cycle activation and apoptosis may be induced by the presence of Aβ.
In the chapters that follow, we will present our experimental studies designed to assess
whether cell cycle activation and apoptosis result in alterations in APP processing.
2.3. Cell Cycle Activation
AD is a neurodegenerative disease, and neurons are typically thought of as
terminally differentiated, post-mitotic cells that do not enter the cell cycle.
stems from the unique functional architecture of neuronal networks.

This idea
During

development, neural progenitor cells migrate to their destination, undergo terminal
differentiation, and integrate their axons and dendrites into the neuronal circuitry. These
neurons remain integrated in a complex network throughout the life of the organism.
Although it is known that neural precursor cells can divide and the newly formed
daughter cells can migrate and differentiate into mature neurons, the ability of mature
neurons to divide is debatable. A more widely accepted, and relatively intuitive, view
suggests that neurons are not able to undergo mitosis, since entry into mitosis and
subsequent cytokinesis would require cytostructural reorganization that would impair
neuronal connectivity and function [11]. In fact, there are rare cases in which binucleated
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neurons have been found in AD brain, suggesting that neurons may attempt to divide but
fail to undergo cytokinesis [12].
Neurons constituitively express cell cycle markers, including cyclins D, A, B, and
E, cyclin dependent kinases (cdks) 1, 2, 4, and 5, as well as cyclin dependent kinase
inhibitors (cdk inhibitors) [11, 13]. The expression of these markers in the normal brain
suggests a non-canonical role of these cell cycle related proteins in normal neuronal
function, possibly involved in synaptic plasticity or stability [13].

However, under

cytotoxic stress such as DNA damage, oxidative stress, or trophic factor deprivation,
cyclins and cdks are expressed in a sequential manner indicative of aberrant cell cycle
reentry, rather than non-canonical roles for these proteins [11, 14-17].
The proteins most strongly associated with AD pathology, APP and tau, have both
been shown to be regulated in a cell cycle dependent manner. APP is phosphorylated at
threonine 668 in a cell cycle dependent manner, specifically enhanced during the mitosis
phase of the cell cycle [18, 19]. Tau has also been shown to be phosphorylated in a
mitosis specific manner [20-25]. These studies suggest that the cell cycle activation
associated with AD could result in the modification of AD related proteins.

The

phosphorylation of these proteins can, in turn, affect their propensity to form aggregates
and thus contribute to the development of AD pathology.
In addition to the contribution of these proteins toward the development of AD
pathology, there is clear evidence for the involvement of AD-related proteins APP, PS,
and tau in the cell division cycle. The association of these proteins with the cell cycle
machinery suggests that they may play a regulatory role in the cell cycle. For example,
the presenilins associate closely with centrosomes and the kinetochore, suggesting a role
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for the presenilins in the modulation of cell cycle [26-29]. Further evidence for a close
association between presenilins and cell cycle regulation comes from in vitro studies
showing that overexpression of PS1 leads to G1 arrest, and that this arrest can be
potentiated by overexpression of PS1 mutants [30]. Knock-in mice expressing mutant
PS1(M136V) show increased expression of cyclin D1, a G1-associated protein, in
cortical neurons [31]. Treatment of neurons expressing mutant PS1 with the cell cycle
inhibitor quercetin, but not a gamma secretase inhibitor, protected these cells from
undergoing apoptosis [31]. Together, this suggests that expression of mutant PS1 is
associated with aberrant cell cycle activation, which in turn leads to the induction of
apoptosis independent of gamma secretase activity. In addition, blocking the cell cycle by
down regulating cyclin D1 using a small interfering RNA construct also reversed the
neurodegeneration observed in PS1 mutant neurons [31], further suggesting that the
apoptosis and neurodegeneration seen in PS1 mutant neurons is mediated by aberrant
cell-cycle reentry.

Importantly, FAD patients expressing mutated PS1 also show

abnormal accumulation of cyclin D1 in the temporal cortex, supporting the validity and
relevance of these models to the study of AD as it occurs in the human patient, as well as
the hypothesis that aberrant cell cycle reentry may play a significant role in the
neurodegeneration characteristic of AD.
Numerous studies have suggested that aberrant cell cycle activation occurs in the
AD brain. For example, Ki-67, a DNA binding protein involved in cell division, is
upregulated in the hippocampus of AD patients [32, 33]. This protein is not usually
present in cells arrested in G0, but begins to accumulate in G1 and peaks during M phase,
suggesting that diseased neurons are not maintained in a fully-differentiated state. In
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addition, the master regulator of the cell cycle, retinoblastoma protein (Rb), has been
shown to be phosphorylated in the brains of AD patients [34, 35]. In cycling cells, Rb
binds to E2F and suppresses transcription of E2F dependent genes required for cell cycle
progression. Upon phosphorylation, Rb dissociates from E2F resulting in transactivation
of genes and cell cycle progression. The phosphorylation of Rb observed in AD brains
is, therefore, indicative of cell cycle dysregulation. 2
Other cell cycle associated proteins such as PCNA, cdk4, the cdk-activating
kinase cdk7, and cyclins D, E, and B have also been reported to be upregulated in AD
patients, with cyclin B/cdc2 expression associated with tau phosphorylation [36-39]. In
fact, there has even been one report of binucleated neurons present in AD brains [12], but
not in normal controls. This suggests that some cells may progress through the cell cycle
as far as anaphase, albeit a rare event [40].
Cyclin B1/cdc2 complexes have also been shown to be upregulated in the AD
brain. These complexes are observed in NFT-containing and NFT-susceptible neurons,
and have been shown to be capable of phosphorylating tau in vitro at M-phase specific
phosphoepitopes [41, 42]. Increased levels of CIP-1-associated regulator of Cyclin B
(CARB) have also been observed in the tangle-bearing neurons of the AD brain. CARB,
through its association with cyclin B and p21, is one of the regulators involved in the
G2/M phase of the cell cycle [43, 44]. Interestingly, inducing cell cycle activation in
neurons by adenoviral expression of oncogenes such as c-myc and ras is sufficient to
induce tau phosphorylation, as well as conformational changes in tau typically seen in
AD [45].

2

Rb and E2F regulation of the cell cycle will be discussed further in section 2.4.1.1.1.
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These conformational changes in tau can be detected using a conformationspecific antibody, Alz50, which was initially raised against AD brain homogenates.
Alz50 was, in turn, used to purify PHF from AD brains, which were then used to raise
seven different antibodies against PHF – the TG and MC series of antibodies from the
laboratory of Peter Davies (Albert Einstein School of Medicine, NY). Interestingly, all of
these antibodies, when used on an asynchronous population of dividing cells from
multiple lineages, such as MSN cells, HeLa cells, human lymphocytes, human B cells,
human astrocytes, and mouse or rat fibroblasts, specifically stain mitotic cells and do not
stain cells in interphase. This suggests that the epitopes phosphorylated in PHF from
human AD brains are the same epitopes phosphorylated during mitosis [42], and further
supports the notion that cell cycle dysregulation may be important in the development of
tau pathology in AD.
2.3.1.

Aβ-Induced Cell Cycle Activation

There is extensive evidence of aberrant activation of the mitogen-activated protein
kinase (MAPK) pathways in AD [For review, see 46]. Since these pathways are typically
activated by extracellular stimuli, this suggests that both entry into the cell cycle and tau
phosphorylation can occur downstream of a mitogenic extracellular signal. One potential
candidate for a mitogenic signaling molecule that can induce tau phosphorylation and
apoptosis in neurons is Aβ itself.
There is some evidence that preparations of oligomeric, but not monomeric, Aβ
can induce cell cycle events, including DNA synthesis, in dissociated cortical neurons
[47]. Furthermore, picomolar concentrations of Aβ1-42 induced cyclin D1 expression,
indicative of the G1 phase of the cell cycle, while micromolar concentrations of Aβ1-42
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resulted in cyclin B1 expression, indicative of G2.

R1.40 mice, which express human

APP with a Swedish mutation and show evidence of cell cycle events, do not show
evidence of cell cycle activation when BACE is not present, indicating that
amyloidogenic processing of APP may be required to elicit cell cycle activation in these
mice and further implicating Aβ as a mitogenic signal [47].
Aβ has also been shown to interact with RAGE receptors, which may provide a
mechanism for Aβ-induced cell cycle activation [48, 49]. Further evidence suggests that
stimulation of integrins and activation of focal adhesion kinases may also be involved in
this process [50]. Given the evidence that Aβ may be able to elicit a mitogenic response
from cells, the hypothesis that cell cycle activation may play an important role in AD is
not at odds with the widely accepted amyloid cascade hypothesis, but rather provides a
mechanism through which Aβ may induce tau phosphorylation and neurodegeneration.
2.4. Cell Death in Alzheimer’s Disease
Although loss of neuronal tissue is characteristic of AD, the specific way in which
cells die in AD is not entirely clear. There is evidence supporting the induction of
apoptosis, especially in vitro when cells are treated with Aβ [51-55]. However, while
some characteristics of apoptosis have been observed in the AD brain, other pathological
features seem inconsistent with apoptosis as a mechanism of cell death. For example, the
so-called “ghost tangles” – extracellular aggregates of tau observed in the AD brain, still
maintain the shape of the neuron in which they were formed [56, 57]. If the cell had
broken down into apoptotic bodies as part of the apoptotic process, these ghost tangles
would not persist. Additionally, tau is detected in the cerebrospinal fluid of AD patients.
The presence of this intracellular protein in the extracellular space suggests a breakdown
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of the cellular membrane. Such a breakdown is not typically associated with apoptosis,
but instead is more characteristic of necrotic cell death.
Furthermore, with the aggregation of Aβ in the extracellular space and the
formation of intraneuronal neurofibrillary tangles, AD may be considered a protein
misfolding disorder. The misfolding of tau, in addition to mitochondrial dysfunction,
places great stress on the lysosomal pathway, and evidence exists in support of autophagy
in AD [58-60]. While autophagy is likely induced as a protective response meant to
degrade misfolded proteins and damaged organelles, it is not clear whether autophagy in
AD is protective or actually contributes to cell death [59].
In this section, we will review the evidence in support of apoptosis, necrosis, and
autophagy as players in the cell death observed in AD, briefly describing each process
and presenting evidence evaluating the relative contributions of each process to
neurodegeneration in the AD brain.
2.4.1.

Evidence for Apoptosis-Mediated Cell Death in Alzheimer’s Disease

Apoptosis is often described as “programmed cell death” or “cellular suicide.” It
is a gene-directed process that is important for the development of adult tissue by
eliminating cells that are damaged or otherwise unwanted or unneeded [61]. Apoptosis is
energetically expensive, requiring the production and orchestration of complex molecular
events and ultimately resulting in the shrinkage and breakdown of the cell into apoptotic
bodies which may then be phagocytosed by microglia [62]. The entire process is largely
contained and does not elicit an immune response – an important difference when
compared to necrotic cell death.
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The mechanisms by which apoptotic cell death occurs have been and continue to
be extensively studied. The process of apoptosis is regulated largely by the sequential
activation of various cysteine-dependent aspartate-specific proteases, or caspases. There
are two pathways through which caspases are activated – an intrinsic and an extrinsic
pathway [for review, see 63]. The intrinsic pathway is initiated by the mitochondria,
which, in response to an apoptotic stimulus, release cytochrome c into the cytosol [64].
The release of cytochrome c is largely regulated by the Bcl-2 family of proteins. The
released cytochrome c binds to apoptosis protease activating factor-1 (Apaf-1), inducing
a conformational change in Apaf-1. This conformational change allows Apaf-1 to bind to
ATP, which results in its oligomerization to form an apopotosome. Procaspase-9 is
recruited to the apoptosome through interaction of the caspase recruitment domains
(CARDs) on both enzymes. This results in the activation of caspase-9, which can then
cleave and activate downstream executioner caspases such as caspase-3 [65]. This
process is under tight regulation by inhibitor of apoptosis proteins (IAPs), which are in
turn regulated by the proapoptotic mitochondrial protein Smac/Diablo [63, 65].
The extrinsic pathway is activated by binding of a ligand to a death receptor at the
cell surface. There are a number of cell surface proteins that contain a “death domain”
allowing them to signal apoptosis.
receptors (DR), and Fas.

These receptors include TNF receptor 1, death

Upon binding a ligand, these proteins trimerize and the

associated conformation change allows the cytoplasmic death domain to bind adapter
molecules, which in turn bind and activate procaspase-8 or -10. Active caspase 8/10 can
then activate executioner caspases such as 3/7, resulting in apoptosis [63].
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Apoptosis is characterized by a number of morphological changes to cells,
including membrane blebbing, chromatin condensation, nuclear shrinkage, and nuclear
fragmentation.

The plasma membrane, however, remains largely intact until the

lattermost portion of the apoptotic program [61].

Apoptotic DNA fragmentation is

characterized by DNA laddering on an agarose gel, with oligonucleosome sized
fragments (multiples of ~180 base pairs) [61, 66].

Identifying apoptosis in tissue,

therefore, is generally done by observation of these morphological changes as well as
examination of the activation states of various caspases and cleavage of target proteins by
executioner caspases. 3
In the nervous system, apoptosis is particularly important in development. It is
the major process through which pruning is achieved and therefore essential for the
development of the adult brain [for review, see 67]. It has been estimated that half of the
cells born in the developing nervous system die via an apoptotic pathway [68]. The loss
of these cells allows for optimization of synaptic connections and pattern formation
required for the proper “wiring” of the adult brain to develop. The determination of
which cells survive and which cells die seems to be dependent on connections to a
postsynaptic target (the formation of synapses) and competition for neurotrophic factors
[68]. Only the cells and synapses that form stable, active connections as well as trophic
support are retained, the others are eliminated or “pruned” from the system.

The

regulation of apoptosis in the developing nervous system involves complex regulation
between pro-apoptotic, for example Bax, and anti-apoptotic, for example Bcl-2, proteins
[67].

3

The roles of various caspases in the initiation and execution of apoptosis is further described in
section 3.2.3.
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2.4.1.1.

Aβ-Mediated Induction of Apoptosis via Cell Cycle Activation

Since neurons do not possess functional cell cycle machinery, this aberrant
reentry typically results in abortive exit from cell cycle and apoptosis [11]. Incapable of
undergoing cell division or transformation, neurons undertake apoptosis as an alternative
mechanism. The observation that neurons which aberrantly enter the cell cycle undergo
apoptosis, combined with the upregulation of cell cycle regulators in AD, led to the
hypothesis that cell cycle deregulation plays a significant role in AD pathogenesis [11].
We and others have hypothesized that Aβ acts as a mitogenic signal which
promotes aberrant cell cycle activation that can lead to both tau phosphorylation and
neuronal death. This neuronal death may be mediated by the “guardian of the genome”
p53, which has been shown to be overexpressed, altered in its conformation, and
posttranslationally modified in AD. These alterations in p53 likely reduce its function,
resulting in increased APP expression and tau phosphorylation that, in addition to
promoting apoptosis, could also contribute to both major pathological hallmarks of AD.
Treatment of cells with Aβ induces increased expression of DNA polymerase-β,
PCNA, and the p49 and p48 subunits of DNA primase, suggesting entry into S-phase and
upregulation of the DNA replication machinery. In neurons challenged with Aβ, DNA
primase, DNA polymerase-β, and DNA polymerase-δ are loaded into the replication fork,
and p53 expression is increased [69, 70]. P53 is a transcription factor that plays an
important role in mediating apoptosis in response to DNA damage. Alternatively, cdc2
has also been suggested as a potential mechanistic link between aberrant cell cycle
activation in neurons and apoptosis. Specifically, cdc2 phosphorylates BAD, the bcl-2
associated death promoter, and thereby inducing apoptosis [71]. Cell cycle activation
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associated apoptosis may occur through cdc2/BAD-dependent and/or p53-dependent
mechanisms.
It has also been suggested that Aβ-induced apoptosis is APP dependent, as APP
knockout neurons are less susceptible to Aβ-induced neurotoxicity [72]. Importantly, γsecretase derived fragments of APP have been shown to induce the expression of p53
[73], and AD-associated mutations in PS1 result in increased expression of p53 [74].
This suggests that Aβ-induced, APP-dependent apoptosis may be mediated by p53. The
importance of p53 in neurodegeneration in AD is further supported by the observation
that p53 expression is increased in the hippocampi of AD patients [75, 76], and that
polymorphisms in the gene encoding p53 are associated with increased risk for late-onset
AD [77]. In fact, two independent groups have suggested that specific conformational
alterations of p53 may be promising biomarkers that may be useful in the diagnosis of
AD [78, 79].

In addition to conformational alterations, alterations in the

glutathionylation of p53 have also been suggested to be involved in AD pathogenesis by
preventing p53 tetramer formation, which is required for DNA binding and normal p53
function [80].
Interestingly, p53 has been shown to regulate the expression of APP by reducing
the binding of Sp1 to the APP promoter [81]. The β-secretase enzyme BACE may also
be regulated in a similar manner, as there is also an Sp1 binding region within the BACE
promoter [82, 83]. Increases in p53, therefore, are normally associated with decreased
expression of APP. In AD, however, p53 function appears to be compromised due to
glutathionylation and conformational alterations that prevent its normal function. p53
dysfunction may, therefore, increase APP expression and contribute to amyloidogenesis.
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Surprisingly, mice haplodeficient in p73, a member of the p53 family with
neuronal specific expression, show an age-dependent accumulation of phospho-tau and
neurodegeneration [84]. This suggests that p53, whose normal function is described as
the “guardian of the genome” in cell division, could potentially contribute to all three
major pathological hallmarks of AD – Aβ accumulation, P-tau accumulation, and
neurodegeneration.
2.4.1.1.1.

Rb and E2F in Cell Cycle Progression

Expression of cyclin D1 and E are associated with activation of the G1 phase of
the cell cycle. Cyclin D1 associates with cdk4 and 6 and cyclin E associates with cdk2,
all of which have been shown to be upregulated in neurons under cytotoxic stress such as
DNA damage, oxidative stress, or trophic factor deprivation [11, 14, 16, 17, 85-87]. The
cyclin D1/cdk4-6 and cyclin E/cdk2 complexes then induce phosphorylation of the
master regulator of cell cycle, Rb [88-90].
In non-cycling cells under normal conditions, Rb binds E2F and thereby inhibits
the transactivation of genes under the control of E2F.

Upon phosphorylation, Rb

becomes inactive and dissociates from E2F allowing transcriptional activation of E2Fdependent genes to occur. Thus phosphorylation of Rb promotes passage of cells through
the G1/S checkpoint allowing cell proliferation [88, 91-93].
Interestingly, expression of a mutant form of Rb which cannot be phosphorylated
protected neurons from apoptosis, suggesting that cell cycle related Rb phosphorylation
may be an important event leading to neuronal apoptosis [94, 95]. In addition to the
phosphorylation mutant of Rb, in vivo inhibitors of cyclin-dependent kinases (cdkis),
including p21, p16, and p27, have also been shown to be neuroprotective [96]. Cdk
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inhibitors function by binding to cdks and inhibiting their interaction with cyclins. Since
the coupling of cdks with partner cyclins is essential for cdk activity, the binding of cdk
inhibitors to cyclins prevents cyclin-dependent phosphorylation and inactivation of Rb.
In vitro studies utilizing cortical neurons in which apoptosis has been induced using DNA
damaging agents indicate that overexpression of cdk inhibitors, including p16 and p21,
can protect neurons from imminent apoptosis [97].
2.4.1.1.2.

Aβ-Induced Aberrations in Rb/E2F

Apoptosis induced by Aβ treatment of neurons has also been shown to be
associated with increased cdk4 activity in vitro, as well as hyperphosphorylation and
inactivation of Rb [98, 99]. Inhibition of E2F by overexpression of a dominant negative
form of dp1, the dimerization partner of E2F, protected the cells from Aβ-induced
apoptosis, suggesting that Aβ-mediated apoptosis involves E2F activity and therefore cell
cycle activation. Similarly, preventing the phosphorylation of Rb through expression of a
constitutively active phosphorylation mutant of Rb prevents DNA damage- and axotomyinduced apoptosis in neurons [94, 95].
The evidence discussed thus far has suggested that aberrant phosphorylation of
Rb in neurons is a pathological response to Aβ toxicity and DNA damage.

The

phosphorylation of Rb, subsequent dissociation of Rb from E2F, and transcriptional
activation of E2F-regulated genes, are events associated with cell cycle progression. In
neurons, these events can lead to apoptosis, supporting the hypothesis that aberrant cell
cycle activation may be responsible for the neurodegeneration seen in AD.
This hypothesis is further supported by the observation that there are increased
levels of phosphorylated Rb in the brains of AD patients as compared to cognitively
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normal age-matched controls. In addition, the subcellular localization of Rb and E2F is
also altered in the AD brain, with hyperphosphorylated Rb found in the nucleus and E2F
in the cytoplasm. While these abnormal features were not significantly associated with
tangle-bearing neurons, they were detected in neurons surrounding Aβ plaques, these
suggest a role of Rb/E2F mediated cell cycle activation in Aβ-mediated toxicity and
therefore in AD pathogenesis [100]. Similar to transactivation of genes, E2F-dependent
de-repression of genes are also associated with induction of neuronal apoptosis. For
example, it has been shown that the trophic factor withdrawal and DNA damage-induced
apoptosis in neurons are associated with de-repression of Myb family of genes, C and BMyb [101, 102]. This suggests that the inactivation of Rb by cdks induce pro-apoptotic
genes by transactivation and de-repression, and an inhibition of inactivation of Rb could
be significant to the neuron’s survival.
Interestingly, these effects were not isolated to neuronal populations, as glia also
showed positive immunoreactivity to E2F and Rb. In addition to neuronal death, glial
death has also been shown to be involved in AD, and plaque formation is associated with
gliosis in transgenic mice expressing the Swedish mutation of APP under a thy1 promoter
(APP23). This gliosis is associated with expression of cell cycle regulatory proteins,
including cyclin D1, E and B1 as well as nuclear translocation of cdk4 [103].
The apparent involvement of cell cycle related events in the degeneration of both
neurons and glia support the hypothesis that AD is caused by mitotic defects, and that the
unwarranted cell cycle activation observed in the AD brain could strongly contribute to
cellular and neuritic loss, ultimately leading to the cortical atrophy characteristic of AD.
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2.4.1.2.

Other Forms of Cell Death in AD

2.4.1.2.1.

Necrosis

Necrosis, unlike apoptosis, is a passive process. Apoptosis is much more active,
requiring RNA and protein synthesis to progress [66]. Therefore, apoptosis is much more
energetically taxing. If a cell does not have the energetic resources to undergo apoptosis,
it may undergo necrosis. In necrosis, cells essentially swell and rupture, leaking cellular
contents into the extracellular space.

One of the most notable differences between

necrosis and apoptosis is that while in apoptosis membrane integrity is maintained as
cells fragment into apoptotic bodies, during necrosis membrane integrity is lost.
Therefore, while apoptosis does not induce an inflammatory response, in necrosis
inflammation is induced due to cell lysis and spilling of cellular contents [66].
Morphological changes associated with necrosis include cellular edema,
mitochondrial swelling, and breakdown of the nuclei. Chromatin aggregates, but does
not condense into regular and definable structures – the condensed chromatin is more
poorly defined [104]. The major difference between apoptosis and necrosis is the state of
the membrane and the nature of the DNA fragmentation. Similar to apoptosis, DNA
fragmentation also occurs during necrosis, however, the degradation is more random.
The random cleavages characteristic of necrosis appears as a smear by electrophoresis,
unlike the laddering pattern observed from apoptotic cells [61, 66].
Necrosis occurs when cells are exposed to extreme stress such that they are no
longer capable of maintaining their integrity. Examples of necrotic conditions include
extreme hypoxia, high temperatures, contact with toxic compounds, and mechanical
strain [105]. Necrosis is typically thought of as a chaotic process without a defined and
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predictable mechanism, but some specific biochemical pathways can play major roles in
necrotic cell death. Unlike in apoptosis, which utilizes a pathway specific for execution
of the apoptotic process, the biochemistry of necrosis involves cellular pathways involved
in other cell functions, not necessarily performing aberrantly.

For example, during

excitotoxic stress such as that seen in stroke, calcium channels open and allow calcium to
enter the cell. This response to an excitatory signal is the normal function of these
channels, however in the presence of too much excitatory stimulus (e.g. glutamate), too
much calcium enters the cell and leads to calcium overload. The membrane potential is
perturbed; both Na+ and Ca++ enter the cell, and the cell swells. Calcium homeostasis is
disrupted and may result in mobilization of the Ca++ stores of the endoplasmic
reticulum, further contributing to the overload of intracellular calcium and ultimately
leading to necrotic cell death [105]. In addition to disruption of calcium homeostasis,
magnesium and zinc dysregulation can also lead to necrotic cell death, as can
perturbations in the intracellular pH.
Because membranes break down during necrosis, cellular contents are released.
This is often measured by release of lactate dehydrogenase (LDH).

However,

morphological degeneration of cells after Aβ treatment is not temporally associated with
LDH release.

This suggests that membranes remain intact as cells die due to Aβ

exposure, supporting the argument that in AD cells die from apoptosis rather than
necrosis, at least in in vitro systems [61].

However, even some of the strongest

proponents of apoptosis as the primary cause of cell death in AD have observed and
reported necrotic cell death under certain conditions in neuronal cell culture, suggesting
that neurons may be susceptible to death via either pathway. More specifically, it appears
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that in culture conditions with lower levels of glucose (5 mM), cells are susceptible to
necrosis, whereas in cultures with higher levels of glucose (25 mM) cells are susceptible
to death via apoptosis [61].
Morphological evidence of necrosis is apparent in the AD brain. In addition to
DNA fragmentation, which occurs in both apoptosis and necrosis, mitochondrial swelling
is observed in the AD brain. Similarly, chromatin forms aggregates but does not form
well-defined, electron-dense structures as is the case in apoptotic cell death [104].
Furthermore, neuroinflammation is a well-established component of AD pathology.
Death by necrosis could be a contributing factor to this neuroinflammation, whereas
apoptotic cell death would not.
2.4.1.2.2.

Autophagy

In apoptosis, cells die via a well-defined mechanism purposefully designed for
cellular death. In necrosis, we see cellular functions operating in their normal capacities,
though the stresses placed on the cell exceed the cell’s ability to maintain homeostatic
function, ultimately resulting in death. Autophagy is an independent mechanism whose
normal function is to remove and turnover cellular components using the endosomallysosomal system, yet may contribute to an alternative form of programmed cell death.
Autophagy, unlike apoptosis, does not work exclusively within the realm of cell death –
this turnover is a normal physiological process. Lysosomal degradation is important to
remove proteins from the system that are no longer required. Autophagy is involved in
the cellular response to nutrient deprivation, allowing cells to recycle nutrients when an
extracellular source is not available. In addition, autophagy may be important for the
regulation of cellular metabolism, morphogenesis, differentiation, and cellular defense
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[58]. Importantly, autophagy is responsible for the removal of accumulated neurotoxic
aggregates, damaged organelles and membranes, as well as cellular inclusions.
Autophagy is therefore an important tool in the maintenance of homeostasis. While
autophagy is a major contributor to cell survival, in conditions of excess stress or
activation of this system can lead to autophagic cell death.
The basic mechanism of autophagy begins with the sequestration of materials to
be removed in the autophagosome, which fuses with the lysosome to form an autophagic
vacuole. The normal, unstressed cell will typically show only basal levels of autophagy.
This level is upregulated in order to replenish the pool of available amino acids and
glucose to allow for protein synthesis in the absence of growth factors. Additionally,
activation may occur if major organization to the cellular architecture is required [58].
The contribution of autophagy to cell death is not as well understood and is
somewhat controversial. Autophagy may contribute to cell death either upstream of
caspase activation or perhaps independent of caspase activation.

The major

morphological evidence of autophagy is the formation of autophagosomes and
autophagic vacuoles, microvilli on the cell surface, and chromatin condensation [58].
In AD there seems to be extensive dysfunction of the lysosomal system, and
autophagosomes are evident within dystrophic neurites, though they are not observed in
axons and dendrites [59]. These vacuoles progressively accumulate, which may be
reflective of impairment of the lysosomal system and failure of the autophagosomes to
fuse with lysosomes. Importantly, both APP and the secretases can be found in the
autophagosome, which may result in the autophagosome being the major intracellular
pool of Aβ peptide and potentially contributing to plaque formation [59, 106].
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Interestingly, PS1, one of the subunits of the γ-secretase complex, is enriched in the
autophagosome. Mutation of PS1 in familial AD leads to lysosomal pathology and cell
loss, suggesting that PS1 may be directly involved in the autophagy pathway [59].
2.4.1.3.

Comments on Cell Death in AD

One thing to consider is that, although we define these different death pathways as
distinct pathways, the boundaries between forms of cell death are not clear; there is likely
significant crosstalk between systems, making our delineation of specific pathways
somewhat arbitrary [107]. Necrosis and apoptosis, for example, have long been thought
of as dichotomous. However, it is plausible that a cell could initiate apoptosis and be
unable to complete it, and die via necrosis or some other cell death pathway.
Similarly, we typically categorize neurodevelopment and neurodegeneration at
opposite sides of a spectrum. While this categorization is not surprising – one occurs at
the beginning, the other the end – it is also somewhat arbitrary and potentially incorrect.
In neurodevelopment, an estimated fifty percent of neurons die during the pruning
process as the young brain takes its final adult shape. The cells that are eliminated are
those that fail to form stable synaptic connections with other cells and do not receive
trophic support. In neurodegenerative diseases like AD, there is synaptic degeneration
and a loss of trophic support. In the case of the developing brain, the synapses and
support never existed, in the diseased brain they no longer exist. Regardless of the
history behind the circumstances, the neuron’s response is the same – the cell dies.
In the case of the developing nervous system, the young cell is likely quite
capable of successfully and efficiently committing suicide. The aged cell, however, may
be less well equipped, plagued with chaperone, lysosomal, and metabolic stress, and
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unable to efficiently complete the energetically taxing process of apoptosis. The cell
death observed in AD is, therefore, prolonged, perhaps to the point that apoptosis is
aborted, a phenomenon sometime referred to as abortosis.
Aborted apoptosis may be consistent with the observation that although DNA
fragmentation is observed in the AD brain, other features of apoptosis, including
chromatin condensation, cell shrinkage, and nuclear fragmentation, are not typically seen.
Although apoptosis is initiated and parts of the process are completed, others are not.
Interestingly, the act of cell shrinkage and nuclear fragmentation requires large structural
changes that would require a dynamic and functional cytoskeletal system. Evidence of
microtubule dysfunction is also present in the AD brain [29, 108-110], which may impair
the cell’s ability to complete the apoptotic process. In addition, the cytoarchitecture of a
mature neuron is more complex than that of an immature neuron, and may have been
maintained that way for decades. The breakdown of such a stable and complex
architecture may not be possible with an impaired microtubule regulatory system.
It is interesting to note that the cognitive deficits observed in AD need not be
caused by loss of neurons. Loss of synaptic connectivity would be sufficient to result in
cognitive impairments. It is widely accepted that Aβ can induce the formation of
abnormalities in the neurites (axons, dendrites, etc) of neurons and result in the
degeneration of these neurites. This would disrupt brain circuits in the vicinity of the
plaques, which can often be observed in the hippocampus and cortex, thereby resulting in
the dementia observed in AD patients.
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2.5. Closing Remarks
In this chapter, we have discussed the correlation between amyloid plaque load,
tau pathology, and cognitive function. While amyloid is thought to be central to the
disease process in AD, it is tau pathology, not amyloid pathology, that correlates more
closely with cognitive dysfunction. This can be explained by the presence of small
oligomers of Aβ. While amyloid plaque pathology is poorly correlated with cognitive
dysfunction, the concentration of soluble forms of Aβ correlates more closely.
Tau pathology follows a predictable course through the brain that is so consistent
it is commonly used to stage pathology.

Neurofibrillary tangles form first in the

entorhinal cortex, then progress into the hippocampus and ultimately into the neocortex.
Here, we present the hypothesis that, if Aβ is upstream of tau pathology and tau
pathology follows this predictable course through the brain, Aβ production may also
propogate through the brain in an anatomical fashion.
Finally, we present two broad cellular processes induced in cells when exposed to
Aβ, apoptosis and cell cycle activation. As we will discuss in subsequent chapters, both
of these processes could contribute to alterations in processing of the amyloid precursor
protein. APP has been previously shown to be directly cleaved by caspases, though the
contribution to amyloidogenesis is not entirely clear. Further, phosphorylation of APP
occurs in a cell-cycle dependent manner, though whether cell cycle activation results in
changes in APP proteolysis is also not clear. In the chapters that follow, we will also
present a series of experiments designed to characterize the proteolysis of APP during
apoptosis and cell cycle activation.
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CHAPTER 3: CLASSICAL PROCESSING OF APP DURING P53-DEPENDENT
APOPTOSIS 1

3.1. Chapter Synopsis
In the preceding chapters we have discussed the pathological hallmarks of AD
including amyloid plaques, neurofibrillary tangles, and cell death, as well as discussed
some of the prevailing hypotheses of AD, including the amyloid cascade hypothesis, the
anatomical cascade hypothesis, and the cell cycle hypothesis of AD. We have reviewed
the literature regarding evidence of both cell cycle activation and various forms of cell
death in AD, including apoptosis.
We have also presented a hypothesis that describes an intersection of the three
hypotheses mentioned above. We predict that, given the observation that tau pathology
progresses in a predictable pattern through the brain, and that Aβ can elicit cell cycle
activation and, consequently, phosphorylation of tau at epitopes associated with both
mitosis and AD, Aβ may also progress in a similar pattern. Further, we hypothesize that
p53-induced apoptosis and/or cell cycle activation may provide a mechanism for this
progression.
In the current chapter, we first review the mechanism behind p53-dependent
apoptosis, and present our model concerning changes in APP processing during p53dependent apoptosis. We then present our findings concerning the processing of APP
1

Portions of this chapter have been previously published (Fiorelli et al., 2013) and are utilized
with the permission of the publisher. See Appendices B and C.
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during p53-depedent apoptosis, and discuss the relevance of these findings for AD
pathogenesis in the context of our hypothesis.
3.2. P53-Dependent Apoptosis
As described in section 2.4.1.1 in chapter 2, Aβ is capable of inducing activation
of p53 and p53-dependent apoptosis. In this section, we will describe the function of p53
and its role in apoptosis.
3.2.1. Function of P53
P53 was initially identified as an oncogene, due in part to the fact that it tends to
be overexpressed in many different tumor-derived cell lines. Later, however, it was
shown that the oncogenic potential of p53 actually derives from mutation of the gene,
typically within its DNA-binding region, and often exerting dominant-negative effects on
wild-type p53 [1]. In fact, wild-type p53 acts as a potent tumor suppressor due to its role
both in allowing DNA repair and in initiating apoptosis in cells in which DNA damage is
irreparable [1].
P53 performs these two important functions through its activity as a transcription
factor. P53 transcriptionally regulates genes involved in cell cycle arrest and apoptotic
cell death. The levels of p53 under normal conditions are quite low, but when cells are
under stress from DNA damage, oxidative stress, or other cellular stressors p53 is posttranslationally modified by phosphorylation and/or acetylation.

This stabilizes the

protein and allows it to accumulate in the nucleus [1]. If p53 levels in the nucleus are
sufficiently elevated, transactivation of pro-apoptotic genes can occur.
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3.2.2. Mechanism of P53-Dependent Apoptosis Induction
P53 transcriptionally regulates many proapoptotic genes, including Bax. Bax can
form heterodimers with other pro-apoptotic members of the bcl-2 family of proteins,
which interact with the mitochondrial voltage-dependent anion channel (VDAC), leading
to a loss of membrane potential across the mitochondrial membrane.

A loss of

mitochondrial membrane potential leads to the release of cytochrome c from the
mitochondria, an important step in the induction of apoptosis [2]. Cytochrome c, once in
the cytoplasm, can bind to Apaf-1 [2], leading to the formation of a multi-subunit protein
complex referred to as the apoptosome [3]. Caspase-9 is recruited to the apoptosome
complex, resulting in the activation of caspase-9 – an initiator caspase. Caspase-9 can
then cleave and activate other downstream caspases.
3.2.3. Downstream Effectors of Apoptosis
Following initiation of apoptosis through cytochrome c release, assembly of the
apoptosome, and activation of caspase-9, an initiator caspase, occurs. Caspase-9 can then
cleave and activate caspase-3 and caspase-7, executioner caspases, which act on cellular
targets and execute the apoptotic process. Executioner caspases cleave a variety of
intracellular targets, including nuclear lamins, poly-(ADP ribose) polymerase (PARP),
and inhibitor of caspase-activated DNase (ICAD).
Nuclear lamins are the proteins that form the structural framework for the nucleus
and are essential for proper function of the nucleus. Nuclear lamins are known to
associate with chromatin, specifically interacting with the tail domains of core histones
[4]. Thus, nuclear lamins provide the nucleoplasmic scaffold for organizing chromatin in
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the nucleus [5]. Degradation of nuclear lamins by caspases results in the breakdown of
the nuclear architecture, leading to nuclear fragmentation characteristic of apoptosis.
PARP is another nuclear protein involved in DNA repair. Its major function is to
detect single-strand DNA breaks, binding to DNA at the site of breakage and
synthesizing a poly (ADP-ribose) chain at the site. This chain acts as a signal for the
enzymatic machinery involved in DNA repair [6]. During apoptosis, however, PARP is
cleaved by executioner caspases, leading to its inactivation [7]. Through this elegant
system, DNA repair, an energetically costly endeavor, is halted when DNA damage is
very extensive, allowing caspase-dependent degradation of chromosomal DNA to
proceed without untoward investment in DNA repair.
ICAD functions as a chaperone for caspase-activated DNase (CAD), binding to
CAD during transcription and complexing with CAD after transcription is complete.
Upon cleavage by executioner caspases, however, ICAD dissociates from CAD, allowing
CAD to enter the nucleus and resulting in the degradation of chromosomal DNA [8],
perpetuating the process of p53-dependent apoptosis.
3.3. Intrinsic vs. Extrinsic Apoptosis
It is important to note that DNA damage and activation of p53 is not the only way
in which apoptosis can be induced. The induction of apoptosis involving cytochrome c
release from the mitochondria, assembly of the apoptosome, and activation of initiator
caspase-9 is referred to as intrinsic apoptosis.

Apoptosis can also be initiated via

extrinsic, receptor-based pathways. This involves the binding of a death ligand to a death
receptor. A common example of this is the binding of Fas Ligand (FasL) to the death
receptor Fas. This results in the formation of a complex that, like the apoptosome,
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recruits other proteins, including an initiator caspase. This complex is referred to as the
death-inducing signaling complex, and assembly of this complex results in the activation
of caspase-8, an initiator caspase that, like caspase-9, can proceed to activate executioner
caspases, resulting in degradation of cellular targets and “execution” of apoptosis as
described in section 1.2.3.
3.4. Modeling P53-Dependent Apoptosis with Camptothecin
As described at the end of chapter 2, we hypothesize that Aβ production may
propogate through the brain in a feed-forward manner, and we focus our investigation on
cellular processes which are both induced by and have the potential to result in
production of Aβ. For our investigations regarding apoptosis we chose to focus on p53dependent apoptosis since, as described in section 2.4.1.1., Aβ-mediated apoptosis
appears to involve p53-dependent mechanisms.
3.4.1. Mechanism of Action of Camptothecin
In order to model p53-dependent apoptosis in vitro, we used the DNA-damaging
agent camptothecin (CPT). CPT is a topoisomerase-I inhibitor, which stabilizes the
interaction of topoisomerase-I with DNA, specifically inhibiting the religation of DNA
by topoisomerase. During DNA synthesis, the stabilization of topoisomerase-1 on the
DNA results in the collision of the advancing replication fork with the
topoisomerase/DNA complex.

Since the DNA has already been nicked by

topoisomerase, synthesis stops as the replication forks reaches the broken DNA,
essentially resulting in double-strand DNA breaks [9]. The extensive DNA damage
resulting from CPT-induced topoisomerase-I inhibition leads to p53-dependent apoptosis.
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Because this damage occurs during DNA synthesis, CPT-induced apoptosis occurs as the
cells attempt to progress through S-phase.
In addition to induction of double strand breaks in DNA, RNA synthesis is also
halted by a similar mechanism. The transcriptional machinery can also collide with the
stabilized topoisomerase/DNA complex, resulting in a halting of transcriptional function
and single-stranded DNA breaks.
3.4.2. H4-APP Cells
In the studies described here, we utilized H4 neuroglioma cells overexpressing
human wild-type APP (H4-APP cells). These cells were obtained as a kind gift from Dr.
Todd Golde from the Mayo Clinic in Jacksonville, FL. Generation of this cell line has
been previously described [10]. Briefly, H4 cells, neuroglioma cells from the brain of a
37 year old Caucasian male (ATCC HTB-148), were grown to 70% confluency in 6-well
plates and tranfected with 1 µg plasmid DNA containing the human wild-type APP gene
preincubated with 3 µL FuGene 6 transfection reagent in serum-free OptiMEM. Cells
were selected for 10-14 days using 800 µg/mL Hygromycin B in OptiMEM with 10%
fetal bovine serum. After initial selection, the concentration of Hygromycin B was
reduced to 200 µg/mL [10]. Once received in our laboratory, cells were maintained in
OptiMEM containing 10% fetal bovine serum, 200 µg/mL Hygromycin B, 100 U/mL
Penicillin and 100 µg/mL Streptomycin.
3.4.3. Induction of Apoptosis in H4-APP Cells
Since CPT, as discussed above, is most efficient at inducing apoptosis in S-phase,
in order to achieve a homogeneous population of apoptotic cells we synchronized cells by
serum starvation for 48 hours in DMEM containing 100 U/mL Penicillin and 100 µg/mL
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Streptomycin.

After serum starvation, cells were serum stimulated and treated

simultaneously with 10 µM CPT and analyzed as they progressed into apoptosis.
3.4.3.1.

Morphological Characteristics of Apoptosis

As shown in Figure 3.1, treatment of cells for three to six hours with 10 µM CPT
results in morphological changes indicative of apoptosis. These include detachment from
the plate, cell shrinkage, and membrane blebbing.

The cells also show DNA

fragmentation (data not shown). Our initial morphological observation of CPT-treated
cells indicate that apoptosis is evident at three hours post treatment, with significant
apoptosis evident at six hours.
3.4.3.2.

Quantification of Apoptosis with Propidium Iodide

In order to quantify the number of cells undergoing apoptosis, cells were
harvested at each time point and fixed in 70% ethanol. Following fixation, cells were
washed and resuspended in PBS containing 5 μg/mL propidium iodide, 0.1% Triton X100, and RNaseA in PBS and incubated at room temperature for 45 minutes. Cells were
then analyzed using a BD LSR II flow cytometer. 2 Results were modeled for cell cycle
progression and apoptosis using ModFit LT.
Propidium iodide stains nucleic acid and is often used to characterize the cell
cycle profile of a population of cells. Normal diploid cells in G1 phase will have a given
DNA content, while cells that have replicated their DNA and are in G2/M phase of cell
cycle will have twice that amount, and cells in the process of replicating their DNA, those
in S-phase, will have DNA content that falls somewhere between these two peaks (Figure

2

These experiments were performed with the kind help of Karoly Szekeres of the USF Health
Morsani College of Medicine Flow Cytometry Core.
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Figure 3.1. CPT induces apoptosis in H4-APP neuroglioma cells . (A) H4-APP cells
were exposed to 10 μM CPT for zero to six hours and examined using brightfield
microscopy. Morphological changes indicative of apoptosis, including cell detachment
and shrinkage, were noted after three hours of treatment and were most pronounced at
six hours.
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3.2A). Apoptotic cells, however, which are undergoing fragmentation of the DNA,
appear as a sub-G1 peak (Figure 3.2B).
The percentage of cells in each phase of the cell cycle and in apoptosis can be
modeled by software, such as ModFit LT or FloJo, that applies these characteristics to
map a series of functions, one for each phase and one for apoptosis, which overly the
curve described by plotting the number of cells against the amount of propidium iodide
staining detected. This modeling software then integrates these functions, allowing us to
determine the relative number of cells that fall within each peak.
When this modeling algorithm is applied to the data for cells treated with CPT we
find that, with regard to the cell cycle profile, there is a significant increase in the cells in
S-phase after six hours of treatment (Figure 3.2C). This is consistent with the mechanism
of action of CPT, as described in section 3.4.1. Given that CPT is most effective during
S-phase, the accumulation of cells in S phase is indicative of an inhibition of progression
through this phase of the cell cycle. With regard to apoptosis, there is a significant
induction of apoptosis in cells treated with CPT after three hours, reaching a maximum
degree of cell death after six hours, with 80% of cells in apoptosis. This suggests that
CPT effectively induces apoptosis in our cellular system.
3.4.3.3.

Biochemical Characteristics of Apoptosis

P53-dependent apoptosis, as described in section 3.2, involves a dramatic increase
in the levels of P53 in the nucleus, followed by sequential activation of caspasedependent cleavage of cellular targets including PARP. In order to verify that apoptosis
was actually occurring in the H4 cells, lysates were prepared in RIPA lysate buffer,
loaded on to 10-20% tricine gels, and proteins separated by polyacrylamide gel
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Figure 3.2. CPT induces apoptosis in H4-APP neuroglioma cells after three to six
hours. (A) H4-APP cells growing asynchronously in culture were fixed and DNA
stained with propidium iodide. DNA content of cells was determined by flow
cytometry. Untreated cells show a typical cell cycle profile, with a major peak at G1,
elevated through S phase, and a minor peak for the G1/M phases. (B) Cells treated
with CPT for 6 hours prior to collection show a sub-G1 population indicative of
apoptosis. (C) The cell cycle profile of cells treated with 10 µM CPT for 0.5-12 hours
indicates that at the six hour and 12 hour time points, time points associated with
extensive apoptosis, cells accumulate in S-phase (asterisks indicates significant
difference from untreated, p<0.001). (D) Quantification of the number of cells
undergoing apoptosis with CPT treatment shows that apoptosis is significantly induced
with a three hour CPT treatment, and six hour treatment results in approximately 80%
of cells in apoptosis.
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electrophoresis (PAGE). Protein in gels were transferred to 0.2 µm nitrocellulose and
immunobloted for P53 and PARP. As shown in Figure 3.3A, p53 was significantly
induced after treatment with CPT for three to six hours – the same time frame which
identified apoptosis by both morphological assessment of cells in culture (Figure 3.1) and
by propidium iodide staining and flow cytometry (Figure 3.2). The induction of P53 by
CPT is quantified in Figure 3.3B.

Further, PARP is also cleaved at these time points,

suggesting activation of executioner caspases.
Taken together, the results presented here suggest that CPT effectively induces
P53-dependent apoptosis in H4-APP cells after three to six hours of treatment.
Therefore, further experiments investigating the effects of P53-dependent apoptosis were
performed using 10 µM CPT for three to six hours.
3.5. Processing of APP During P53-Dependent Apoptosis
The goal of this set of experiments is to determine whether P53-dependent
apoptosis has an effect on processing of APP.

As described in section 1.7, Aβ is

generated from sequential cleavage of APP by β-secretase and γ-secretase. Jin el al have
described an increase in γ-secretase activity with P53-dependent apoptosis [11]. Here
they treated CHO cells overexpressing the C99 fragment of APP with CPT and showed a
dose-dependent increase in γ-secretase activity as determined by a luciferase-based assay.
Further, as γ-secretase activity increased, C99 levels decreased, suggesting that the γsecretase activity may be resulting in the cleavage of C99 to generate Aβ, though the
generation of Aβ was not assessed in this model [11]. In a separate model in which both
human APP with the Swedish mutation (APP(KM670/671NL) and β-secretase is
overexpressed, the CPT-dependent increase in γ-secretase activity did result in an
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Figure 3.3. P53 induction and PARP cleavage in H4-APP cells treated with CPT for
three to six hours. (A) Representative blot from three independent experiments
performed to determine the levels of p53 and PARP upon treatment with 10 µM CPT
for zero to six hours. CPT-induced apoptosis is associated with a time-dependent
induction in p53 (A, top panel) and cleavage of PARP (A, middle panel). Reprobe of
p53 blot with an antibody against β-actin shows equal protein loading (A, bottom
panel). (B) Quantification of p53 blot shows a significant induction after one hour,
p<0.001. Post hoc analysis reveals that each group is significantly different from all
other groups.
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increase in Aβ generation [11]. The authors did not, however, assess whether β-secretase
or α-secretase activity were altered with CPT treatment.
It is also worth noting that while this work was being performed in our laboratory,
another group reported that p53 is capable of regulating the expression of APP in
neuroblastoma cells and primary neuronal cultures [12]. This seems to be mediated by a
p53-dependent reduction in the binding of Sp1 to the APP promoter. When p53 is
overexpressed or cells are treated with CPT, the binding of Sp1 to the APP promoter is
suppressed and APP expression is reduced.
3.5.1. Assessing α- and β-Secretase Activity
Although the activity of γ-secretase is known to increase during p53-dependent
apoptosis, the α- and β-secretase cleavage steps are the rate limiting enzymatic steps in
APP proteolysis, and also the steps that dictate amyloidogenic vs. non-amyloidogenic
processing.

Therefore, we decided to assess the activity of α- and β-secretase to

determine whether APP processing is indeed shifted toward amyloidogenesis in our
model.
3.5.1.1.

FRET-Based Assays

In order to assess the relative activities of α- and β-secretase, we first attempted to
utilize commercially available fluorescence resonance energy transfer (FRET)-based
assays. A schematic depicting these assays is shown in Figure 3.4. In these assays, the
portion of the APP peptide cleaved by the enzyme of interest is conjugated to 5-(2′aminoethyl) aminonapthalene-1-sulfonic acid (EDANS) and 4-(4′-dimethylaminophenylazo) benzoic acid (DABCYL). The EDANS moiety has an excitation wavelength
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Figure 3.4. Assessing β-secretase activity using an EDANS/DABCYL reporter system.
Peptide fragments representing the portion of APP cleaved by β-secretase are
conjugated to EDANS and DABCYL molecules. If the peptide is not cleaved,
DABCYL efficiently absorbs fluorescent emissions from EDANS, quenching the
signal. However, when the peptide is cleaved EDANS is physically separated from
DABCYL, allowing a fluorescent signal to be emitted. This signal is proportionate to
the amount of substrate cleaved.
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of 336 nm and emits at a wavelength of 490 nm. This acts as a fluorescence donor for the
DABCYL moiety, which absorbs light at the same wavelength, effectively quenching
fluorescence from the EDANS moiety. When the substrate is cleaved by the secretase,
however, the EDANS and DABCYL moiety are physically separated from one another
and the DABCYL moiety can no longer quench the light emitted by the EDANS moiety.
The 490 nm light emitted by EDANS can be measured using a plate reader capable of
exciting at around 336 nm and reading fluorescent light at around 490 nm. The amount
of fluorescence measured is directly proportional to the amount of substrate cleaved by
the secretases in the assays.
3.5.1.2.

Utility of FRET-Based Assays with Camptothecin

Cells were treated with various concentrations of CPT for 24 hours and lysates
prepared in the provided buffer according to the manufacturer’s instructions (R&D
Systems catalog number FP003), Lysates were combined with substrate in a black-96well plate and read on a BioTek plate reader using an excitation wavelength of 360 nm
and reading at a wavelength of 460 nm. The apparent β-secretase activity observed in
this assay increases in a dose-responsive manner as shown in Figure 3.5A. When cells
are treated with 10 µM CPT for 0-24 hours, an interesting pattern is observed. Cells
which are not treated with CPT (the 0 hour time point), show very little apparent βsecretase activity. When CPT was added the maximal detection of apparent β-secretase
activity occurred during the earliest time points, with intensity of the signal slowly fading
over time (Figure 3.5B)
It is worth noting that the data depicted in Figure 3.5 are presented as a fold
change over background. In calculating this change, a ratio is taken between the sample
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Figure 3.5. Apparent β-secretase activity increases with exposure to CPT. (A)
Exposure to increasing concentrations of CPT for 24 hours is associated with an
apparent dose-dependent increase in β-secretase activity as measured by a
commercially available FRET-based assay over three independent experiments.
Asterisk indicates significant difference from untreated controls, p<0.01. (B)
Exposure to 10 μM CPT for 0-24 hours is associated with an increase in apparent βsecretase activity at all time points where CPT is present.
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of interest and the basal fluorescence present in a sample in which there is no substrate
and only lysate is present. For the dose response, the background sample utilized did not
contain CPT, while in the time course the background sample did contain CPT. Note that
there is a 10-fold difference in the scale of the axis between Figure 3.5A and 3.5B. In
Figure 3.5B the untreated sample, which did not contain CPT, shows a reduction in the
the apparent β-secretase activity as compared to a sample containing CPT but no
substrate whatsoever, thereby yielding a fold change over background of less than one.
This concerned us, as it suggested that the signal detected in the assay was not fully
dependent on the presence of the substrate, though it did seem that, based on the dose
response, the signal was dependent on the presence of CPT.
A review of the literature on the CPT molecule revealed that CPT is actually
fluorescent, with an excitation wavelength of approximately 370 nm and an emission
wavelength of approximately 470 nm [13]. The excitation and emission wavelengths of
EDANS, the reporter in this assay, are 336 nm and 490 nm, respectively, and the plate
reader used in this assay used an excitation wavelength of 340 nm and read emitted light
at 460 nm. Due to the significant overlap between the spectra of EDANS and the spectra
of CPT, we conclude that this particular assay is incompatible with the use of CPT.
3.5.1.3.

γ-Secretase Inhibition

The finding that these secretase assays are unsuitable for determining CPTdependent changes in secretase activity forced us to find alternative ways to measure αand β-secretase activity. Given that (1) our goal was specifically to assess the relative
activity of α- and β-secretase with APP as a substrate, (2) α- and β-secretase are the rate
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Figure 3.6. C99 and C83 accumulate with γ-secretase inhibition by Compound E.
Treatment with various concentrations of Compound E for 24 hours results in the
accumulation of C-terminal fragments due to γ-secretase inhibition as detected by
western blot. Using a Licor Odyssey Infrared Imager, we are able to double-label the
same protein at two epitopes. In the top and bottom panels, the C-terminus of APP is
labeled with a secondary antibody emitting light at a wavelength of 700 nm (red),
while Aβ1-16 (the 6E10 epitope) is labeled using a secondary antibody emitting light at
800 nm (green). Bands representing fragments that contain both the C-terminus and
the 6E10 epitope (full length APP in the top panel and C99 in the bottom panel) appear
as yellow-orange. A reprobe of the same blots with actin was also performed, and is
shown in green in the middle panel.
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limiting enzymatic steps in their respective proteolytic pathways, and (3) the activity of γsecretase during CPT-induced p53-dependent apoptosis had been previously assessed, we
decided to utilize γ-secretase inhibition to prevent the turnover of C83 and C99 to p3 and
Aβ (respectively) and AICD. This would allow us to isolate the production of C83 and
C99 in order to determine relative α- and β-secretase activity. In order to inhibit γsecretase we used the potent, non-competitive γ-secretase inhibitor Compound E [14],
which at a concentration of 1 nM effectively inhibited γ-secretase as evident by the
accumulation of the α- and β- cleaved fragments C83 and C99 shown in Figure 3.6.
The lack of a dose-dependent increase in C99 and C83 levels in this experiment
suggests that concentrations lower than 1 nM may indeed be sufficient to inhibit γsecretase in our model. It should be noted that concentrations of Compound E used in the
literature range from 30 nM to 300 nM [14-16], though the IC50 of Compound E reported
in the literature is 7 nM [17]. In spite of the lack of a dose response, we decided to use a
concentration of 1 nM for further experimentation based on the fact that this
concentration was below the reported IC50 for the compound, suggesting that it was
within a range where we would not expect excessive off-target effects.
3.5.1.4.

Visualization of C-Terminal APP Fragments During P53-

Dependent Apoptosis
In order to assess CPT-dependent changes in APP processing, we treated cell with
1 nM Compound E for 24 hours, then treated with 10 µM CPT for 30 minutes to three
hours or cells were left untreated. Cell lysates were then analyzed by western blot for
APP and its proteolytic fragments using antibodies against the Aβ-region (6E10) (FLAPP), the C-terminus of APP (C83 and C99), and β-actin (Actin). A representative blot
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Figure 3.7. C99 generation is reduced and C83 production maintained with CPT
treatment in the presence of Compound E. (A) Treatment with 10 µM CPT for zero
to three hours in the presence of Compound E leads to a decrease in full length APP,
decreased levels of C99, and maintained levels of C83 in CPT treated cells as
detected by western blot, with actin shown as a protein loading control. (B)
Quantification of FL-APP detected after treatment with Compound E for 24 hours
and CPT for 0-3 hours. Analysis by two way ANOVA revealed a significant effect
of CPT treatment, with treated cells showing lower levels of FL-APP than untreated
controls, F(1,29)=4.51,p=0.046. Histogram shows the mean of three independent
experiments, ± SEM. (C) Quantification of the ratio of C99 to FL-APP after
treatment with compound E and CPT. No significant effect of treatment is observed.
(D) Quantification of the ratio of C83 to FL-APP after treatment with compound E
and CPT. A significant effect of treatment over time was observed as determined by
two way ANOVA, F(4,29)=8.32, p=0.007, with the ratio of C83 to FL-APP
increasing over time in CPT. Both histograms show the mean of three independent
experiments, ± SEM.
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shown in Figure 3.7A. As expected, based on the literature indicating a decrease in the
expression of APP during P53-dependent apoptosis [12], quantification of the levels of
FL APP across three independent experiments showed a significant decrease in the levels
of APP with CPT treatment (Figure 3.7B). Since APP expression is known to decrease
and a decrease in FL-APP was observed in our model, we took the ratio of the C-terminal
fragments to FL-APP. This provides us with some indication of secretase activity –
maintained secretase activity would be indicated by a reduction in C-terminal fragment
levels that paralleled the levels of FL-APP, leading to no change in the ratio of Cterminal fragment to APP. Indeed, this is exactly the pattern observed for C99 (Figure
3.7A and C). C83, on the other hand, is maintained in spite of decreasing availability of
the substrate (Figure 3.7A and D), potentially indicating an increase in the activity of αsecretase in spite of a decrease in the levels of FL-APP. This upregulation of α-secretase
activity may be a compensatory mechanism, allowing the production of sAPPα to be
maintained in spite of decreasing APP, suggesting an important role of sAPPα in cellular
function.
3.5.1.5.

Secretase Levels and Localization During P53-Dependent

Apoptosis
In order to assess the levels and localization of α-, β-, and γ-secretases, we
performed immunostaining for ADAM-10, BACE, and PS1. BACE was localized to the
cell membrane as well as intracellular compartments morphologically consistent with the
golgi apparatus. PS1 was heavily colocalized with BACE in these same compartments in
both treated and untreated cells. Immunostaining for both BACE and PS1 showed no
significant change in the levels or localization of either protein (Figure 3.8A).
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Figure 3.8. Immunocytochemistry of H4-APP cells with and without CPT treatment.
Cells treated with 10 µM CPT and untreated controls were co-stained with BACE
(green) and PS1 (red) antibodies, using Alexa Fluor 488 and 594 as secondary
antibodies, respectively. No significant changes in levels or localization of BACE or
PS1 were observed. (B) ADAM-10 levels and localization were also assessed, and
there appeared to be an induction in the diffuse ADAM-10 staining in CPT treated
cells. (C) Quantification of ADAM-10 staining was performed using ImageJ. Cell
perimeters as well as areas of positive staining were identified, allowing us to
determine the percentage of the area of the cell occupied by positive staining.
Quantification across all images taken reveals a significant increase in the percent
area of the cell occupied by ADAM-10, t=4.631, p<0.001.
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ADAM-10 staining was more diffuse and increased when cells were treated with CPT
(Figure 3.8B). The area of the cell occupied by ADAM-10 stain was quantified using
ImageJ, and showed a significant increase in cells treated with CPT (Figure 3.8C).
3.5.1.6.

Fragments of APP Secreted During P53-Dependent Apoptosis

Based on the observation that C83 was maintained while C99 levels were
reduced, along with immunostaining results which suggested that BACE and PS1 were
unchanged while ADAM-10 seemed to increase, it appears that during p53-dependent
apoptosis α-secretase activity is enhanced while β-secretase activity remains unchanged
as total levels of APP are reduced. We, therefore, hypothesized that Aβ levels would be
reduced during p53-dependent apoptosis, while sAPPα levels would likely remain
unchanged – both N-terminal fragments paralleling the changes observed within the Cterminal fragments.
In order to test this directly, we next measured the secretion of sAPPα and Aβ in
apoptotic and non-apoptotic cells. H4-APP cells were treated with 10 μM CPT or left
untreated and media was collected every hour for six hours. Media samples were
analyzed by western blot using 6E10 antibody to determine the levels of secreted APP
fragments. A significant reduction in the levels of sAPPα was observed in the tissue
culture supernatant from cells treated with CPT compared to the levels in media from
untreated cells (Figure 3.9A and B). This was surprising considering that C83 levels
were maintained during apoptosis under γ-secretase inhibition as described in section
3.5.1.4.

This raises the possibility that APP may be processed differently during

apoptosis, and the likelihood of this is described in chapter 4.
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Figure 3.9. CPT treatment is associated with decreased production of sAPPα and
Aβ. (A) H4-APP cells were treated with or without 10 µM CPT and tissue culture
supernatants were collected at every hour for six hours. The supernatants were
boiled with Laemmli sample buffer and analyzed by PAGE and western blot using
6E10 antibodies.(B) Quantification of data from untreated and CPT treated cells
after six hours of treatment with 10 µM CPT. (C) Tissue culture supernatant from
H4-APP cells treated with or without CPT for one to six hours was
immunoprecipitated using 6E10 antibody and western blotted using the same
antibody. CPT treatment resulted in a decrease in the levels of sAPPα as well as Aβ
in the tissue culture supernatant (representative of two independent experiments).
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We also assessed Aβ levels by immunoprecipitation and western blot analysis
using 6E10 antibody for both capture and detection. Like sAPPα, Aβ levels were reduced
in the tissue culture supernatants from CPT treated cells compared to the untreated
controls, and this reduction was visible at all the time points examined (Figure 3.9 C).
This is consistent with the observation that C99 is reduced in the lysates of cells during
p53-dependent apoptosis.
3.6. Summary of Results
In these experiments, we have shown that CPT induces apoptosis in H4-APP cells
within three to six hours and that apoptosis is p53 dependent. In our model, apoptosis is
associated with an increase in ADAM-10 levels, but no change in BACE or PS1. When
cells are treated with CPT in the presence of the γ-secretase inhibitor Compound E, we
see a decrease in the levels of C99 that parallels a decrease in the levels of full length
APP. Coupled with a decrease in the expression of full length APP previously described
[12] this suggest that β-secretase activity is unchanged. Under these same conditions,
however, we see that C83 levels are maintained in spite of decreased expression of the
APP. This is consistent with the observation that ADAM-10 is increased in cells and
suggests that α-secretase activity may be increased in cells undergoing p53-dependent
apoptosis.
Aβ secretion is decreased in cells treated with CPT, which is consistent with the
observation that full length APP and C99 levels are reduced. Secreted sAPPα, on the
other hand, is reduced during p53-dependent apoptosis in spite of maintained levels of
C83 and decreased levels of sAPPα. This may suggest that there is an alternative
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cleavage happening within the ectodomain of APP, which precludes the production of
sAPPα.
3.7. Conclusions
3.7.1. Aβ Production is Not Increased During P53-Dependent Apoptosis
While the ability of Aβ to induce apoptosis has been well established, the effects
of apoptosis on Aβ production are not yet clear. To our knowledge, only one study has
been performed in which Aβ levels were assessed during p53-dependent apoptosis. This
study was performed in HEK cells that overexpressed both APP with a Swedish mutation
and, importantly, β-secretase [11]. The use of cells of non-neuronal origin, as well as the
overexpression of β-secretase, may have contributed to higher levels of Aβ production
than would occur in more neuronal cells that do not overexpress β-secretase.
The apparent differences observed between our study and that of Jin et al may
also be related to differences in endocytosis between HEK cells and our H4 cells. One
study has identified that the effects of endocytosis inhibitors are vastly different between
HEK cells and C6 cells (a glioma cell line), suggesting perhaps that basal levels of
endocytosis, and thus basal levels of amyloidogenic processing, are inherently different
in HEK cells as compared to neuroglioma [18].
Apoptosis in neurons has been shown to be associated with caspase-3-mediated
cleavage of APP at the C-terminus [19]. This cleavage of APP generates a 31 amino acid
fragment from the C-terminus of APP, C31, which has been shown to be neurotoxic [20].
The effect of caspase cleavage on secretase processing of APP and Aβ production is not
clearly understood. Co-localization of active caspase-3 with amyloid plaques and with
caspase-cleaved APP has been observed in AD brain, which led to the hypothesis that
117

caspase activation may lead to enhanced Aβ generation and plaque formation [21, 22].
However, this correlation does not necessarily indicate that caspase cleavage of APP
increases Aβ generation, especially given that truncation of APP at the C-terminus
removes the endocytosis signal from APP and affects its internalization. If the
internalization of APP is reduced by caspase-mediated truncation, this may in fact
decrease Aβ production, as endocytosis is required for cleavage of APP via the
amyloidogenic pathway [23].
Our findings in our neuroglioma cell line that Aβ levels are not, in fact, elevated
during p53-dependent apoptosis is consistent with the observation that activation of
caspase-3 results in the removal of C31, which includes the endocytosis signal. In
chapter 4, we will present evidence that the cleavage of APP to form C31 is occurring
during CPT-induced p53 dependent apoptosis, which may contribute to the decreased
production of Aβ observed in these cells during apoptosis.
3.7.2. sAPPα is Decreased During P53-Dependent Apoptosis
In addition to a decrease in the production of Aβ, we also observed a decrease in
the production of sAPPα. Changes in sAPPα are of particular interest, as sAPPα has been
implicated in protecting neurons and synapses from apoptosis [24-26]. Our studies
suggest that changes in APP processing associated with apoptosis could lead to decreased
levels of sAPPα in the local microenvironment, making cells in that environment more
prone to degeneration.
3.7.2.1.

Role of APP and sAPPα

sAPPα is released from neurons in an activity-dependent manner and has been
shown to have neurotropic effects, promoting long-term neuron survival, as well as
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neurite outgrowth and synaptogenesis [For review, see 26]. During development, activity
dependent survival, synaptogenesis, and synapse strengthening are vital to establishing
the connectivity of the brain.

sAPPα, through its activity-dependent release and

neurotrophic and neurotropic activity, may be involved in establishing and maintaining
neural connections in an activity-dependent manner. As the popular idiom “use it or lose
it” suggests, active synapses are stable synapses, and it is these synapses that persist long
term. This may be achieved, at least in part, through the release and downstream effects
of sAPPα.
While the function of APP is not entirely clear 3 – it was discovered and named for
because it is the precursor of Aβ – it is not inconceivable that the function of APP is
closely tied to the effects of sAPPα. The structure of APP, with its large extracellular
domain, one transmembrane pass, and modest intracellular domain, suggests that the
extracellular portion, functionally, is the “business end” of the protein, with the
membrane tether and intracellular domain important for trafficking to the surface of the
cell.
A loss of sAPPα, therefore, may negatively affect synapse formation, synaptic
stability, and cell survival. Even in the absence of Aβ, a loss of sAPPα production may
contribute to memory loss and neuronal degeneration seen in AD.
3.8. Closing Remarks
In this chapter, we have assessed the effects of p53 dependent apoptosis, induced
by the topoisomerase inhibitor CPT, on H4 cells overexpressing human, wild-type APP
with regard to classical processing by secretases. We present evidence that β-secretase
3

For more information regarding endogenous functions of APP, see section 6.4.3.1.
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activity is not changed, and Aβ production is reduced, which could be due to a reduction
in the expression of APP. While we observe evidence for an increase in α-secretase
activity including increased ADAM-10 levels and maintained levels of C83 in spite of
decreased expression of APP, we actually see a decrease in the levels of the neurotrophic
sAPPα fragment.
The incongruity of the finding that C83 is maintained while sAPPα is reduced
could be explained by alternative cleavage of APP in the extracellular domain. The
secretases are only a few examples of a number of different proteases that cleave APP at
many sites along the peptide. In the next chapter, we will explore the possibility of
alternative cleavage of APP that precludes the formation of sAPPα, and present evidence
for an apoptosis-dependent cleavage of APP within the near extracellular domain.
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CHAPTER 4: ALTERNATIVE PROCESSING OF APP DURING
P53-DEPENDENT APOPTOSIS 1

4.1.Chapter Synopsis
In the previous chapter, we discussed the effect of p53-dependent apoptosis on
classical processing of APP, i.e. processing of APP by secretases.

This classical

processing is particularly important with regard to the pathogenesis of AD, as according
to the widely accepted amyloid cascade hypothesis Aβ, a proteolytic fragment of APP
generated by amyloidogenic processing pathway, is central to disease pathogenesis. Aβ
can induce phosphorylation of tau and neurodegeneration. Based on the anatomical
progression of downstream pathology through the brain, we hypothesized that the
intracellular pathways induced by Aβ exposure may help to stimulate the production of
Aβ. Evidence of p53-dependent apoptosis has been observed in the AD brain, and some
evidence for upregulation of γ-secretase activity during p53-dependent apoptosis has
been observed.
In the previous chapter, we focused on determining whether p53-dependent
apoptosis is associated with an increase in Aβ production. The literature regarding
production of Aβ during apoptosis is mixed, with some literature suggesting there is an
increase in the production of Aβ and some literature suggesting that Aβ is reduced. The
latter view is more consistent with evidence that suggests that caspase cleavage of APP at
1

Portions of this chapter have been previously published (Fiorelli et al., 2013) and are utilized
with the permission of the publisher. See Appendices B and C.

124

the C-terminus results in the removal of the endocytosis domain, as endocytosis is
required for Aβ production [2].

We find that during p53-dependent apoptosis Aβ

production is decreased, with sAPPα production decreasing as well. This decrease in the
neurotrophic fragment may be detrimental to cells in the local microenvironment, as
sAPPα is involved in cell survival and synaptic stability.
Importantly, when we assessed levels of the C-terminal fragments of APP under
γ-secretase inhibition, we saw no change in the levels of C83, the C-terminal fragment
associated with α-secretase cleavage.

This is inconsistent with the observation that

sAPPα levels are reduced, suggesting that there may be alternative cleavage of APP
occurring during p53-dependent apoptosis.
In the current chapter, we assess alternative cleavage of APP during p53dependent apoptosis. Utilizing the model system presented in chapter 2, we provide
evidence for the generation of novel proteolytic fragments approximately 25 kDa in size
and immunoreactive to antibodies against the Aβ-region and the C-terminal caspase site.
In vitro studies show the formation of one of these fragments in primary neurons, and
both of these fragments in H4 neuroglioma cells undergoing apoptosis. Inhibition of the
generation of fragments with caspase inhibitors suggests that caspase-3 and/or caspase-7
may play a role in the formation of these fragments. In vivo studies also suggest that
production of a similar fragment occurs in transgenic mice overexpressing human APP.
In addition, activation of the same proteases associated with generation of this proteolytic
fragment in vitro is seen in the vicinity of Aβ plaques in vivo. In vivo in our transgenic
animals, the C-terminus appears to be retained in the ~25 kDa fragment. Modeling of
preoteolytic processing of APP suggests that this fragmentation may involve proteolysis
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in the near extracellular domain. Our studies using small peptide inhibitors of caspases,
and shRNA to caspase-3 and caspase-7 show that the cleavage of APP during apoptosis is
more specific to caspase-7 than caspase-3. The production of these specific proteolytic
fragments, as well as the involvement of caspase-7 in the cleavage of APP, suggest a
potentially pathogenic role for this caspase in APP processing and neurodegeneration and
warrant further investigation.
4.2.Alternative Cleavage of APP
In addition to cleavage by secretases, APP can also be cleaved by a number of
different proteases, including proteases such as calpains and caspases [3-8]. In this
section, we will review the literature regarding cleavage of APP by these other proteases.
4.2.1. Cleavage of APP by Caspases
In apoptotic cells APP is known to be cleaved by caspase-3 at three distinct sites
[4, 9]. Two of these sites, DNVD*S198 and DYAD*G220, are located near the N-terminus
of APP, while a third site, VEVD*A740, is located near the C-terminus. Since the
cleavage at VEVD*A740 could be prevented with the small peptide inhibitor DEVDFMK, this cleavage has been attributed to caspase-3 [4]. Caspase-3 is known to be
upregulated in neurons of the AD brain, especially late in the disease process [10].
Cleavage at the C-terminal caspase site on APP by caspase-3 generates a 31 amino-acid
C-terminal fragment referred to as C31.
It has been shown that Aβ can induce apoptosis, involving activation of caspase3, and activation of caspase-3 can induce generation of the C31 fragment, which has been
shown to induce apoptosis [11]. Aβ treatment of N2a cells results in enhanced apoptosis
in cells that overexpress full length APP as compared to untransfected N2a cells,
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indicating that Aβ-induced neurotoxicity is mediated by APP or a proteolytic fragment
thereof. In cells in which the VEVD*A740 site has been mutated to VEVAA740 [11], or in
cells in which APP has been truncated such that the entire C31 peptide is removed,
apoptosis is not enhanced. This suggests that the C31 peptide is toxic and mediates Aβinduced cytotoxicity. C31 is known to translocate to the nucleus, which may play a role
in the induction of apoptosis, but the specific mechanism of C31-induced
neurodegeneration is not yet clear, though it seems to involve a heterodimerization of
C99 and C31 [12].
While the importance of caspase cleavage of APP at the C-terminus, thought to be
primary site of caspase cleavage on the APP protein, is beginning to be well understood,
the cleavage of APP at other sites along the entire APP protein, such as the two Nterminal sites, are not well understood.
4.2.2. Cleavage of APP by Calpain
In addition to cleavage of APP by caspases, early reports suggested that APP can
also be cleaved primarily at the N-terminus by calpain-I, resulting in the generation of an
~25 kDa N-terminal fragment of APP [5]. Calpain-I is a calcium-sensitive protease
important for normal neuronal functions.

In neurodegenerative diseases, however,

calcium homeostasis is disrupted, resulting in aberrant, pathological activation of
calpains. The excessive cleavage of calpain substrates that occurs with elevated levels of
intracellular calcium can be detrimental to normal neuronal function [13].
Given that the primary calpain-I cleavage site is within the N-terminus of APP,
calpain cleavage of APP prevents the production of full length neurotrophic sAPPα
fragment, though the region of sAPPα required for its neuroprotective effects seems to be
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located at the C-terminus of sAPPα, as the sAPPβ fragment does not show the same
neuroprotective effects.. Like the caspase sites in the N-terminus of APP, the importance
of this cleavage is not well understood.
4.2.3. Cleavage of APP by MT-MMPs
APP has also been shown to be cleaved by membrane type matrix
metalloproteases (MT-MMPs). These metalloprotease appear to be capable of cleaving
APP at multiple sites in the extracellular domain in vitro, though it is not clear if all of the
sites identified in this study are active in vivo [14]. It is, however, evident that MTMMPs do in fact cleave APP in vivo, and that this cleavage is enhanced in AD.
Fragments generated by cleavage at the α-secretase site as well as one of the sites
identified in vitro, SFGA*D626, has been isolated from the cerebral spinal fluid of patients
with AD [1, 14].
While the functional role of metalloprotease cleavage of APP is not clear, it’s
interesting to note that the fragments observed in the cerebrospinal fluid of AD patients
are generated from α-secretase cleaved APP.

In order for α-secretase to confer its

neuroprotective effects, the C-terminus of sAPPα, beyond the β-secretase site, must be
present. While sAPPα is neurotrophic, sAPPβ is 50- to 100- fold less so [15]. The
cleavage of APP by MMPs at this site would remove the C-terminus of sAPPα, largely
removing the neuroprotective potential of sAPPα. It is not clear whether these MMP
cleaved fragments are capable of providing neuroprotection in their own right.
4.3.Proteolysis of APP During P53-Dependent Apoptosis
It is evident from the literature reviewed in this chapter thus far that the
alternative proteolysis of APP by enzymes other than secretases, though known to exist,
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is vastly underappreciated and understudied. In order to more fully characterize the
proteolysis of APP during p53-dependent apoptosis, we assessed the proteolytic
fragments of APP formed after H4-APP cells, as well as primary rat neurons, were
subjected to DNA damage-induced apoptosis.
4.3.1. Proteolysis in H4-APP Cells
To assess the proteolytic processing of APP, we performed western blot analyses
of lysates from H4-APP cells treated with CPT for different time periods using 6E10 and
caspase-cleaved APP antibodies. The 6E10 antibody was raised against amino acids 1-16
of the Aβ region in APP while caspase-cleaved APP antibody was raised using a
synthetic peptide preceding the aspartic acid residue (APP739) in the C-terminal caspasecleavage site of APP, and affinity purified to specifically detect APP cleaved at this site
[4].
Western blot analysis of samples run on 10-20% Tricine gels using the 6E10
antibody showed the appearance of novel cleaved APP fragments in lysates from cells
undergoing apoptosis, but not in those from untreated samples (Figure 4.1A, top panel).
CPT treatment was associated with a decrease in full length APP (Figure 4.1A top panel
and second panel showing a lighter exposure of the full length APP). Together, these
results suggest that the 6E10-binding domain of APP is cleaved from the full length
protein during apoptosis. The blots also showed a decrease in a 6E10 reactive APP
fragment migrating approximately at 12 kDa in cells treated with APP, which we believe
corresponds to the β-secretase cleaved C-terminal fragment of APP, C99 of APP.
Reprobe of the blots with caspase-cleaved APP antibody detected two bands, one
running approximately at 78 kDa, which was not altered under apoptotic conditions, and
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Figure 4.1. CPT-induced apoptosis of H4-APP cells is associated with the formation
of novel APP fragments: (A) Lysates from H4-APP cells were separated on 10-20 %
tricine gel and western blot analysis performed using 6E10. A time-dependent increase
in the level of APP fragments is observed in the apoptotic cells. A short exposure of
the blot shows a decrease in the levels of full length APP in a time-dependent manner
in the CPT treated cells (second panel). The blot was reprobed with caspase-cleaved
APP antibody, showing a time-dependent increase in the cleaved fragments in
apoptotic cells (third panel). The lower panel shows the reprobe of the blot with an
antibody against β-actin to show protein loading. (B) Lysates from H4-APP cells
treated with CPT for one, three, and six hours were separated on a 15 % Tris-Glycine
gel and analyzed by western blot using 6E10 and caspase-cleaved APP antibodies.
6E10 antibody shows the appearance of the cleaved fragment (second panel) of APP
with a concomitant decrease in the levels of full length APP after CPT treatment (top
panel). Caspase-cleaved APP antibody shows much stronger immunoreactivity to the
proteolytic fragments (third panel). Probing for β-actin showed equal amount of
protein loading on the gels. (C) Quantification of the bottom band detected by
caspase-cleaved APP antibody, with normalization to actin, revealed a significant
induction in this band after six hours of CPT treatment, p=0.018.

130

a lower migrating band around 25 kDa which showed a time-dependent increase in
lysates from apoptotic cells Figure 4.1A, third panel). Analysis of lysates from H4-APP
cells after one, three, and six hours of treatments with CPT showed similar results on a
15% Tris-glycine gel (Figure 4.1B, top and second panel).
Reprobe of these blots with the caspase-cleaved APP antibody showed that two
bands, which migrate between 25 and 37 kDa, are detected by this antibody (Figure 4.1B,
third panel). This suggested to us that at least one of these bands could be similar or the
same as that detected by 6E10 antibodies. Quantification of the lower caspase-cleaved
APP fragment from three independent experiments showed a significant increase in APP
cleavage under apoptotic conditions (Figure 4.1C).

Because the detection of this

fragment was most efficient with the caspase cleaved APP antibody, we used this
antibody for most of our subsequent studies.
4.4.Caspase Inhibition Prevents Production of Novel Proteolytic Fragments and
Suggest Involvement of Group II Caspases
In order to determine whether these fragments are formed by caspase cleavage of
APP, H4-APP cells were pretreated with either the group II caspase inhibitor zDEVDFMK or the broad-spectrum caspase inhibitor zVAD-FMK for one hour, and then treated
with or without CPT for six hours. Flow cytometric analysis of propidium iodide stained
cells revealed that caspase inhibitors protected the cells against CPT-induced apoptosis
(Figure 4.2A). Importantly, western blot analysis of the cell lysates revealed a significant
reduction in CPT-induced generation of the novel fragments in the presence of zDEVDFMK and more significant inhibition with zVAD-FMK (Figure 4.2B). This is quantified
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Figure 4.2. Formation of the ~25-35 kDa fragments is caspase-dependent. (A)
Quantification of the number of cells undergoing apoptosis in the presence and
absence of caspase inhibitors and CPT, as analyzed by flow cytometry with propidium
iodide staining. Asterisks indicate a significant difference between groups, p<0.05. (B)
Western blot analysis of the H4-APP cells showed a strong reduction in the formation
of the new fragments in the presence of zDEVD-FMK. In the presence of zVADFMK, the formation of these bands was completely abolished. Reprobe of these blots
with an antibody against β-actin shows protein loading on gels. (C) Quantification of
the bottom band detected by the caspase-cleaved APP antibody, normalized to actin,
from three independent experiments, reveals significant attenuation in the formation of
the fragments by caspase inhibitors, with the six hour CPT treated sample showing a
significant difference from all other groups, p<0.05. Note that a logarithmic scale is
used in this panel.
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in Figure 4.2C – note that given the magnitude of these changes a logarithmic scale is
used in this figure.
A similar effect is seen in H4 cells that are not overexpressing APP as well, with
inhibition of caspases abolishing the formation of this fragment as detected by both
caspase cleaved APP antibodies and, though the detection is weak, 6E10 (Figure 4.3),
suggesting that the formation of this fragment is not a consequence of overexpression of
APP. Taken together, these data suggest that these fragments are generated in a caspasedependent manner, and the strong inhibition of generation of this fragment with the
group-II caspase inhibitor zDEVD-FMK suggests that caspase-3 and/or caspase-7 may be
involved in this cleavage.
4.5.Group II Caspase Activation is Associated with Fragment Formation in H4APP cells
In order to determine whether caspase-3 and/or caspase-7 may be responsible for
the cleavage of APP in our model, we assessed levels and localization of cleaved and
potentially active caspases in cells undergoing apoptosis in response to CPT. Both
cleaved caspase-3 and cleaved caspase-7 were significantly induced following a six hour
treatment with CPT (Figure 4.4A). We observed a slight mobility shift in cleaved
caspase-7 in cells treated with zDEVD-FMK, the reason for which is unclear at this point
(Figure 4.4A, second panel). When compared to cleavage of caspase-3, cleavage of
caspase-7 seemed to correlate more closely with the formation of these novel fragments
(Figure 4.4A, third panel), suggesting that activation of caspase-7 may be associated with
proteolytic cleavage of APP and generation of these fragments. Induction of cleaved
caspase-3 and cleaved caspase-7 were also evident by immunocytochemistry after CPT
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Figure 4.3. Inhibition of APP cleavage by caspase inhibitors. Treatment of H4 glioma
cells with caspase inhibitors show inhibition of APP processing: H4 glioma cells were
left untreated or treated with CPT for one, two, three or six hours or pre-treated for
one hour with Z-DEVD-FMK or ZVAD-FMK and treated with CPT for six hours and
cell lysates were prepared and separated on a 15% Tris-glycine gel and analyzed by
western blot using 6E10 (A) and caspase-cleaved APP (B & C) antibodies. 6E10
antibody (A) shows the appearance of the cleaved fragment of APP with a
concomitant decrease in the levels of full length APP (top panel) after CPT treatment.
The formation of the fragment is inhibited by treatment of the cells with Z-DEVDFMK and Z-VAD-FMK, which was associated with slight increase in full length APP.
Caspase-cleaved APP antibody shows a much stronger immunoreactivity to the
proteolytic fragments (C, long exposure). The short exposure (B) from the caspasecleaved APP blot shows inhibition of band formation by z-DEVD-FMK and Z-VADFMK, the long exposure shows that the inhibition was more efficient in cells treated
with Z-VAD-FMK. Probing for β-actin (D) showed equal amount of protein loading
on the gels.
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treatment (Figure 4.4B and 4.4C, respectively). Both cleaved caspase-3 and cleaved
caspase-7 co-localized with 6E10 staining in H4-APP cells, suggesting that this close
proximity of APP with active caspases in apoptotic cells may facilitate APP proteolysis.
The levels of APP in caspase-positive cells were lower compared to non-apoptotic cells.
4.6.Group II Caspase Cleavage is Also Associated with Fragment Formation in
Neurons
Caspase-3 and caspase-7 up-regulation and activation have been observed in AD
brains [10]. Although caspase-3 activation has been associated with apoptosis in neurons
[16], the role of caspase-7 in this process has not been established. To assess whether
caspase-7 activation occurs in neurons undergoing apoptosis, we analyzed rat cortical
neurons treated with CPT. Neurons were treated with CPT for 12 hours and
immunostained using antibodies against cleaved caspase-3 or -7. MAP2 was used as a
neuronal marker. Analysis of the cells under a fluorescent microscope showed a
significant induction in the levels of cleaved caspase-3 and cleaved caspase-7 in neurons
undergoing apoptosis (Figure 4.5A and 4.5B). In cells that showed substantial caspase
activation, staining with the neuronal marker MAP2 was diminished, though MAP2
staining in the distal neurites (not shown) persisted. Together with cell morphology, this
suggests that despite decreased MAP2 immunoreactivity these cells are indeed dying
neurons. Western blot analysis of neuronal lysates treated with CPT for 12 hours also
showed induction of both cleaved caspase-3 and cleaved caspase-7 in CPT treated cells
(Figure 4.5C). This could be partially inhibited by the group II caspase inhibitor zDEVDFMK and the pan-caspase inhibitor zVAD-FMK. Analysis of the cell lysate with caspasecleaved APP antibody revealed the formation of an ~25 kDa fragment under apoptotic
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Figure 4.4. Activation of caspase-3 and -7 is associated with APP proteolysis in
apoptotic cells: (A) H4-APP cells were treated with CPT in the presence and absence
of caspase inhibitors for six hours and analyzed by western blot using antibodies
directed against cleaved caspase-3 or cleaved caspase-7. Cleavage of caspase-3
(topmost panel) and caspase-7 (second panel) was observed in cells treated with CPT.
The cleavage of these caspases was associated with an induction in the formation of
the fragments detected by caspase-cleaved APP antibody (third panel). Blots were
probed for β-actin as a loading control (bottom panel). Immunocytochemical analysis
of H4-APP cells also showed significant induction in cleaved caspase-3 (B) and
cleaved caspase-7 (C) after one and six hours of exposure to CPT. Cells were coimmunostained with 6E10 antibody (green) to show colocalization of both active
caspase-3 and active caspase-7 (red) with APP (green) (Magnification: 63X). Cells
showing increased levels of cleaved caspases also showed a reduction in the level of
APP signal intensity, consistent with the decrease in full length APP observed by
western blot in Figure 4.1 A and 4.1 B. Hoechst was used to visualize the nuclei of the
cells.
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Figure 4.5. Apoptosis is associated with induction of cleaved caspase-3 and cleaved
caspase-7 in primary cortical neurons: Primary neurons were cultured from E18
embryonic rat cortices for seven days, followed by treatment with 10 µM CPT to
induce apoptosis. A and B show immunocytochemistry with MAP2 as a neuronal
marker (green) and cleaved caspase-7 (A) or cleaved caspase-3 (B) antibodies (red)
(Magnification: 63X). Hoechst staining, shown to the right of panels A and B, shows
condensed or fragmented nuclei (indicative of apoptosis) in cells positive for cleaved
caspases, whereas MAP2 positive neurons in the untreated samples show intact nuclei.
(C) Western blot analysis of the lysates from neurons treated with CPT for 12 hours
showed a significant induction in cleaved caspase-3 (top panel) and cleaved caspase-7
(second panel) levels. Activation of caspases was partially attenuated in the presence
of 10 µM zDEVD-FMK and zVAD-FMK. Analysis of the lysates with an antibody
generated against caspase-cleaved APP detected a single band of ~25 kDa size. The
level of this fragment was attenuated slightly in the presence of caspase inhibitors
(third panel). A reprobe of this blot using an antibody against β-Actin was performed
as a control for protein loading (bottom panel).
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conditions, the levels of which were attenuated in the presence of caspase inhibitors. This
suggests that both caspase-3 and caspase-7 are present in neurons and are activated under
apoptotic conditions.
4.7.Proteolysis of APP In Vivo in Transgenic Mice
In order to assess the various proteolytic fragments generated in a transgenic
mouse model of amyloid deposition, PS-APP mice overexpressing mutant forms of
human APP(V717F) and presenilin-1 (PS1) were used.

These mice show plaque

deposition at approximately 8-10 months of age [17, 18]. Brains from 10 month old PSAPP mice were homogenized in RIPA lysis buffer and the various proteolytic fragments
assessed by western blot as shown in Figure 4.6. Prominent bands observed with 6E10
included full-length APP, C99, Aβ, and an ~25 kDa band (Figure 4.6A), similar in size to
the fragment observed in vitro during p53-dependent apoptosis. A similar ~25 kDa band
has been observed in human AD tissue with 6E10, where it has been described as a
hexamer of Aβ [19]. However, as seen in Figure 4.6B, a similar sized fragment from the
transgenic mice expressing human APP is also detected by a C-terminal antibody,
suggesting that this fragment contains the C-terminus of APP. One would not expect a Cterminal antibody to detect a hexamer of Aβ, as Aβ oligomers should not contain the Cterminus of APP.
Quantification of the gels showed that full length APP is elevated 2 fold in PSAPP animals as detected by the C-APP antibody, while the C-terminal fragments are
increased approximately 4-fold. In contrast, the ~25 kDa fragment was elevated 7-fold in
the PS-APP mice (Figure 4.6 C). This significant increase in the ~25 kDa fragment over
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Figure 4.6. Characterization of APP proteolytic fragments from 10 month old PSAPP mice. (A) Western immunoblot analysis performed using 6E10, an antibody
directed against the Aβ region of human APP. This antibody is specific to human
APP, so no banding is observed in nontransgenic (Ntg) mice. The brain extracts from
the transgenic mice show the full length APP, Aβ, a band corresponding to the βsecretase cleaved C-terminal fragment of APP, C99, as well as a ~25 kDa band of
unknown origin. (B) Western blotting performed using an antibody directed against
the C-terminus of APP. The C-terminal antibody is raised against 9 aa from the Cterminus of APP and, unlike 6E10 antibody, detects both mouse and human APP. The
blots show bands corresponding to full length APP, α- and β- secretase cleaved Cterminal fragments of APP, C83 and C99 respectively, as well as the ~25 kDa band
observed with 6E10 antibody in both Ntg and PS/APP brain extracts. (C)
Quantification of the blots shown in B reveals an approximately 2 fold increase in full
length APP in PS-APP mice and an approximately 4 fold increase in the C-terminal
fragments compared to the Ntg mice. Levels of the ~25 kDa band, however, are 7
times higher in PS/APP mice than in Ntg. Asterisks indicate significant difference
from Ntg, p<0.01.
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the full length APP, along with the fact that the PS/APP mice develop pathology while
nontransgenic mice do not, warrant an investigation on the significance of this
intermediate proteolytic fragment in development of AD pathology.
4.7.1. Caspase Cleavage In Vivo in Transgenic Mice
Since the proteolytic fragment observed in vitro was dependent on the activation
of caspase-3 and/or -7, we set out to determine whether the ~25 kDa fragment in the
brain extracts of PS/APP mice is associated with activation of caspases -3 and -7. We
performed immunostaining analysis using antibodies towards the cleaved forms of these
caspases on the brains of PS/APP mice. We observed an increase in the levels of both
active caspase-3 and -7 proximal to amyloid deposits as detected by co-staining with the
6E10 and the corresponding cleaved caspase antibodies (Figure 4.7A and B). Confocal
analysis of the co-stained sections showed colocalization of APP with both cleaved
caspase-7 and cleaved caspase-3 in the vicinity of the plaques (Figure 4.7A and B
respectively and the corresponding insets). This suggests that these caspases may cleave
APP in vivo at the novel site reported here, and potentially contribute to the
neurodegeneration associated with AD via production of the ~25 kDa fragment or via a
reduction in the levels of sAPPα, which has been shown to have a protective antiapoptotic effect on neurons.
4.8.Modeling of APP and Identification of a Potential Caspase Site
The novel APP fragments observed in lysates from cells undergoing apoptosis
immunoreacted with 6E10 and the C-terminal caspase cleavage site-specific antibodies.
The only fragment generated by secretase cleavage of APP that would immunoreact with
both of these antibodies would be the C99 fragment that is truncated by cleavage at
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Figure 4.7. Active caspase-3 and -7 are observed in the vicinity of Aβ plaques in PSAPP transgenic mice. (A) Brain tissue from 10 month old PS-APP transgenic mice
were stained with antibodies to APP (6E10, green), and cleaved caspase-7 (red), and
the nuclei were counterstained with Hoechst. Co-localization of cleaved caspase-7
(red) and 6E10 (green) was observed in the vicinity of Aβ plaques. The inset shows a
closer view of one area of colocalization. (B) Similarly, co-localization of cleaved
caspase-3 (red) and 6E10 (green) was also observed in the vicinity of Aβ plaques.
Samples were visualized using a confocal imager and analyzed using the Fluoview 2.0
software. Images are shown at 14x magnification (10x objective with 1.4x digital
zoom). Confocal microscopy was performed with the kind assistance of Dr. Beyong
Cha at the USF Health microscopy core.

141

VEVD*A740. Such a fragment would have a predicted molecular weight of ~8 kDa. As
this is considerably smaller than the molecular weight of the fragments generated under
apoptotic conditions, we scanned APP for other known proteolytic sites, such as those
cleaved by calpains, caspases, and MT-MMPs, to determine whether APP fragments with
molecular weights similar to those we observed could be generated by proteases other
than the secretases. Figure 4.8 shows a ball-and-chain model of APP with various
proteolytic sites numbered. The grid towards the right of Figure 4.8 shows the predicted
molecular weight of fragments generated by cleavage at a single site (light gray boxes,
showing molecular weight of N-terminal and C-terminal fragments, respectively), or the
internal fragment generated by cleavage at two sites identified by the intersection of a
row and column. For example, cleavage at the β-secretase site (row 5) and the γ-secretase
site (column 7) generates a fragment with a predicted molecular weight of ~4.5 kDa, Aβ.
These estimated molecular weights are based on the amino acid structure at neutral pH
with no post-translational modifications and are calculated using the APP770 isoform. For
fragments containing the 6E10 epitope, the molecular weight is bolded and underlined.
Since we suspected that the cleavage may be caspase-dependent, based upon the
response to inhibitors, we also utilized a support vector machine (SVM)-based predictive
model to detect potential caspase cleavage sites in APP [20]. We identified a potential
group II caspase site, DEVD*E563, approximately 25 kDa from the C-terminal end of
APP, indicated by the asterisk in Figure 4.8. Based upon the predicted molecular weight
of the fragments identified by bioinformatic analysis, we suspect that the fragments
observed in this study are generated by cleavage at either this novel caspase site, or by
sequential cleavage by MT-MMPs in the extracellular domain and caspases at
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Figure 4.8. Bioinformatic prediction of potential proteolytic sites involved in
generation of the novel APP fragments. The figure shows a schematic depicting
known proteolytic sites on APP, and table identifying these various sites on APP770
isoform. Each site is assigned a number starting from the N-terminus, with a putative
caspase cleavage site (DEVD*E563) identified by a support vector machine-based
caspase substrate predictive model identified using an asterisk. The right side of the
table is a grid illustrating the predicted molecular weights of fragments generated by
cleavage at one or two of the sites identified. Each cell contains the predicted
molecular weight for a fragment generated by cleavages at the site identified in the left
side of the table and by number in the top row of the grid. The light gray cells on the
diagonal, those where both row and column represent the same site, indicate cleavage
at a single site with predicted molecular weight of the N-terminal and C-terminal
fragments listed, respectively. The white cells show the molecular weight of the
internal fragment generated by cleavage at two different sites. The molecular weights
of fragments containing the 6E10 epitope (Aβ1-16) are bolded and underlined. Note
that sites in the near extracellular domain, specifically the putative caspase site and the
MT-MMP site, could potentially generate fragments similar in size and
immunoreactivity to the fragments we observed.
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VEVD*A740. Interestingly, cleavage in this manner would not preclude amyloidogenic or
nonamyloidogenic processing of APP. It would, however, prevent the generation of the
α-secretase-cleaved N-terminal fragment of APP, sAPPα, which has neuroprotective and
anti-apoptotic properties and therefore a depletion of this fragment may have deleterious
effect on cell survival.
4.9.MMP-Dependent Changes in APP Processing
Based on the bioinformatic analysis of APP it is possible that the ~ 25 kD Cterminal fragment observed during p53-dependent apoptosis may be generated by
cleavage by either MT-MMPs or group II caspases in the extracellular domain and
caspase-3 in the C-terminal domain. In order to assess whether APP is being cleaved by
MMPs in our H4-APP cells, we treated H4-APP cells with 25 µM GM6001, an MMPinhibitor (Figure 4.9). Even in the absence of CPT, treatment with GM6001 resulted in a
significant induction of the β-cleaved C-terminal fragment C99. These changes are
quantified in Figure 4.9B. This suggests that MMP inhibition has unanticipated effects
on classical processing APP. While we would have liked to assess the effect of MMP
inhibition in the CPT-treated condition, the increased pronounced enhancement of βcleaved fragments with GM6001 is potentially confounding. If the ~25 kDa fragment is
MMP-dependent, we would expect to see a decrease in the levels of this fragment when
cells are pretreated with GM6001.

However, the large induction in β-secretase

processing seen with GM6001 would also result in a decrease in this fragment, as the
fragment does contain the β-secretase site. Given these potential confounds, we decided
to not pursue the MMP-mediated processing of APP at this point, and instead focus on
caspase- dependent cleavage of APP.
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Figure 4.9. MMP-dependent changes in APP processing. H4-APP cells were treated
with 25 µM GM6001 for seven hours and protein lysates collected. Equal amounts of
protein were loaded onto 12% tris-glycine gels and electrophoresed for analysis by
western blot. (A) Two representative, independent experiements showing an increase
in the levels of C99 after treatment with GM6001 is shown. MMP-16, an MMP
predicted to cleave APP in the near extracellular domain [1], increases slightly upon
treatment with 25 µM GM6001. (B) Quantification of the levels of C99 over 3
independent experiments show a nearly 3-fold increase in C99 with GM6001
treatment. Asterisks indicate significant difference, P<0.05. Error bars show ±
standard deviation.
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4.10. Studies with shRNA Suggest a Role for Caspase-7 in APP Proteolysis
The similarity in substrate specificity and lack of specific inhibitors capable of
discriminating between group II caspases make it challenging to determine whether a
specific proteolytic event is attributable to caspase-3, caspase-7, or both. Although it is
classically difficult, we attempted to down-regulate each specific caspase using shRNA to
caspase-3 and caspase-7 in order to examine whether down-regulation of these caspases
have any effect on cleavage of APP to generate the fragments we have observed. Sets of
four shRNA clones each to caspase-3 and caspase-7 were obtained from OriGene
(Rockville, MD) and were transiently transfected into H4-APP cells using Turbofectin
8.0 (OriGene) according to the manufacturer’s protocol. Initial studies showed that
maximum down-regulation was obtained with clones one and four of each shRNA set,
and we decided to use clone four of each shRNA set in our studies. Western blot analysis
showed no down-regulation with a control shRNA (Figure 4.10A, lane 2 top and middle
panel), while cells transiently transfected with shRNA to caspase-7 showed downregulation predominately of caspase-7 (Figure 4.10A, lane 4). Cells transiently
transfected with shRNA to caspase-3 showed down-regulation of both caspase-3 and
caspase-7, indicating that the shRNA to caspases-3 was not specific for this caspase
(Figure 4.10A, lane 3). Cells transfected with shRNA to caspase-7 showed downregulation of two bands around 25-35 kDa on the western blots, which could be splice
variants of procaspase-7 [21]. From the transient transfection experiments, we conclude
that: (1) the effect of shRNA transfection are sequence dependent, as the control shRNA
showed no effects, (2) shRNA to caspase-7 down-regulates caspase-7, and (3) the shRNA
to caspase-3 used down-regulates both caspase-3 and caspase-7.
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Figure 4.10. Down-regulation of caspase-3 and caspase-7 reduces the generation of
~25-35 kDa caspase-cleaved APP fragments in CPT treated H4-APP cells. (A) H4APP cells were transiently transfected with shRNA to caspase-3 or shRNA to caspase7 and the down-regulation of the respective caspases analyzed after 48 hours using
antibodies against caspase-3 (top panel) and caspase-7 (second panel). The lower
panel in (A) shows the actin probe of the blot to show protein loading. (B) H4-APP
cells stably transfected with shRNA to caspase-3 or caspase-7 were analyzed using the
respective caspase antibodies. Reprobing of the blot with β-actin antibody shows
protein levels on the blot (bottom panel). (C) Quantification of the levels of caspase-3
and caspase-7 in stably transfected cells from three independent experiments (as
represented in B), normalized to β-actin. An approximately 86% decrease in fulllength caspase-3 levels were observed in cells transfected with shRNA to caspase-3 or
shRNA to caspase-7. Similarly, an approximately 49 % decrease in caspase-3 levels
was observed with shRNA to caspase-3, and a 56 % decrease in caspase-7 levels was
observed with shRNA to caspase-7. Induction of cleaved caspase-3 was observed with
shRNA to caspase-7, but no induction of cleaved caspase-7 was observed with shRNA
to caspase-3. (D) Western blot analysis of the lysates with antibody to caspase-cleaved
APP showed a reduction in the levels of the cleaved fragment in the shRNA
transfected cells after three hours of treatment with 10 µM CPT. The figure shows
data from two experiments treated with CPT (E) Quantification of data from three
independent experiments (representative figure is shown in panel D), normalized to
actin, shows a 31% reduction in caspase-cleaved APP with shRNA to caspase-3 and a
90% reduction in cells transfected with shRNA to caspase-7. Asterisks indicate
significant differences, p<0.05.
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We also performed stable transfections of these same shRNAs into H4-APP cells
(Figure 4.10B and C) and detected a significant reduction in full length caspase-3 and -7
with both shRNA clones (Figure 4.10B, top panel and third panel). Interestingly, in
addition to inhibiting the expression of caspase-7, cells stably transfected with shRNA to
caspase-7 showed an increase in cleaved caspase-3 (Figure 4.10B, second panel). Cells
transfected with shRNA to caspase-3 did not show any up-regulation of cleaved caspase7. This is not surprising as caspase-3, which is involved in the cleavage of caspase-7, was
downregulated in these cells. Figure 4.10B shows a representative blot from one of three
independent experiments; the results from these experiments were quantified and are
presented in Figure 4.10C. Data from the stable shRNA transfection studies suggest that:
(1) Similar to transient transfections, shRNA to caspase-3 resulted in down-regulation of
both caspase-3 and caspase-7, (2) as with transient transfection, shRNA to caspase-7 was
specific for caspase-7, and (3) stable knockdown of caspase-7 leads to an increase in
cleavage of caspase-3 to the active form.
We next examined APP fragment formation in stably transfected cells treated
with or without CPT by western blot analysis using the caspase-cleaved APP antibody
(Figure 4.10D and E). Cells stably transfected with shRNA to caspase-3 showed a partial
reduction in the levels of the cleaved fragments, while shRNA to caspase-7, which
downregulated caspase-7 and induced cleavage of caspase-3, resulted in a substantial
decrease in the levels of the fragments. This suggests that, although both caspase-3 and -7
may be capable of cleaving APP, caspase-7 is more directly associated with the formation
of the fragments, as substantial down-regulation of these fragments was observed with
shRNA to caspase-7, even in the presence of increased levels of cleaved caspase-3.
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4.11. Conclusions
In this chapter, we present our findings that under apoptotic conditions, APP is
processed alternatively to generate fragments that are detected by antibodies directed
towards Aβ region and C-terminal caspase cleavage site on APP. Similar fragments are
observed in an APP-expressing transgenic mouse model as well. Based upon the size and
immunoreactivity we conclude that the generation of these fragments involves cleavage
within the ectodomain of APP, beyond the β-secretase cleaving site. Experiments with
small peptide inhibitors of caspases and shRNA to caspases-3 and -7 suggest that these
fragments are generated by a mechanism involving group-II caspases, and preferentially
involving caspase-7. Based upon fragment size, immunoreactivity, and bioinformatic
analysis of the APP sequence, we hypothesize that these fragments may be generated by
cleavage of APP within the near ectodomain, potentially by MT-MMPs or caspases, and
at the C-terminal domain by caspases. Cleavage within the near ectodomain prevents the
production of sAPPα, which is neuroprotective and anti-apoptotic.
We used H4 neuroglioma cells overexpressing APP as a model system where
apoptosis was induced using the DNA damaging agent CPT. Although the levels of
apoptosis is higher in our in vitro system as compared to the human condition, a nearhomogeneous population of APP expressing apoptotic cells allows us to study changes in
potentially intermediate proteolytic fragments of APP generated during apoptosis. In the
human condition, even small changes in APP processing, over the decades-long disease
process, may have significant impact on pathology development. Changes in sAPPα are
of particular interest, as sAPPα has been implicated in protecting neurons and synapses
from apoptosis [22]. Our studies suggest that changes in APP processing associated with
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apoptosis could lead to decreased levels of sAPPα in the local microenvironment, making
cells in that environment more prone to degeneration. Whether the altered processing of
APP described here occurs in vivo in human AD brains needs to be established. However,
analysis of brain extracts from mice overexpressing human APP [23-25] and human AD
patients [19] have shown generation of similarly sized proteolytic products detected by
6E10 antibody. These APP metabolites are often interpreted as oligomeric Aβ, though
they may in fact be other proteolytic fragments of APP that contain the 6E10 epitope.
Further, proteomic analysis of cerebrospinal fluid from AD patients has resulted in the
identification of 11 short peptides that vary in N-terminal start site but end just before the
α-secretase cleavage site. The N-termini of these fragments are formed by cleavages that
occur in the near extracellular domain of APP [14]. The precise origin of these fragments
and the proteases that generate them are not clear, but their existence suggests that there
is active proteolysis in the ectodomain region, beyond the β-secretase site, of APP in
human AD brains. These data, as well as our results presented here thus suggest that,
APP undergoes altered processing under degenerative and apoptotic conditions and a
detailed analysis of the APP proteolysis may identify hitherto unknown intermediates as
well as the importance of these cleavages in pathology development.
Apoptosis in neurons has been shown to be associated with caspase-3-mediated
cleavage of APP at the C-terminus [11]. This cleavage of APP generates a 31 amino acid
fragment from the C-terminus of APP, C31, which has been shown to be neurotoxic [26].
The effect of caspase cleavage on secretase processing of APP and Aβ production is not
clearly understood. Co-localization of active caspase-3 with amyloid plaques and with
caspase-cleaved APP has been observed in AD brain, which led to the hypothesis that
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caspase activation may lead to enhanced Aβ generation and plaque formation [4, 27].
However, this correlation does not necessarily indicate that caspase-dependent cleavage
of APP increases Aβ generation, especially given that truncation of APP at the Cterminus removes the endocytosis signal from APP and affects its internalization. If the
internalization of APP is reduced by caspase-mediated truncation, this may in fact
decrease Aβ production, as endocytosis is required for cleavage of APP via the
amyloidogenic pathway [2]. Our results support this hypothesis and are consistent with
the findings presented in chapter 3, showing that apoptosis is associated with a decrease
in generation of Aβ and sAPPα, as well as an increase in the formation of alternatively
processed APP fragments.
Further, our data also suggest that in addition to cleavage by caspase-3, APP can
be cleaved by caspase-7, and that caspase-7 may cleave APP at a novel site in the
ectodomain. Such a cleavage would generate a C-terminal fragment of ~25 kDa. This
cleavage would likely occur after endocytosis of APP, within a luminal space, as
DEVD*E563 (based on APP770) lies in the extracellular domain of APP. Interestingly,
caspase-7, but not caspase-3, has been shown to translocate to an endosomal-lysosomal
compartment under inflammatory and apoptotic conditions [28]. This would allow
caspase-7, but not caspase-3, access to DEVD*E563, explaining the apparent preference
for caspase-7 over caspase-3 observed in our studies.
Once APP is cleaved at this novel site, the fragment generated could undergo
further proteolysis. We observed a decrease in the levels of secreted Aβ and the C99
fragments in cells undergoing apoptosis, and this paralleled with a decrease in full-length
APP as well as sAPPα. While changes in the levels of these fragments may be indicative
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of decreased expression of APP [29], the concomitant increase in the ~25-35 kDa
fragments observed here suggests that these changes are at least partially due to altered
proteolysis. Formation of these fragments precludes the production of sAPPα, and the
fragments themselves could be further processed by secretases and caspases, including
cleavage by caspase-3 to generate the neurotoxic fragment C31. Further analysis of
ectodomain cleavage of APP and the functions of the fragments generated is certainly
warranted, as any alterations in APP processing may have important implications for
pathology development in AD.
Studies in individuals with an increased risk for developing AD (those with a
Clinical Dementia Rating of 0.5) show up-regulation of caspase-1 and caspase-7 in the
entorhinal cortex [10]. Caspase-1, also known as interleukin converting enzyme, is
associated with neuroinflammation and has been shown to cleave and activate caspase-7
in vitro [30]. The up-regulation of both of these caspases early in the disease process
suggests that neuroinflammation may induce activation of caspase-7 and alternative
processing of APP. Up-regulation of caspase-1 and caspase-7, but not TUNEL-positive
cells, have been reported in the brains of patients with a Clinical Dementia Rating of 0.5.
Patients with more advanced dementia, Clinical Dementia Rating of 5, show upregulation
of other caspases, including caspase-3, and a massive increase in TUNEL-positive cells
[10]. This indicates that, despite its traditional role as an executioner caspase, caspase-7
may actually be acting early in the disease process, prior to the onset of apoptosis, and
may play a physiological role in neurons outside of the apoptotic pathway. This is
supported by our shRNA experiments, in which caspase-3 cleavage was observed in cells
stably transfected with shRNA to caspase-7, even under non-apoptotic conditions (Figure
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4.10B). The compensatory up-regulation of cleaved caspase-3, the closest homologue to
caspase-7, under non-apoptotic conditions suggests an important physiological role for
caspase-7 outside of apoptosis. While the role of caspase-3 in APP cleavage is beginning
to be well understood, the role of caspase-7 in neuronal function, as well as caspase-7
mediated cleavage of APP, warrants further investigation.
The notion that caspase activation has a physiological role outside of apoptosis is
not new. Caspases are thought to play an important role in modulating synaptic plasticity
and long term memory [31-34]. APP and its proteolytic fragments have also been
implicated in synaptic plasticity and neurite outgrowth [for review, see 35]. sAPPα has
been shown to have substantial trophic effects on synaptic plasticity [36]. At low
concentrations, even Aβ appears to have a positive effect on synaptic plasticity [37],
though at high concentrations Aβ aggregates and induces neurodegeneration [38]. The
alternative APP processing events described in the studies presented here preclude the
generation of the neurotrophic sAPPα fragment. This is confirmed by the observation that
sAPPα levels are decreased under apoptotic conditions. They do not, however, preclude
the formation of the neurotoxic Aβ and C31 fragments. It is possible that the fragments
generated under apoptotic conditions are intermediate fragments of APP which may be
further processed by secretases to generate Aβ and/or C31. The cleavage of APP that
generates these fragments may, therefore, enhance neurodegeneration by decreasing the
availability of sAPPα to provide neuroprotection while still allowing the production of
the toxic fragments. This suggests that neuroinflammation-induced caspase-7 activation
could shift APP into an alternative cleavage pathway that is potentially cytotoxic, and
inhibition of this pathway may protect neurons against cytotoxicity.
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4.12. Closing Remarks
In the previous chapter, we presented the finding that p53-dependent apoptosis
was associated with a decrease in the Aβ and sAPPα. This could be due to a decrease in
expression of the substrate or a decrease in the relative activity of the enzymes. Using γsecretase inhibition, we determined that there was likely no change in β-secretase
activity, but α-secretase activity was sustained. In this chapter, we present the finding
that during p53-depedent apoptosis, alternative, caspase-dependent processing of APP
occurs, including an apparent cleavage in the near extracellular domain. While this
cleavage precludes the production of sAPPα, it does not preclude the production of Aβ.
Nevertheless, as discussed in Chapter 3, there is no increase in Aβ during p53-dependent
apoptosis. Therefore, our hypothesis that Aβ production may propagate through the brain
due to APP processing during p53-dependent apoptosis is not supported by our data.
Models of p53-dependent apoptosis rely on the induction of DNA damage. In the
case of CPT-dependent apoptosis, this is achieved by damaging DNA during its
synthesis. Therefore, the changes we see during p53-dependent apoptosis in our model
could also reflect cell cycle dependent changes that occur during S-phase. In the next
chapter, we will focus cell cycle dependent changes in APP and its processing.
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CHAPTER 5: PROCESSING OF APP DURING CELL CYCLE 1

5.1. Chapter Synopsis
In the previous chapters, we have discussed the hypothesis that Aβ production
may propagate through the brain in an anatomical fashion, similar to that seen in tau, and
have discussed two potential mechanisms by which this could occur – p53-dependent
apoptosis and./or aberrant cell cycle activation. We have explored the possibility that
p53-dependent apoptosis may result in increased production of Aβ, and found that in fact
there is no increase in Aβ production during p53-dependent apoptosis. There is instead a
decrease in both Aβ and sAPPα. Further, there is an increase in an ~25 proteolytic
fragment that is caspase-dependent and appears to involve cleavage of APP in the near
ectodomain.

This cleavage precludes the production of the neurotrophic sAPPα

fragment, but does not preclude the production of Aβ.
In p53-dependent apoptosis, apoptosis is induced primarily in S-phase. In this
chapter, we assess S-phase dependent processing of APP.

Further, we discuss the

evidence in the literature from our lab and others that indicates that cell-cycle related
events, such as the phosphorylation of APP, can affect downstream processing. Finally,
we will present evidence that mitotic phosphorylation of APP is associated with
amyloidogenesis and discuss the potential mechanistic relationship between APP
phosphorylation and amyloidogenic processing.
1

Some results in this chapter have been previously published (Judge et al., 2011) and are utilized
with the permission of the publisher. See Appendix B.
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5.2. Cell Cycle Dependent Processing of APP
Our findings regarding decreased levels and processing of APP during p53dependent apoptosis raised the question as to whether these effects were due specifically
to apoptotic processes or if these changes are related to cells in S-phase.

P53, as

discussed in Chapter 3, transcriptionally regulates genes involved in cell cycle arrest and
apoptotic cell death [2]. This confers the ability of p53 to gauge whether a replicating
cell’s DNA is in sufficiently healthy condition to be replicated, and transcriptionally halt
cell growth to allow for repair. In our model of CPT-dependent apoptosis, DNA-damage
occurs due to topoisomerase inhibition and therefore accumulates during S-phase. As
shown in Figure 3.2 (see Chapter 3), the number of cells in S-phase increases when cells
are undergoing CPT-dependent apoptosis. This accumulation of cells in S-phase is
indicative of an S-phase block, suggesting that any changes observed at these time points
could be indicative of changes in processing dependent on cell cycle, and more
specifically S-phase.
5.2.1.

Modeling Cell Cycle with Aphidicolin

In order to obtain a synchronous population of cells in S-phase, we arrested cells using
the DNA polymerase inhibitor aphidicolin. Because in an asynchronous population the
vast majority of cells are in G0/G1, and because in our experience doubling of a culture
of H4-APP cells takes approximately 18 hours, treatment of H4-APP cells with 5 µg/mL
aphidicolin for 18 hours results in cells that are arrested late in early S-phase. When
aphidicolin, and therefore DNA polymerase inhibition, is removed the cells begin to
replicate their DNA. This process can be visualized using propidium iodide to stain the
DNA content of cells.

When these cells are stained with propidium iodide and
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Figure 5.1. Effectiveness of aphidicolin block and release in H4-APP cells. H4-APP
cells were arrested with 5 µg/mL aphidicolin for 18 hours, then aphidicolin removed
and cells were allowed to continue to grow in normal growth media for 1-6 hours.
Cells were fixed and stained with propidium iodide (PI) and analyzed via flow
cytometry. DNA content indicates that cells progress synchronously into S-phase
following aphidicolin release.
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collected at each hour post-stimulation, the DNA content of these cells steadily increases
(Figure 5.1).

This allows us to model cells as they progress through S-phase and

potentially into G2/M-phase, though the longer the duration post-aphidicolin block, the
more asynchronous these cells become.
5.2.2.

Cell Cycle Dependent Changes in APP Processing

When cells are treated with aphidicolin and not released, they are arrested in early
S-phase. As is evident in Figure 5.1, cells are approximately halfway through S-phase
after 4 hours post-aphidicolin. We treated cells with 5 µg/mL aphidicolin for 18 hours,
then allowed them to cycle for 12 hours post release. H4-APP cells treated with 100
ng/mL nocodazole for 18 hours served as positive control for an M-phase specific
population. Nocodazole is a microtubule depolymerizing agent that results in the arrest
of cells primarily in M-phase.
Cells were lysed and equal amounts of protein run on a 12% Tris-Glycine gel for
analysis by western blot. Using 6E10 and a C-terminal APP antibody, we can detect both
full length APP and the C83/C99 C-terminal fragments. We see a reduction in both full
length APP and a decrease in the levels of C-terminal fragments with aphidicolin
treatment that is sustained until 12 hours post release, at which point APP levels begin to
increase again. Nocodazole treatment suggests that APP levels, both full length and
processed forms, are higher during M-phase. Therefore, the increase observed in the full
length form of APP after 12 hours of serum stimulation after aphidicolin block may be
indicative of cells beginning to enter M-phase. Temporally, the processed forms of APP
appear to lag behind that of the full length forms – aphidicolin treatment alone decreases
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Figure 5.2. Aphidicolin block and release and nocodazole arrest reveal cell cycle
dependent processing of APP. Cells were treated with 5 µg/mL aphidicolin for 18
hours, after which aphidicolin was removed, the cells washed twice with PBS, and
serum containing media added. Additionally, another sample was arrested in M-phase
using 100 ng/mL nocodazole for 18 hours as a positive control for M-phase cells.
Lysates were analyzed by western blot using 6E10 and C-terminal APP antibodies
(cAPP). Full length APP was reduced as cells went through S-phase (aphidicolin
treatment, 4 hour release, and 8 hour release conditions), with processed forms reduced
in the 4 hour and 8 hour release conditions. Full length APP and processed forms were
increased during M-phase.
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full length APP, but a reduction in C-terminal fragments is not seen until the 4 hour time
point. Similarly, an increase in full length APP is observed at the 12 hour time point, but
an increase in the C-terminal fragments is not yet observed, though nocodazole treatment
indicates that the C-terminal fragments are somewhat higher during M-phase.
5.3. Cell Cycle Dependent Phosphorylation of APP
M-phase dependent changes in APP are not limited to expression and proteolysis.
Our lab and others have previously described cell-cycle dependent phosphorylation of
APP at threonine 668. The first report of cell-cycle dependent phosphorylation, from
Suzuki and colleagues, showed that in vitro purified cdc2/cyclin B complex, a cell cycle
dependent kinase complex active during M-phase, could phosphorylate a synthetic
peptide consisting of APP645-694 as well as APP663-676 [3]. The latter peptide contains only
one threonine, suggesting the residue phosphorylated was threonine 668. Subsequent
work from Li-Huei Tsai’s laboratory identified elevated levels of P-APPT668 in the brains
of AD patients, which appeared to colocolize with BACE1 in the endosomes. Further,
the β-secretase cleaved fragment C-terminal fragment C99 had a higher propensity to be
phosphorylated than the corresponding α-secretase cleaved fragment C83, suggesting that
the phosphorylation of APP at threonine 668 may be associated with amyloidogenic
processing [4].
Further, PC12 cells arrested at the G2/M-phase with nocodazole in the presence
of [32P]-orthophosphate results in labeling of both full length and C-terminal fragments of
APP.

There was also an increase in the relative level of C-terminal fragments as

compared to full length APP, suggesting that there may be an increase in processing in a
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Figure 5.3. Phosphorylation of APP is elevated during M-phase. Asynchronously
growing H4-APP cells were fixed by PIPES fixation and stained using an antibody
against phosphorylated APP (P-APP), along with α-tubulin and Hoechst to visualize
mitotic spindles. Cells undergoing mitosis, which secreted more Aβ as shown in Figure
5.4, also had elevated levels of P-APP.
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Figure 5.4. Mitosis-specific phosphorylation of APP. H4-APP cells were growth
arrested by serum starvation for 48 hr and serum stimulated with and without
roscovitine, olomoucine, or aphidicolin for 12 hr, and 100 ng/mL nocodazole, 10 µM
vinblastine, or 100 ng/mL taxol for 16 hr. Cell extracts were prepared and equal
amounts of proteins were immunoprecipitated using 6E10 antibody and western
blotted using P-APP antibody (A). B) APP levels in total lysate analyzed using 6E10
antibody. Panel C shows reprobe of blot B (without stripping) with actin antibody
showing equal amount of proteins on gel. The histogram in panel D shows the percent
of P-APP in cells under the different treatment conditions. The data represent the mean
of three independent experiments with standard deviation shown. Cells arrested in
metaphase showed significantly higher levels of P-APP (P< 0.05). Panel E shows the
FACS analysis data from cells treated with cell cycle inhibitors. Cells were treated
with roscovitine or aphidicolin for 12 hr or nocodazole or taxol for 16 hr and fixed and
stained using propidium iodide before analysis on a FACS machine. Mean percent of
cells in different phases of the cell cycle from three independent experiments is shown.
Reprinted from Judge, M., et al., Mitosis-specific phosphorylation of amyloid
precursor protein at threonine 668 leads to its altered processing and association with
centrosomes. Mol Neurodegener, 2011. 6: p. 80. [1].
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cell cycle and/or phosphorylation dependent manner [3]. In fact, APP phosphorylation
does appear to occur in a cell-cycle dependent manner when analyzed in asynchronously
growing cells. Mitotic spindles can be easily visualized using antibodies against αtubulin along with staining of chromatin with Hoechst. When cells stained in this manner
are also stained with an antibody specifically recognizing APP phosphorylated at
threonine 668, we see that phosphorylated APP levels are elevated specifically in cells
undergoing mitosis (Figure 5.3).
Subsequent research in our own laboratory has shown an upregulation of both cell
cycle regulatory proteins, including cyclin D1, cyclin E, and P-cdc2, as well as elevated
levels of APP phosphorylated at threonine 668, in transgenic mice overexpressing APP,
as well as in double transgenic mice overexpressing PS1 and APP, as compared to
nontransgenic littermate controls [1]. Further, we have previously reported that in H4APP cells treated with cell cycle inhibitors such as taxol, nocodazole, and vinblastine
have elevated levels of P-APP as compared to cells treated with inhibitors that act at the
G1/S checkpoint in cell cycle or early in S-phase, such as aphidicolin, roscovitine, and
olomoucine.

Levels of C-terminal fragments are also elevated during M-phase as

compared to G1/S-phase, suggesting that APP processing may be enhanced by the
phosphorylation of APP. Two figures from this study, performed by Judge et al., are
reproduced here in figures 5.4 and 5.5 [1]. 2
In order to assess whether Aβ levels were elevated during M-phase, cells were
serum starved and stimulated or treated with various cell cycle inhibitors.
Immunoprecipitation using 6E10 antibody was performed on both the media (for secreted
Aβ) and the lysates (for intracellular Aβ) and the results are shown in Figure 5.4.
2

For copyright permissions regarding the use of this work see Appendix B.
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Figure 5.5. Aβ generation is altered in a cell cycle-dependent manner. H4-APP cells
were synchronized by serum starvation and stimulated with serum containing media
plus or minus 50 µM olomoucine, 20 µM roscovitine, 5 µg/mL aphidicolin, 100 ng/mL
nocodazole, 10 µM vinblastine, or 100 ng/mL taxol. Cell culture supernatants (A and
C) and cell extracts (B and D) were immunoprecipitated and western blotted using
6E10 antibody. Control was performed similarly to the rest of the samples, except no
primary antibody was used in immunoprecipitation assay. Cell culture supernatant
showed a time dependent increase in Aβ generation upon serum stimulation (A and C).
The extracts showed similar results, which was visible only after longer exposure of
the blot (D). Panels C and D represent longer exposure of the bottom part of the blots
shown in A and B to show the Aβ levels in cell extracts. In both the cases roscovitine
treatment was associated with a decrease in the level of secreted and cellular Aβ.
Secreted APP was not altered in the supernatant although the level of APP and C-APP
fragments are increased in the extracts prepared from nocodazole and vinblastinearrested cells. Panel E and F show mean percent of Aβ (compared to secreted and full
length APP) from three independent experiments under different treatment conditions.
Data that showed significant changes are marked using a star (P < 0.05). Reprinted
from Judge, M., et al., Mitosis-specific phosphorylation of amyloid precursor protein
at threonine 668 leads to its altered processing and association with centrosomes. Mol
Neurodegener, 2011. 6: p. 80 [1].
169

Levels of Aβ were higher in cells that had been stimulated with serum for 14 hours or
longer, i.e. cells that had been cycling long enough to have entered M-phase. Treatment
with taxol, a microtubule stabilizing agent that yields a moderately effective M-phase
block, results in a significant induction in Aβ levels in the media, while treatment with
nocodazole or vinblastine, microtubule destabilizing agents which result in a more potent
M-phase block, resulted in elevated levels of intracellular Aβ. This may be indicative of
a failure of Aβ secretion, potentially due to the microtubule destabilization caused by
these agents.

Regardless of whether the Aβ was detected extracellularly or

intracellularly, it appears that Aβ generation is indeed enhanced during M-phase.
Roscovitine treatment, interestingly, sharply reduced Aβ production below
baseline levels. Roscovitine is an inhibitor of cdk2, cdc2, and cdk5. As discussed in
section 5.3, cdc2, when complexed with cyclin B, is capable of phosphorylating APP [3].
Cdk5 has also been shown to mediate phosphorylation of APP [5]. Prevention of Aβ
production by inhibition of these specific APP-phosphorylating kinases strongly suggests
that phosphorylation of APP by cdc2 and/or cdk5 contributes to its processing via the
amyloidogenic pathway. In the section that follows, we will discuss evidence from the
literature that further supports this notion and present a mechanism by which Aβproduction may be mediated in a cell-cycle dependent manner.
5.4. Function of APP Phosphorylation
The functional importance of phosphorylation of APP is not entirely clear. In
addition to being mediated by cdc2 and cdk5, APP can also be phosphorylated at
threonine 668 by c-Jun N-terminal kinase 3 (JNK3) and glycogen synthase kinase 3β
(GSK3β) [6, 7], Phosphorylation of APP seems to affect its localization, as APP
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phosphorylation has been shown to induce its localization to nerve terminals and that this
localization requires kinesin-1 [8], and studies in our own lab have illustrated that during
mitosis phosphorylated APP localizes to the centrosome [1]. Both of these observations
strongly suggest that not only is phosphorylation of APP important for regulating the
subcellular localization of this protein, but suggest that this localization may be mediated
by interactions between APP and kinesin-1, as kinesin is localized to the spindle poles
during mitosis and is also a major motor protein responsible for anterograde transport
along the axon. Importantly, APP can directly bind to the light chain of kinesin-1, and it
has been hypothesized that one of APP’s normal functions may be to mediate the
interaction between kinesin-1 and other cargo molecules [9]. 3
Fourteen amino acids away from the threonine-668 site in APP is a YENPTY
motif, which appears to be vital for the endocytosis of APP. This region is also important
for interaction with various other proteins, including Fe65 and Mint family of proteins.
The phosphorylation of APP at threonine 668 induces a conformational change in the Cterminal domain that can affect the binding to these interacting proteins. Blocking the
interaction of APP with Fe65 results in a shift toward non-amyloidogenic processing
[10], suggesting that Fe65 binding to APP promotes amyloidogenic processing.
5.4.1.

Phosphorylation and Endocytosis

Fe65 is known to modulate the endocytosis of both APP and LRP, promoting
clatherin-mediated endocytosis and internalization of the APP peptide [11].
Phosphorylation can result in the induction of a conformational change in APP, which
appears to be mediated by the prolyl isomerase Pin1 [12], inducing a conformational

3

For further discussion of the endogenous function of APP, see section 6.4.3.1.
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change in APP that negatively affects the binding of Fe65 [13].

Nevertheless,

phosphorylated APP is also known to be enriched in endocytic fractions [4]. This
suggests that binding of Fe65 and interaction of the Fe65/APP complex with LRP
promotes endocytosis, and phosphorylation of APP may occur within the endocytic
pathway. This in turn may have implications for the processing of APP.
5.4.2.

Phosphorylation and APP Processing

The endocytosis of APP is thought to contribute to its amyloidogenic processing
as BACE1 and APP colocalize in endosomal compartments [4]. In hippocampal neurons
in the AD brain, colocalization of phosphorylated APP and BACE is seen in large
vesicular bodies that also colocalize with endosomal markers [4].

Further,

phosphorylated APP cofractionates with BACE1 and endosomal markers, suggesting that
these proteins are indeed colocalized in the endosomes.

Importantly, C-terminal

fragments generated by β-secretase cleavage (i.e. C99) are preferentially phosphorylated
as compared to their α-secretase generated counterparts (i.e. C83), suggesting that
phosphorylation is associated with an increased propensity for APP to be processed via
an amyloidogenic pathway [4]. Preventing APP phosphorylation by inhibition of kinases
or mutation of the threonine 668 site also prevents generation of Aβ, strongly suggesting
that the phosphorylation of APP contributes to its amyloidogenic processing [4]
It’s also important to note that the phosphorylation of APP at threonine 668
renders APP less likely to be cleaved by caspases at the C-terminus, which occurs at
aspartate 664 [14]. The notion that this phosphorylation is associated with increased
amyloidogenesis, but is incompatable with caspase cleavage, is consistent with the
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observations we presented in Chapter 3, suggesting that caspase activation is associated
with decreased amyloidogenic processing of APP.
5.5. Endocytosis and APP Processing
Obviously, APP can only be cleaved by β-secretase when it is in the same
subcellular compartment as the secretase. The finding that both β-secretase and APP, and
significantly phosphorylated APP, colocalize to endosomes strongly suggests that both
phosphorylation and endocytosis are important for amyloidogenic processing. While it
has long been suggested that endocytosis is a requirement for Aβ generation, the specific
compartment in which Aβ is generated has been a matter of some debate, with candidate
organelles including the endoplasmic reticulum, trans-golgi network, early and late
endosomes, and lysosomes having been recognized as sites.
A recent study elegantly assessed this question using an siRNA approach to
inhibit various proteins along the endosomal sorting pathway to determine where Aβ is
generated. Three different endosomal sorting complexes required for transport (ESCRT)
were targeted:

ESCRT-0, which mediates sorting of endosomal cargoes, ESCRT-I,

important for membrane budding, ESCRT-III, important for fusion with multivesicular
bodies, and VPS4, required for the breakdown of the ESCRT-III complex to allow
recycling and continuation of the process. Blocking each of these steps in the endosomal
pathway allowed these investigators to isolate where in the pathway Aβ was being
produced [15]. Knockdown of components of the ESCRT-0 and ESCRT-II complexes
resulted in retention of APP in the early endosomes and a decrease in Aβ production,
while depletion of components of the ESCRT-III pathway and/or VPS4 results in
accumulation of APP in the trans-golgi network and increased APP processing and
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generation of Aβ. [15]. This suggests that APP, which is endocytosed and recycled to the
trans-golgi network is processed in an amyloidogenic fashion from an endocytosed pool.
5.6. Cell Cycle Dependent Production of Aβ
The data we presented earlier in this chapter suggest that APP is phosphorylated
in a cell cycle dependent manner. The phosphorylation of APP seems to be associated
with its localization within the endosomes, suggesting that either APP phosphorylation
enhances the endocytosis of APP or that APP is phosphorylated within endocytic
vesicles. Regardless of the specific compartment in which the phosphorylation occurs, it
is evident from the literature that APP which is endocytosed and recycled to the transgolgi network tends to be processed via an amyloidogenic pathway, and that C-terminal
fragments generated during amyloidogenic processing of APP tend to be phosphorylated
at threonine 668.
The evidence that suggests that phosphorylation of APP is associated with
enhanced amyloidogenic processing is consistent with the observations from our
laboratory that (1) cells undergoing mitosis have elevated levels of phosphorylated APP
and (2) arrest of cells in mitosis is associated with an increase in the production of Aβ.
Taken together, we can conclude that mitosis-dependent APP phosphorylation
contributes to increased Aβ generation during mitosis.
5.7. Conclusions
From the data presented and evidence from the literature presented in this chapter,
we can begin to draw together a mechanism for mitotic generation of Aβ. APP can be
endocytosed via clathrin-mediated endocytosis, likely associated with interaction with
Fe65 and LRP.

If the cell is undergoing mitosis, the presence of cyclin B-cdc2
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complexes result in elevated phosphorylation of APP.

Outside of mitosis this

phosphorylation may be mediated by other kinases, but the enhancement of this
processing is likely mediated by cdc2-dependent phosphorylation.
While it is not clear whether phosphorylation of APP has a direct effect on the
propensity of APP to be endocytosed or whether APP is phosphorylated after
endocytosis, it does appear that the phosphorylation of APP can mediate its further
interactions and downstream processing. Following phosphorylation, the prolylisomerase Pin1 can induce isomerization of APP, which results in decreased
amyloidogenic processing. In the disease condition, however, Pin1 levels are reduced,
and thus isomerization of APP is reduced. This allows APP, now localized in the
endocytic compartment and phosphorylated, to be cleaved in an amyloidogenic manner.
The enhancement of phosphorylation of APP, occurring during mitosis, is therefore
associated with an increase in amyloidogenic processing.
Given that isomerization of phosphorylated APP by Pin1 can act as a switch,
shuttling APP towards non-amyloidogenic processing when isomerization occurs and
allowing amyloidogenic processing to occur if isomerization does not occur, increasing
the function of Pin1 may be of great benefit in preventing amyloid production.
Interestingly, Pin1 can also mediate conformational changes in tau, making it a very
attractive target to curb disease progression.
5.8. Closing Remarks
In these experiments, we have investigated the role of cell-cycle dependent
changes on amyloidogenic processing. Our broad working hypothesis, as presented in
chapter 2, suggests that Aβ can induce cell cycle activation and p53 dependent apoptosis
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in cells. Given the fact that AD pathology tends to spread through the brain, we tested
the hypothesis that p53-dependent apoptosis and/or cell cycle activation may induce
amyloidogenesis, establishing a feed-forward process and allowing pathology to
propagate through the brain.
While our experiments regarding p53-dependent apoptosis did not support this
hypothesis, as Aβ levels were decreased during p53-dependent apoptosis, we did find that
p53-dependent apoptosis was associated with a decrease in the production of sAPPα,
likely due to ectodomain cleavage of APP. The experiments presented in this chapter,
however, do suggest that aberrant cell cycle activation can induce the phosphorylation of
APP, and that this phosphorylation of APP is associated with enhanced amyloidogenic
processing.
Therefore, while our hypothesis that the p53-dependent apoptosis may increase
Aβ production and allow propagation of Aβ through the brain is not supported, the
hypothesis that aberrant cell-cycle activation may lead to amyloidogenesis is supported
by the evidence. Together, with the literature suggesting that Aβ can elicit aberrant cellcycle related events, this suggests that Aβ can induce cell cycle activation, which in turn
results in mitotic phosphorylation of APP and increased processing of APP via an
amyloidogenic pathway. The cell-cycle related increase in amyloidogenic processing
results in an increase in secreted Aβ in the local microenvironment, which may result in
the induction of aberrant cell cycle related events in surrounding cells.
Importantly, in addition to APP, tau is also heavily phosphorylated during mitosis
– the same epitopes on tau that are phosphorylated during AD are phosphorylated during
mitosis. The intracellular phosphorylation of tau leads to the formation of paired helical
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filaments and ultimately neurofibrillary tangles, impairing intracellular trafficking and
metabolism and contributing to the demise of the cell. Thus, Aβ, in inducing aberrant
cell cycle entry, leads to both the phosphorylation of tau and an increase in the generation
of Aβ, allowing disease pathology to spread through the brain. The implications of this
research for our understanding of disease pathogenesis and disease treatment will be
further discussed in the next chapter.
Interestingly, recent studies have suggested that, in addition to its apparent
position downstream of amyloid in disease pathogenesis, phosphorylated tau can also be
transferred transynaptically, allowing tau pathology to spread from one region to another
directly through the neuronal circuitry. This presents an alternative mechanism by which
tau pathology, at least, may propogate through the brain. This alternative mechanism,
will also be discussed further in the next and final chapter.
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CHAPTER 6: DISCUSSION

6.1. Chapter Synopsis
In the preceding chapters, we have discussed the hypothesis that Aβ production
induces cell cycle activation and p53-dependent apoptosis, and have explored the
possibility that changes in APP processing associated with p53-dependent apoptosis and
cell cycle activation may result in increased generation of Aβ. In chapter 3, we presented
our evidence suggesting that in our apoptosis model there is no increase in Aβ
production; rather we see a decrease in the levels of both Aβ and sAPPα. P53-dependent
apoptosis was, however, associated with an increase in formation of a ~25 kDa protein
fragments which appears to involve cleavage by group II caspases, and show some
preference for caspase-7 over caspase-3.
Although our model of apoptosis was not associated with an increase in the
production of Aβ, we did see an increase in the production of Aβ occurring in a cell cycle
dependent manner, with a decrease in APP levels and processing during S-phase and an
increase in APP levels and processing during M-phase. Our lab and others have reported
that the phosphorylation of APP occurs in a cell cycle dependent manner, and the same
phase associated with APP phosphorylation were also associated with an increase in Aβ
production. This is consistent with findings from other laboratories, which suggest that
APP, and the BACE-cleaved fragment C99, colocalize with BACE in the endocytic
compartment both colocalizes with BACE1 and tend to be phosphorylated.
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In the current chapter, we will discuss the significance of our findings regarding
classical processing of APP, in particular the decrease in sAPPα, as well as discuss
findings from others regarding amyloidogenic processing in other models of cell death.
We will also review the literature regarding alternative processing of APP in the near
extracellular domain.

We will then discuss the relative importance of cell cycle

dependent changes in APP, focusing on changes related to APP phosphorylation,
including interactions with the APP binding protein Fe65.
Next, we will discuss the implications of our work on the anatomical cascade
hypothesis, as well as an alternative explanation of propogation of pathology that stems
from some recent literature regarding direct transmission to misfolded tau across the
synapse. Finally, we will discuss the implications of this research for the treatment of
AD.
6.2. Classical Processing of APP During Apoptosis
In chapter 3, we presented our findings regarding secretase-mediated processing
of APP in cells undergoing p53-dependent apoptosis following CPT treatment. We
found that, with regard to the C-terminal fragments, C83 levels were maintained while
C99 levels were reduced. This was seen during γ-secretase inhibition, which allowed us
both to isolate the α- and β- processing steps and account for the possibility of increased
γ-secretase activity described in the literature [1]. This would suggest that α-mediated
proteolysis is increased while β-mediated proteolysis is decreased. Immunoprecipitation
of the media for secreted fragments, however, revealed a decrease in both Aβ and sAPPα.
The decrease in Aβ is consistent with the finding that C99 production is decreased. The
decrease in sAPPα levels observed, however, seemed initially to be inconsistent with the
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finding that C83 production was sustained. However, our findings presented in chapter 4
provide evidence for increased cleavage of APP within the near ectodomain in cells
undergoing apoptosis. This would preclude the production of sAPPα, and explains why,
though C83 levels are maintained, sAPPα levels are reduced.
6.2.1.

Significance of a Decrease in sAPPα

The reduction in the levels of sAPPα are of particular significance because sAPPα
is known to be neurotrophic. sAPPα has been shown to inhibit calcium currents and
increase potassium currents, stabilizing membrane potentials and protecting cells against
excitotocity [2-4]. Importantly, sAPPα is released from neurons in an activity-dependent
manner [5], suggesting that it may play a role in buffering depolarizing currents, for
example dampening post-synaptic responses in response to high-frequency stimulation.
A decrease in the levels of sAPPα may, therefore, leave cells vulnerable to excitotoxic
stress due to impaired calcium homeostasis.
In addition to these neuroprotective effects, sAPPα also appears to be capable of
enhancing memory. Intracerebroventricular sAPPα administration in rats has been shown
to result in enhanced learning and memory performance, increased long-term
potentiation, and enhanced N-methyl D-aspartate receptor mediated currents [6]. Further,
sAPPα can increase the proliferation rates of neural stem cells, promote neurite
outgrowth, and lead to increased synaptogenesis [5, 7]. A decrease in sAPPα, as is
observed during p53-dependent apoptosis, may therefore result in memory impairment
even when the production of Aβ is reduced.
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6.2.2.

Results From Other Models of Apoptosis

While we do not observe an increase in the levels of Aβ in cells undergoing p53dependent apoptosis, other laboratories have seen increases in Aβ production in cells
undergoing this type of apoptosis as well as in cells undergoing cell death by other
means. Jin et al. reported increases in Aβ production in cells undergoing p53-dependent
apoptosis using CPT treatment of HEK cells overexpressing APP with the Swedish
mutation and BACE1 [1]. The most significant differences between their study and ours
is the overexpression of BACE1 and use of mutant APP, as well as the duration of
treatment with the DNA-damaging agents, which at 24-48 hours is much longer than our
treatments. In our experience and in our cell lines, treatment for that duration results in a
completely dead culture, while treatment for 3-6 hours allows us to measure things
occurring during the apoptotic process. Together with the overexpression of BACE1, this
suggests that the increase in Aβ production observed in the Jin et al. study [1] may be a
consequence of colocalization of high levels of BACE1 and APPSwe in apoptotic bodies,
and not necessarily indicative of processing occurring while the cells are in the process of
undergoing apoptosis.
Beyond p53-dependent apoptosis, other forms of cell death have been shown to
be associated with increased production of Aβ. For example, induction of apoptosis
using the staurosporine in a murine neuroblastoma cell line (N2a cells) has been shown to
increase Aβ production nearly 3-fold, with the majority of this Aβ accumulating
intracellularly in the endoplasmic reticulum [8]. In PC12 cells, staurosporine treatment
results in an approximately 2.5 fold increase in the secretion of Aβ [9]. Interestingly, in
serum free conditions this increase can be inhibited using a selective ERK inhibitor,
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while in the presence of serum the same ERK inhibitor does not inhibit staurosporineinduced Aβ secretion. A similar pattern is observed with respect to the phosphorylation
of APP, with P-APP detected in each condition where Aβ is produced. This suggests that
in non-cycling cells, phosphorylation of APP is mediated by ERK, whereas in cycling
cells this phosphorylation is mediated by other kinases, such as cdc2/cyclin B.
Trophic factor deprivation has also been shown to elicit caspase-6 dependent
degeneration of axons and neuronal death. This appears to involve the death receptor
DR6, which can act upstream of caspase-6. Importantly sAPPβ has been shown to be a
ligand for DR6, and growth factor deprivation is also associated with an increase in the
production of sAPPβ. This suggests that trophic factor deprivation can result in enhanced
amyloidogenic processing of APP, which can lead to DR6 mediated cell death in
surrounding neurons [10].
In CPT-dependent apoptosis, cells are most stressed as they enter into S-phase,
and do not progress into M-phase, where cell cycle dependent phosphorylation occurs.
This explains why, in the case of CPT-induced apoptosis, an increase in Aβ is not seen,
whereas in staurosporine-induced apoptosis an increase in Aβ generation is observed.
This suggests that the phosphorylation of APP, by ERK or cyclin-dependent kinases, is
necessary for Aβ generation, even during apoptosis.
6.3. Alternative Processing of APP During Apoptosis
In addition to processing by secretases, APP can also be cleaved by many
different proteases, including caspases, calpains, and matrix metalloproteases. In chapter
4, we presented evidence of a caspase-dependent proteolytic event which results in the
formation of fragments of APP that is detected at ~25 kDa.
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The size and

immunoreactivity of the fragments suggests that they are generated by cleavage of APP
in the near ectodomain. While there have been a few reports of evidence of proteolysis in
this region, the specifics of the proteolysis in this region are not well understood.
6.3.1.

MMP-Dependent Cleavage of APP

One important study isolated cerebrospinal fluid from AD patients and control
individuals and performed proteomic analysis by mass spectrometry, identifying 11 novel
fragments, seven of which were upregulated in AD[11]. One of these fragments, called 45 to 15 in this study, would result from cleavage by α-secretase at the C-terminus of the
fragment and by cleavage at SFGA*D626. This same site was also identified in a study in
which various membrane-type matrix metalloproteases (MT-MMPs) were overexpressed
along with APP. In this study, the C-terminal fragment resulting from this cleavage was
detectable in the cell lysates, by western blot on a 12% SDS-PAGE gel, and seemed to
run much smaller than the molecular weight predicted for a peptide containing the entire
C-terminus from this site onwards. However, only the N-terminus of these fragments
were sequenced, leaving the possibility that this peptide is also cleaved somewhere
towards the C-terminus, perhaps at the γ-secretase site [12].
6.3.2.

ST101-Dependent Cleavage of APP

In addition to cleavage by MMPs, a recent study from Frank Laferla’s laboratory
has described a proteolytic fragment generated from APP that is approximately 17 kDa in
size and generated in the presence of the azaindolizinone derivative spiro[imidazo[1,2s]pyridine-3,2-idan]-2(3H)-one (ST101).

While the protease responsible for the

generation of this fragment is not clear, it does appear that it involves a proteolytic event
approximately 150 amino acids from the C-terminus, within the range of the 11 sites
185

identified from the cerebrospinal fluid of patients [11, 13]. Perhaps the most interesting
feature of this particular proteolytic event is the fact that it is associated with a decrease
in the production of Aβ, despite the fact that the C-terminal fragment resulting from this
cleavage contains both the β- and γ-secretase sites. This suggests that the proteolytic
event that generates this fragment is somehow incompatible with amyloidogenic
processing, through mechanisms that are as yet unclear.
6.3.3.

Caspase Cleavage of APP

The work we have presented in chapter 4 focused on the caspase-dependent
generation of a ~25 kDa proteolytic fragment during CPT-induced apoptosis. Caspase
cleavage of APP has been described at three distinct sites along the APP peptide – two at
the N-terminus and one at the C-terminus [14]. The C-terminal caspase site is by far the
most studied, and cleavage of APP at this site generates a 31 amino acid fragment from
the C-terminus of APP, C31, which has been shown to be neurotoxic [15]. This cleavage
has been attributed to cleavage by caspase-3, -6, and -8 [14, 16, 17]. Our studies further
suggest that caspase-7 may also be involved in the cleavage of APP, as shRNA to
caspase-7 decreases the production of the ~25 kDa fragment even in the presence of
increased levels of cleaved caspase-3.
6.3.3.1.

Inflammation and Activation of Caspase-7

Although few studies have investigated the importance of caspase-7 activation in
AD, the few that have suggest that caspase-7 activation occurs relatively early in the
disease process. Studies in individuals with an increased risk for developing AD (those
with a Clinical Dementia Rating of 0.5) show up-regulation of caspase-1 and caspase-7 in
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the entorhinal cortex [18], one of the first areas affected in AD. TgCRND8 mice show
activation of caspase-7, but not caspase-3, in the vicinity of Aβ plaques [19].
Caspase-1, also known as interleukin converting enzyme, is associated with
neuroinflammation and has been shown to cleave and activate caspase-7 in vitro [20].
The upregulation of caspase-1 in AD is well established, and it is thought to contribute to
neurodegeneration via activation of interleukin-1β, a proinflammatory cytokine which is
also elevated in AD and is considered to be fundamental to the inflammatory state of the
AD brain [21].
The upregulation of both caspase-1 (interleukin converting enzyme) and
mediation of inflammation by IL-1β strongly suggest that active caspase-1 is an
important player in mediating the inflammatory response in AD. Caspase-1 can activate
both caspase-3 and caspase-7, and caspase-7 and caspase-1 mRNA levels are increased
early in the disease process. Taken together, this suggests that caspase-7 may be active
early in the disease process, and may be related to neuroinflammation through regulation
by caspase-1.
6.3.3.1.1.

Caspase-3 vs. Caspase-7

Caspase-3 and caspase-7 are often thought of as largely homologous caspases,
and indeed a large number of substrates can be cleaved by both caspases. However,
caspase-3 knockout is typically embryonically lethal, with gross abnormalities in brain
development due to decreased apoptosis, caspase-7 knockout mice are viable. This
suggests that apoptotic functions may be largely mediated by caspase-3, which is further
supported by the fact that caspase-7 appears to be more specific and caspase-3 more
promiscuous [22].

Importantly, caspase-3 is also more effective than caspase-7 in
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cleaving caspase-6, -9, and -2, which may provide a positive feedback loop promoting
apoptosis. This implies that, compared to caspase-3, caspase-7 is less effective as an
executioner caspase. Importantly, it also appears that caspase-3 and caspase-7 may
localize to different cellular compartments, as caspase-7 has been identified in endosomal
structures, while caspase-3 has not [23].
Our data using shRNA suggests that caspase-7 may have alternative functions
outside of apoptosis, as stable knockdown of caspase-7 using shRNA resulted in the
activation of caspase-3, the closest homologous caspase. This was not seen in transient
transfections, suggesting that cells which have decreased levels of caspase-7 for an
extended period of time compensate for the loss of the enzyme by upregulating cleaved
caspase-3. It has been suggested that caspases may play an important role in synaptic
plasticity, cell survival, proliferation, and differentiation [24], but non-apoptotic functions
of caspases are not well understood and warrant further investigation.
6.3.3.2.

Caspase Cleavage of Tau

While we have focused primarily on the cleavage of APP, it should be noted that
tau can also be cleaved by caspases at aspartate 421. Caspase-cleaved tau has been
observed in the AD brain. Cleaved tau is especially prone to aggregation, serve as a seed
for aggregation of tau in vitro. Cleaved tau rapidly adopts an MC1 conformation – so
named for the conformation-specific antibody used to detect it – a conformation
associated with the early stages of neurofibrillary tangle formation [For review, see 25].
This cleavage can be performed by caspase-3, but can also be performed by other
caspases including caspase-1, -6, -7, and -8 [25]. Interestingly, TgCRND8, which as
mentioned above showed activation of caspase-7 but not caspase-3, show both cleavage
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of tau and MC1 staining. Caspase-7, MC1, and cleaved tau staining were reduced by
treatment with the caspase inhibitor Q-VD-OPh, suggesting that caspase inhibition may
be beneficial for modulation of tau pathology in vivo [19].
6.4. Cell Cycle Dependent Processing of APP
In addition to investigating caspase related cleavages of APP, we also discussed
the regulation of APP during cell cycle. During S-phase, expression and processing of
APP are reduced and phosphorylation of APP is not detected, however during M-phase
expression, phosphorylation, and amyloidogenic processing of APP are all increased.
This suggests that aberrant cell cycle activation may play a role in amyloid production.
6.4.1.

“Mitosis” in Neurons

The expression of cell cycle related proteins, including cyclins D, A, B, and E,
cdks 1, 2, 4, and 5, in neurons even in normal brain suggest non-canonical roles for these
proteins in the brain [26].

However, the sequential activation of cell cycle related

proteins observed in the entorhinal cortex and the dentate gyrus in response to excitotoxic
damage to the hippocampus suggest that excitotoxic stress may induce aberrant cell cycle
re-entry. Markers of the G1/S phase of cell cycle are present in the brains of mice after
excitotoxic injury, and shortly after the increase in G1/S markers an increase in PHF-1
and APP are observed. An increase in cyclin B is also observed in these brains [27]. The
increase in PHF-1 may be due to upregulation of cyclin B, which along with its binding
partner cdc2 has been shown to induce phosphorylation of tau. We have observed an
increase in APP expression and phosphorylation associated with M-phase as well.
While it is clear that neurons can express markers of cell cycle and that there is
some functional activity of these proteins, neurons are not entirely capable of mitosis due
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to their complex cytoarchitecture. Mitosis involves the reorganization of the cytoskeleton
to form the mitotic spindle. In order to reorganize microtubules, microtubule stabilizing
proteins dissociate from microtubules, allowing their break-down. Tau is one of these
proteins, and in order to dissociate from the microtubules tau is phosphorylated. The
same epitopes that are phosphorylated on tau to induce its dissociation from the
microtubules during mitosis are the epitopes phosphorylated during AD – antibodies
raised against paired helical filaments isolated using the antibody Alz50 from brain
homogenates from AD patients (specifically the TG and MC series of antibodies created
in the laboratory of Peter Davies) stain cells in mitosis.
The notion of “mitosis” in neurons is somewhat controversial, as neurons are
generally thought of as post-mitotic and incapable of cell division. Although this is
almost certainly the case, the aberrant activation of proteins associated with mitosis,
which may well result from sequential activation of proteins associated with earlier
phases of the cell cycle and deregulation of cell cycle checkpoints, could still occur. The
phosphorylation of tau during mitosis can induce reorganization of microtubules and in
neurons cause microtubule destabilization, impaired trafficking, and proteosomal stress
resulting in the formation of neurofibrillary tangles.
6.4.2.

Cell Cycle Dependent Phosphorylation of APP

Beyond the phosphorylation of tau, the phosphorylation of APP also occurs
during mitosis. Suzuki et al. first described mitosis-specific phosphorylation of APP in
1994 and showed that in vitro purified cdc2/cyclin B complex, a cell cycle dependent
kinase complex active during M-phase, could phosphorylate a synthetic peptide
consisting of APP645-694 as well as APP663-676 [28]. The latter peptide contains only one
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threonine, suggesting the residue phosphorylated was threonine 668. Subsequent work
from Li-Huei Tsai’s laboratory identified elevated levels of P-APPT668 in the brains of
AD patients, which appeared to colocolize with BACE1 in the endosomes, suggesting
that the phosphorylation of APP at threonine 668 may be associated with amyloidogenic
processing [29].
Work from our own laboratory has identified an increase in cell cycle markers
cyclin D1 and cyclin E as well as phosphorylation of APP in the brains of transgenic
mice overexpressing human APP and PS1, with animals expressing APP showing
elevated levels compared to nontransgenic animals and PS/APP animals expressing even
higher levels. Staining for phosphorylated APP was also colocalized with phosphoneurofilament staining with NFH antibody, in the vicinity of plaques, suggesting that
conditions in the vicinity of Aβ plaques lead to both phosphorylation of APP and neurite
degeneration. We also reported that inhibition of cell cycle progression was associated
with changes in both the phosphorylation status of APP and changes in APP processing,
where a block at the G1/S transition results in a decrease in APP phosphorylation and
processing and a block in M-phase results in increase phosphorylation of APP and
amyloidogenic processing [30]. This is consistent with the observation from other labs,
which suggest that the phosphorylation of APP is increased in endocytic vesicles, and
that endocytosis of APP is associated with its amyloidogenic processing.
6.4.3.

Phosphorylation and Interaction with Fe65

The specific mechanism by which phosphorylation of APP, mitotic or otherwise,
is associated with endocytosis and increased APP processing is not entirely clear.
Phosphorylation of APP seems to decrease the association of APP with the adaptor
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protein Fe65. APP serves to tether Fe65 to the cell membrane, and the phosphorylation
of APP blocks the interaction of Fe65 with APP, essentially “liberating” Fe65 from its
membrane association [31]. This allows Fe65 to be translocated to the nucleus, where it
can modulate AICD-dependent gene transcription.
AICD, after cleavage by γ-secretase, translocates to the nucleus and modulate
gene transcription. Somewhat paradoxically, it is predominately phosphorylated AICD
that localizes to the nucleus, and the phosphorylation of AICD seems to be vital for its
interaction with Fe65 [32]. Fe65, therefore, seems to bind phosphorylated AICD in the
nucleus, but not phosphorylated APP in the cytoplasm.
Phosphorylation of APP is associated with increased binding of Pin1, a peptidylprolyl cis-trans isomerase which, when APP is phosphorylated Pin1 converts the peptide
to a trans conformation. A loss of Pin1 (and therefore a decrease in the isomerization of
phosphorylated APP) results in an increase in the production of Aβ [33]. This suggests
that it may be the isomerization of surface APP, and not phosphorylation per se, that
results in a decrease in Fe65 binding. Fe65 appears to form a complex with APP and low
density lipoprotein receptor-related protein (LRP), and this interaction appears to
promote the endocytosis of APP and consequent amyloidogenic processing [34]. It is
reasonable to suggest that the decrease in Pin1 seen in AD may result in decreased
isomerization of APP, increased association of Fe65 with APP and LRP, increased
endocytosis of APP, and increased amyloidogenic processing
6.4.3.1.

Reflections on the Function of APP

APP was identified and named for its role in the production of Aβ, and as such the
vast majority of research aimed at understanding APP has focused on its proteolysis to
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the extent that the actual raison d’être for APP has never been entirely clear.
Structurally, the protein resembles a cell surface receptor – the extracellular domain of
APP is complex, folding upon itself with many loops for interacting with other proteins.
There is a single transmembrane domain that tethers it to the membrane, and a rather
short and indescript intracellular domain known to be involved in trafficking and
interactions with adaptor proteins. This structure is consistent with a proposed function
of APP as a receptor which modulates intracellular signaling through binding interactions
at the C-terminus.

A number of proteins have been shown to interact with the

extracellular domain of APP, including Aβ, F-spondin, Netrin-1, and BRI2 [For review,
see 35]. While it is evident that the APP extracellular domain can interact with various
proteins, the function of these interactions are still not clear, and the functional role of
APP as a receptor is still questionable.
Another potential function of APP is in cell and synaptic adhesion, as the
extracellular domain, importantly, interacts with matrix proteins and heparin sulfate
proteoglycans. Indeed, in our own laboratory we have consistently noticed a qualitative
difference in the adhesion of cells expressing APP versus those that do not, with APP
expressing cells adhering more strongly. Interestingly, APP can also form parallel or
antiparallel dimers, possibly playing a role in cell-cell adhesion. This seems to be
particularly important in modulating synaptic strength [For review, see 35]. Importantly,
secretion of α-cleaved forms of APP is activity dependent and enhances synaptic
stability. The importance of APP in regulating synaptic adhesion and stability certainly
warrants further investigation.
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6.5. Anatomical Cascade Hypothesis
Throughout this text, we have referred to the anatomical cascade hypothesis. This
hypothesis serves to bridge the apparent gap between the amyloid cascade hypothesis,
which has become widely accepted, and the fact that intraneuronal tau pathology follows
a predictable progression through the brain. The amyloid cascade hypothesis is strongly
supported and in fact historically rooted in the genetics of familial AD. The entirety of
AD pathology – plaques, neurofibrillary tangles, and neurodegeneration – can and does
occur with duplication or mutation of APP or with gain-of function mutations to PS1.
This strongly suggests that the processing of APP into Aβ is paramount for all aspects of
pathology to occur, and that Aβ lies upstream of tau in the pathogenesis of AD.
However, Aβ-associated pathology, namely amyloid plaques, are found throughout the
cortex and, though they increase in number and often become more dense as the disease
progresses, they do not follow a particular anatomic course through the brain. Tau
pathology, on the other hand, does progress in a predictable fashion, following the same
anatomical course in each patient. There is somewhat of a dichotomy here – if amyloid
does indeed lie upstream of tau, and tau follows this progression through the brain, does
amyloid also follow this progression? It is clear that the deposition of plaques does not,
however the specific pathological species of Aβ, which mediates tau pathology, is not the
plaque but small oligomers. These small, soluble oligomers do not persist for staining by
immunohistochemical techniques. Therefore, while the formation of plaques does not
progress predictably through the brain the production of amyloid and its small, soluble
oligomers may.
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6.5.1.

The Anatomical Cascade via Cell Cycle Activation

We have in this work assessed whether p53-dependent apoptosis or cell cycle
activation may provide a mechanism by which Aβ produced and secreted from one cell
may induce Aβ production in anatomically adjacent regions. Aβ has been shown to
induce both cell cycle activation and apoptosis, so we isolated each process to assess
whether Aβ production is altered. While we did not observe an increase in the production
of Aβ from cells undergoing p53-dependent apoptosis in our model, we do see an
increase in the production of Aβ from cells during mitosis. The schematic presented in
figure 2.1 has been modified to include these findings and is presented in figure 6.1.
Importantly, Aβ has been shown to elicit cell cycle activation. As discussed at
length in chapter 2, Aβ can induce cell cycle related events, including activation of
mitogen-activated protein kinase (MAPK) pathways, cyclin D1 expression, cyclin B1
expression, and Rb phosphorylation.

This induction includes the activation of

cdc2/cyclin B, which can phosphorylate many intracellular proteins including tau and
APP. The phosphorylation of APP has been associated with colocalization of APP and
BACE1 in AD brain, connecting APP phosphorylation with its amyloidogenic processing
[29].

Indeed, as presented in chapter 5, in the same conditions we observe

phosphorylation of APP (namely arrest of cells in M-phase) we observe an increase in
amyloidogenic processing.
Taken together, this suggests that Aβ can induce cell cycle activation and that
cells cycle activation, provided cells get far enough into the cell cycle for mitotic
phosphorylations to occur, can in turn result in an increase in the production of Aβ. This
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Figure 6.1. Schematic of our findings as they apply to the anatomical cascade
hypothesis. As presented in figure 2.1, Aβ has been proposed to act as a mitogenic
signal, and phosphorylation of tau can occur in a cell cycle dependent manner. Since
tau pathology propagates through the brain in a predictable manner and Aβ is
upstream of tau, we hypothesized that Aβ production may also propagate through the
brain in a similar fashion. In this schematic, we illustrate that Aβ elicits cell-cycle
reentry in the cell on the left. If DNA damage is extensive, cells may undergo p53dependent apoptosis. Our findings suggest that p53 dependent apoptosis is
associated with a decrease in sAPPα as well as production of a novel caspase
cleaved proteolytic fragment of APP. If DNA is not sufficiently damaged or if p53
is deficient, cells may advance further in the cycle. Progression of cells into mitosis
is associated with an increase in the phosphorylation of APP and an increase in the
production of Aβ which may then affect surrounding cells, allowing pathology to
propagate through the brain.

196

may occur in cells which either have insufficient DNA damage to enter apoptosis at the
p53 checkpoint or in cells in which p53 is deficient or mutated. Since Aβ is secreted, this
would induce cell cycle activation in cells in the local microenvironment, allowing AD
pathology to spread through the brain.
6.5.2.

Direct Transmission of Tau Across the Neuronal Synapse

While our data suggests that the propagation of tau pathology through the brain
can be explained by cell cycle activation mediated by Aβ secretion, it should be noted
that recently a more direct explanation of the propagation of tau pathology has emerged.
Interestingly, and rather surprisingly, the microtubule-associated protein tau has been
shown to directly spread from one neuron to the next, across the synapse [36-38].
In 2012, two important studies were reported of tau pathology spreading from the
entorhinal cortex to adjacent brain regions. One study from the laboratory of Karen Duff
used a mouse with inducible expression of human tau with the P301L mutation (Tg4510
mice) and crossed these with mice expressing a tetracycline transactivator under the
neuropsin promoter, which drives the expression of the transgene in the entorhinal cortex.
They found that in young mice, tau pathology was isolated to the entorhinal cortex, but in
older mice pathology was found in other structures, including the CA1 region of the
hippocampus and granule cells of the dentate gyrus. This suggests that tau may be
moving from one cell to the next across the synapse [36].
One caveat of this studies is the observation of human tau mRNA in cells of the
dentate gyrus, harvested by laser capture microdissection. Though the authors suggest
that due to the sensitivity of PCR for detection of mRNA it is possible that very few of
the many cells pooled actually express the RNA, they did observe higher levels of human
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tau mRNA in the dentate gyrus of old animals than in young animals, even in cells that
did not have positive staining for tau protein [36]. This suggests that it is possible that
the tetracycline transactivator may be present in these cells and driving the expression of
tau, and that the effects are mediated by “leakage” of the transactivator transgene rather
than by tau protein actually making the trans-synaptic “leap”.
In a separate study from Brad Hyman’s laboratory reported largely similar results
in a mouse model generated independently but using an identical approach (Tg4510 mice
crossed with mice expressing a tetracycline transactivator under the neuropsin promoter).
In this study, they show tau expression in the dentate gyrus but, instead of laser capture
microdissection, use fluorescence in situ hybridization (FISH) to determine whether taupositive cells of the dentate are expressing the transgene or are the recipients of transsynaptic transmission of tau. Importantly, in cells that are positive for human tau protein,
they do not detect the expression of tau mRNA. This suggests that the tau protein
observed in these cells was not expressed by the cells, and instead was expressed in other
cells (presumably in the entorhinal cortex) and taken up by cells of the dentate [37].
Another study from the laboratory of Virginia Lee shows that aggregated tau can
propagate to adjacent regions. In this study, synthetic, preformed tangles were injected
into young PS19 transgenic mice. These mice typically develop tau pathology at 8-9
months of age, but in this study 2-3 month old mice were used. Preformed tangles were
injected unilaterally into a specific location in the hippocampus, and tau pathology was
observed in regions of the hippocampus distal to the injection site, including
contralaterally, and later was observed in other structures including the entorhinal cortex.
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This suggests that the injected tau can be taken up by neurons, and act as “seeds” for the
aggregation of misfolded tau in the brains of these mice [38].
These studies suggest that misfolded tau can be transferred from one cell to the
next, and that this misfolded tau could seed the aggregation of tau in the post-synaptic
cell. Importantly, phosphorylated tau, associated with exosomes, has been reported in the
cerebrospinal fluid of AD patients, suggesting that tau transmission could be occurring in
the human condition.

This present an alternative explanation for the anatomical

progression of tau pathology that is independent of the induction of phosphorylated tau
induced by Aβ. It is possible that both mechanisms work in tandem, with Aβ-inducing
tau phosphorylation and synaptic transmission providing a seed of misfolded tau that
allows phospho-tau native to the postsynaptic cells to aggregate into filaments and
ultimately form tangles.
6.6. Implications for the Treatment of Alzheimer’s Disease
In this chapter, as in the rest of this work, many interrelated pathways of AD
pathogenesis have been presented. Caspase-mediated cleavage of APP and tau have been
discussed, and while caspase-mediated cleavage of APP does not seem to modify
pathology, caspase cleavage of tau results in tau adopting an MC1 configuration and
makes tau prone to aggregation. Because caspases are typically thought of as proteases
involved in the more final stages of cell death, caspase inhibition is generally regarded as
“too little too late.” However, the upregulation of caspase-1 and caspase-7, both of
which are capable of cleaving tau, early in the disease process suggests that these
proteases may have disease-modifying abilities far earlier than neurodegeneration, and
that caspase inhibition, such as with Q-VD-OPh, may provide some benefit. In fact,
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intranasal administration of a caspase-9 inhibitor has been shown to be effective in
preventing axon loss and neurodegeneration following stroke [39].
Our research also strongly implicates cell cycle activation in the pathological
development of AD. Inhibition of cell cycle progression, especially at the G1/S
transition, would likely effectively inhibit cell cycle related phosphorylation of both tau
and APP, leading to a decrease in amyloid production and tau pathology. Of course,
targeting such therapy to neurons may present a technical challenge, and the targeting of
cell cycle inhibition to neurons would also impede neurogenesis, which is also important
for memory. It would take further investigation to determine whether the benefits of cell
cycle inhibition, with regard to Aβ and tau pathology, would outweigh the risk of
impaired neurogenesis, and whether or not this would ultimately have a positive or
negative effect on memory.
Our work also echoes the work of others in illustrating the apparent importance of
the phosphorylation of APP in amyloidogenic processing. This seems to be related to the
trafficking of APP, though the details of this mechanism, likely involving APP
interacting proteins like Fe65, are still being elucidated. The phosphorylation-dependent
isomerization of APP by Pin1 may be an important means of altering APP endocytosis
and preventing amyloidogenic processing. The activity of Pin1 is known to be decreased
in AD – increasing Pin1-mediated isomerization of APP, or potentially disrupting the
interaction between APP, adaptor proteins, and LRP, to prevent endocytosis of APP and
amyloidogenic processing, may also be of significant therapeutic benefit.
The therapeutic approaches presented here focus primarily on early phases of the
disease process. However, the brain is resilient, and disease progression, pathologically,
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is typically quite advanced before patients present with symptoms. Approaches focused
on removing Aβ in patients with moderate to advanced AD using immunotherapy, though
successful in mice, have shown little benefit. Similarly, approaches involving secretase
inhibition have also shown little benefit in clinical trials, though treatment in these cases
may have simply begun too late for a drug that acts on processes that are important early
in disease progression. The approaches presented here, which, like secretase inhibition,
also focus on Aβ production, would be best used early in the disease process.
Therefore, the early detection of AD is paramount in order for these treatment
approaches to be viable. Fortunately, recent advances in the detection of AD pathology,
especially early amyloid deposition, will allow for early detection of disease onset –
provided patients are actually imaged, likely on at least two occasions to determine if
pathology is increasing. Since memory problems are often imperceptible while amyloid
production and deposition is steadily increasing, it may be necessary for imaging to be
done on a prophylactic basis. At the present time this is cost-prohibitive, but now that the
technology has already been developed it is possible that cost will, over the next decade
or so, drop significantly and potentially allow for routine amyloid imaging in a clinical
setting for early detection of AD. The early detection of AD will ultimately broaden the
possibilities for therapeutic intervention.
6.7. Final Remarks
In this chapter, we have discussed the implications of our findings in the context
of the literature and related these findings to our original hypothesis. The broader goal of
this work was to determine whether cell cycle activation or p53-dependent apoptosis
might provide a mechanism for the spread of AD pathology through the brain. While we
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found no evidence to support the role of p53-dependent apoptosis in this processs, we did
find that phosphorylation of APP and amyloidogenic processing was increased in cells
undergoing mitosis. Since Aβ has been shown to induce cell cycle activation, and our
data suggest that cell cycle activation can, in turn, increase the production of Aβ, we
believe that the Aβ-dependent induction of aberrant cell cycle related events in AD could
serve as a driving force in the spread of AD pathology.
The cell cycle dependent increase in Aβ production is directly correlated with the
mitotic phosphorylation of APP, consistent with the literature that suggests that
phosphorylation of APP is associated with its amyloidogenic processing. This strongly
implicates kinases capable of phosphorylating APP as central to the disease process.
Many of the kinases involved in the mitotic phosphorylation of APP are also capable of
phosphorylating tau, suggesting that aberrant cell cycle reentry could drive both Aβ and
tau pathology.

It is important to note that misfolded tau appears to be capable of

spreading from cell to cell within the neuronal network, directly across the synapse. The
presence of this misfolded tau may act as a seed for the aggregation of phosphorylated
tau, allowing pathology to spread in a prion-like manner.
The results presented here suggest various treatment approaches, including
caspase and/or kinase inhibition to prevent the misfolding of tau (as caspase-cleaved and
phosphorylated tau has a strong propensity for aggregation), cell cycle inhibition, or
disruption of APP endocytosis to decrease amyloidogenic processing.

All of these

approaches intercede rather early in the disease process, making early detection of AD
vital to treatment development.

Continued research into these potential approaches
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coupled with earlier detection of the disease process could lead to promising treatments
for early stage Alzheimer’s disease.
6.8. References for Chapter 6
1.

Jin, S.M., et al., DNA damage-inducing agent-elicited gamma-secretase activity is
dependent on Bax/Bcl-2 pathway but not on caspase cascades. Cell Death Differ,
2007. 14(1): p. 189-92.

2.

Furukawa, K., et al., Activation of K+ channels and suppression of neuronal
activity by secreted beta-amyloid-precursor protein. Nature, 1996. 379(6560): p.
74-8.

3.

Barger, S.W., et al., beta-Amyloid precursor protein mismetabolism and loss of
calcium homeostasis in Alzheimer's disease. Ann N Y Acad Sci, 1993. 695: p.
158-64.

4.

Furukawa, K., et al., Increased activity-regulating and neuroprotective efficacy of
alpha-secretase-derived secreted amyloid precursor protein conferred by a Cterminal heparin-binding domain. J Neurochem, 1996. 67(5): p. 1882-96.

5.

Mattson, M.P., et al., Cellular signaling roles of TGF beta, TNF alpha and beta
APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev,
1997. 23(1-2): p. 47-61.

6.

Taylor, C.J., et al., Endogenous secreted amyloid precursor protein-alpha
regulates hippocampal NMDA receptor function, long-term potentiation and
spatial memory. Neurobiol Dis, 2008. 31(2): p. 250-60.

203

7.

Ohsawa, I., et al., Amino-terminal region of secreted form of amyloid precursor
protein stimulates proliferation of neural stem cells. Eur J Neurosci, 1999. 11(6):
p. 1907-13.

8.

Borghi, R., et al., Neuronal apoptosis is accompanied by amyloid beta-protein
accumulation in the endoplasmic reticulum. J Alzheimers Dis, 2002. 4(1): p. 31-7.

9.

Sodhi, C.P., R.G. Perez, and N.R. Gottardi-Littell, Phosphorylation of betaamyloid precursor protein (APP) cytoplasmic tail facilitates amyloidogenic
processing during apoptosis. Brain Res, 2008. 1198: p. 204-12.

10.

Nikolaev, A., et al., APP binds DR6 to trigger axon pruning and neuron death via
distinct caspases. Nature, 2009. 457(7232): p. 981-9.

11.

Portelius, E., et al., Identification of novel APP/Abeta isoforms in human
cerebrospinal fluid. Neurodegener Dis, 2009. 6(3): p. 87-94.

12.

Ahmad, M., et al., Cleavage of amyloid-beta precursor protein (APP) by
membrane-type matrix metalloproteinases. J Biochem, 2006. 139(3): p. 517-26.

13.

Green, K.N., et al., ST101 induces a novel 17 kDa APP cleavage that precludes
Abeta generation in vivo. Ann Neurol, 2011. 69(5): p. 831-44.

14.

Gervais, F.G., et al., Involvement of caspases in proteolytic cleavage of
Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide
formation. Cell, 1999. 97(3): p. 395-406.

15.

Nguyen, T.V., et al., Signal transduction in Alzheimer disease: p21-activated
kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem,
2008. 104(4): p. 1065-80.

204

16.

Lu, D.C., et al., Caspase cleavage of the amyloid precursor protein modulates
amyloid beta-protein toxicity. J Neurochem, 2003. 87(3): p. 733-41.

17.

Pellegrini, L., et al., Alternative, non-secretase processing of Alzheimer's betaamyloid precursor protein during apoptosis by caspase-6 and -8. J Biol Chem,
1999. 274(30): p. 21011-6.

18.

Pompl, P.N., et al., Caspase gene expression in the brain as a function of the
clinical progression of Alzheimer disease. Arch Neurol, 2003. 60(3): p. 369-76.

19.

Rohn, T.T., et al., Caspase activation in transgenic mice with Alzheimer-like
pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh.
Int J Clin Exp Med, 2009. 2(4): p. 300-8.

20.

Lamkanfi, M., et al., Targeted peptidecentric proteomics reveals caspase-7 as a
substrate of the caspase-1 inflammasomes. Molecular & cellular proteomics :
MCP, 2008. 7(12): p. 2350-63.

21.

Greer, M.M., Inflammation and the pathophysiology of Alzheimer's disease.
Dialogues Clin Neurosci, 2000. 2(3): p. 233-9.

22.

Walsh, J.G., et al., Executioner caspase-3 and caspase-7 are functionally distinct
proteases. Proc Natl Acad Sci U S A, 2008. 105(35): p. 12815-9.

23.

Edelmann, B., et al., Caspase-8 and caspase-7 sequentially mediate proteolytic
activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J, 2011.
30(2): p. 379-94.

24.

Lamkanfi, M., et al., Caspases in cell survival, proliferation and differentiation.
Cell Death Differ, 2007. 14(1): p. 44-55.

205

25.

Cotman, C.W., et al., The role of caspase cleavage of tau in Alzheimer disease
neuropathology. J Neuropathol Exp Neurol, 2005. 64(2): p. 104-12.

26.

Schmetsdorf, S., U. Gartner, and T. Arendt, Constitutive expression of
functionally active cyclin-dependent kinases and their binding partners suggests
noncanonical functions of cell cycle regulators in differentiated neurons. Cerebral
Cortex, 2007. 17(8): p. 1821-1829.

27.

Hernández-Ortega, K., P. Ferrera, and C. Arias, Sequential expression of cellcycle regulators and Alzheimer's disease-related proteins in entorhinal cortex
after hippocampal excitotoxic damage. Journal of neuroscience research, 2007.
85(8): p. 1744-1751.

28.

Suzuki, T., et al., Cell cycle-dependent regulation of the phosphorylation and
metabolism of the Alzheimer amyloid precursor protein. EMBO J, 1994. 13(5): p.
1114-22.

29.

Lee, M.S., et al., APP processing is regulated by cytoplasmic phosphorylation. J
Cell Biol, 2003. 163(1): p. 83-95.

30.

Judge, M., et al., Mitosis-specific phosphorylation of amyloid precursor protein at
threonine 668 leads to its altered processing and association with centrosomes.
Mol Neurodegener, 2011. 6: p. 80.

31.

Nakaya, T. and T. Suzuki, Role of APP phosphorylation in FE65-dependent gene
transactivation mediated by AICD. Genes Cells, 2006. 11(6): p. 633-45.

32.

Chang, K.A., et al., Phosphorylation of amyloid precursor protein (APP) at
Thr668 regulates the nuclear translocation of the APP intracellular domain and
induces neurodegeneration. Mol Cell Biol, 2006. 26(11): p. 4327-38.

206

33.

Pastorino, L., et al., The prolyl isomerase Pin1 regulates amyloid precursor
protein processing and amyloid-beta production. Nature, 2006. 440(7083): p.
528-34.

34.

Pietrzik, C.U., et al., FE65 constitutes the functional link between the low-density
lipoprotein receptor-related protein and the amyloid precursor protein. J
Neurosci, 2004. 24(17): p. 4259-65.

35.

Zheng, H. and E.H. Koo, Biology and pathophysiology of the amyloid precursor
protein. Mol Neurodegener, 2011. 6(1): p. 27.

36.

Liu, L., et al., Trans-synaptic spread of tau pathology in vivo. PLoS One, 2012.
7(2): p. e31302.

37.

de Calignon, A., et al., Propagation of tau pathology in a model of early
Alzheimer's disease. Neuron, 2012. 73(4): p. 685-97.

38.

Iba, M., et al., Synthetic tau fibrils mediate transmission of neurofibrillary tangles
in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci, 2013.
33(3): p. 1024-37.

39.

Akpan, N., et al., Intranasal delivery of caspase-9 inhibitor reduces caspase-6dependent axon/neuron loss and improves neurological function after stroke. J
Neurosci, 2011. 31(24): p. 8894-904.

207

APPENDICES

208

Appendix A: Materials and Methods
Ethics Statement
Studies involving animals (primary neuronal culture) were done in accordance
with the rules and regulations set forth by the University of South Florida's Institutional
Animal Care and Use Committee (IACUC). This specific study was approved by the
University’s IACUC committee (Protocol # R3758). Timed pregnant rats at E14 were
purchased from Harlan and cared for by the well-established animal care facility at
University of South Florida (USF), which is accredited by the American Association of
Laboratory Animal Care (AALAC).

Cell Culture and Drug Treatment
Cortical neurons were cultured following published protocols [1]. Somnasol
solution was diluted 1:10 in normal saline and pregnant rats were anaesthetized with 0.7
mL diluted solution to collect embryos at E18. Embryos were removed and brains
collected and placed in a dissecting solution until trituration. 500 mL of dissecting
solution was prepared by combining 25 mL of buffered saline (137 mM NaCl, 5.4 mM
KCl, 0.17 mM Na2HPO4, and 0.22 mM KH2PO4) with 14 mL 9.9 mM Hepes, along with
3 g glucose, and 7.5 g sucrose and adjusting the pH to 7.4 using 1N NaOH. The volume
was brought to 500 mL with ddH2O and filter sterilized. After removal of the meninges
embryonic brains were minced in dissecting solution and placed in 0.25% trypsin for 5
minutes (Life Technologies). Trypsin was removed by centrifugation at 500 x g for 5
minutes and tissue fragments placed back in dissection solution, where they were
triturated by passing through firepolished Pasteur pipettes of three different diameters in
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Appendix A: Materials and Methods (continued)
decreasing order. Dissociated cells were centrifuged at 500 x g and resuspended in
neurobasal media (Life Technologies) containing B27 supplement and plated onto polyL-lysine coated culture plates at a density of approximately 200,000 cells/cm2. Cells were
cultured for seven days prior to initiation of experiments. Apoptosis in neurons was
induced by treatment with 10 µM camptothecin for 12-24 hours (CPT, Sigma) [2-4]. For
experiments involving caspase inhibition, neurons were pretreated with group II caspase
inhibitor zDEVD-FMK or the broad-spectrum caspase inhibitor zVAD-FMK (R&D
Systems, Minneapolis, MN) at 10-20 µM concentrations for 1 hour prior to the addition
of CPT. Caspase inhibitors were present for the entire duration of CPT treatment.
Samples were then collected for western blot analysis as described below[1, 5].
H4 cells expressing APP (H4-APP) were a kind gift from Dr. Todd Golde (Mayo
Clinic, Jacksonville, FL). The generation of this cell line has been previously described
[6]. These cells were cultured in “normal growth media” consisting of Opti-MEM (Life
Technologies) media containing 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1%
penicillin/streptomycin

(Life

Technologies),

and

50

µg/ml

hygromycin

(Life

Technologies) until they reached 60% confluency. For experiments involving serum
deprivation, cells were rinsed twice with DPBS (Fisher) and cultured in DMEM (Life
Technologies) containing penicillin/streptomycin with no serum for 48 hours. After 48
hours, cells were rinsed with DPBS twice more before adding the appropriate treatment
media. For experiments involving caspase inhibition, cells were cultured in 10-20 µM
zDEVD-FMK or zVAD-FMK in normal growth media for one hour prior to induction of
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Appendix A: Materials and Methods (continued)
apoptosis. Cells were then exposed to 10 µM CPT for indicated time periods in the
presence and absence of inhibitors.

Lysate Preparation
After treatment for the indicated times, cells were scraped into culture media, and
pelleted by centrifugation at 500 x g for five minutes at 4°C. Pellets were washed three
times in ice cold PBS (spinning at 500 x g for five minutes at 4°C between washes) and
resuspended in ice cold RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, and 50 mM Tris (pH 8.0)) containing protease inhibitors (1
mM PMSF, 1 mM NaVO4, 1 mM NaF, and one Complete Mini protease inhibitor tablet
per 10 mL (Roche Applied Science, Indianapolis, IN)). Cells were lysed by sonication
using a sonic dismembranator (Thermo Fisher Scientific) on setting 6 for 10 seconds on
ice and the insoluble fraction separated by high-speed centrifugation (20800 x g for 15
min at 4°C). The supernatant containing soluble proteins was retained and analyzed for
total protein content using a Bradford or bicinchoninic assay (BCA) (Thermo Fisher
Scientific, Rockford, IL) following the manufacturer’s protocol. Samples containing
equal amounts of protein were prepared by dilution in 1xRIPA. For loading onto western
blots, samples were prepared in Laemmli sample buffer (4x stock consisting of 200 mM
Tris pH 6.8, 40% v/v glycerol, 50 mM EDTA, 8% SDS, 20% β-mercaptoethanol, and
0.02% bromophenol blue) or Tricine Sample Buffer (Life Technologies) depending on
gel for polyacrylamide gel electrophoresis (PAGE) and western blot analysis.
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Western Blot Analysis
Western blot analyses were performed following established protocols [1, 5].
Briefly, samples were separated by PAGE on either 10-20% tricine (Life Technologies)
or 15% tris-glycine mini gels at 90-125 V. 15% Tris-glycine gels were casted using a
solution of 15% acrylamide, 375 mM Tris (pH8,8), 0.1% SDS, 0.1% APS, and 0.0008%
TEMED (resolving gel), with the stacking gel containing 5% acrylamide, 125 mM tris
pH 6.8, 0.1% SDS, 0.1% APS, and 0.001% TEMED. For running buffer, 1x tricine
running buffer (Life Technologies) was used for 10-20% tricine gels and 1x tris-glycine
running buffer (14.4 g glycine, 2.9 g Tris, and 1 g SDS per liter in ddH2O) was used for
tris-glycine gels. Molecular weight markers used were either SeeBlue Plus 2 (Life
Technologies) or Precision Plus Dual Xtra (BioRad). Proteins were transferred to 0.1 or
0.2 µm nitrocellulose membranes using the XCell SureLock mini-blotting module
(Invitrogen) at 30 V for two hours. Transfer buffer contained 14.4 g glycine and 2.9 g
tris base per liter in ddH2O. The membranes that were used for detection of Aβ were
boiled in PBS for five minutes prior to blocking non-specific binding. Membranes were
blocked in 5% non-fat dry milk prepared in TBS for one hour prior to probing with
primary antibodies overnight. Primary antibodies were diluted in a solution of 3% bovine
serum albumin (BSA) in TBS containing 0.02% sodium azide and included p53 (1:1000,
Cell Signaling) , caspase-3 (1:500, Cell Signaling), caspase-7 (1:500, Cell Signaling),
cleaved caspase-3 (1:500, Cell Signaling), cleaved caspase-7 (1:500, Cell Signaling),
poly ADP-ribose polymerase (PARP) (1:500, Cell Signaling), 6E10 (1:1000, Covance),
caspase-cleaved APP (1:4000, Millipore), and β-actin (1:7000, Sigma). Blots were
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washed four times in PBS containing 0.05% Tween-20 and probed with appropriate
secondary antibodies, either goat anti-mouse or donkey anti-rabbit IgG conjugated to
horseradish peroxidase (both diluted at 1:5000, Thermo Fisher Scientific), for two hours
at room temperature. After further washes, blots were developed using Super Signal West
Pico Enhanced Chemiluminescence (ECL) Substrate (Thermo Fisher Scientific). Images
captured on autoradiography films (MidSci) were scanned for digitization using a flatbed
scanner, and densitometric analysis was performed using ImageJ, image processing and
analysis tool.

Immunoprecipitation
Equal number of cells were plated onto 100 mm tissue culture dishes and cultured
for 24 hours, after which point cells were treated with fresh growth medium in the
absence or presence of CPT (10 µM) for different time periods. At each time point, tissue
culture supernatant from each culture dish was collected and spun down at 1,000 rpm for
five

minutes

to

remove

cell

debris.

The

supernatants

were

subjected

to

immunoprecipitation analysis for secreted APP and Aβ following established protocols
[5]. Briefly, the tissue culture supernatants were incubated with two µl of 6E10 antibody
for two hours at 4oC by end-over-end rotation. 30 µl (packed volume) of protein G
sepharose beads (GE Healthcare) were added, and incubation continued overnight. A
sample incubated with no primary antibody and only protein G sepharose beads served as
control for the immunoprecipitation experiments. At the end of the incubation beads were
collected by centrifugation at 6,000 rpm for 30 seconds and washed with RIPA lysis
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buffer (described above) four times. The pelleted beads were boiled with Laemmli
sample buffer (described above) to solubilize the antigen-antibody complex, separated on
a 10-20 % tris-glycine gel, and western blot analysis performed as described above using
6E10 antibody to determine secreted levels of APP and Aβ.

Immunostaining Analyses
Cells were plated in eight-chamber slides (Nunc) coated with poly-L-lysine
(Sigma). After the indicated treatments, cells were fixed with 4% para-formaldehyde and
immunostaining analysis was performed following established protocols [1, 5, 7]. Slides
were washed with PBS and blocked with 1% BSA in TBS containing 0.1% Triton X-100
for one hour. Slides were then incubated overnight at 4°C in primary antibodies diluted in
blocking buffer which included 6E10 (1:500, Covance), cleaved caspase-3 (1:250, Cell
Signaling), cleaved caspase-7 (1:250, Cell Signaling), and MAP2 (1:1000, Abcam).
Following incubation, slides were washed four times with PBS for five minutes per wash
and incubated with secondary antibodies (goat anti-mouse AlexaFluor 488 (1:1000, Life
Technologies) and goat anti-Rabbit AlexaFluor 594 (1:4000, Life Technologies)) for two
hours in the dark. Slides were then washed twice, counterstained with 1 µg/mL Hoechst
stain (Sigma) diluted in PBS for five minutes, and washed thrice more before
coverslipping using Fluorogel (Electron Microscopy Sciences). Stained cells were
visualized using a Zeiss Imager.Z1 microscope and analyzed using AxioVision Rel 4.6.3
software.
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Flow Cytometry
Cells were lifted using 0.05% trypsin/EDTA (Life Technologies) for two to three
minutes, followed by neutralization of trypsin using normal growth media. Cells were
pelleted by centrifugation at 500 x g for five minutes at 4°C and pellets washed with PBS
twice, centrifuging at 500 x g for five minutes at 4°C between washes. Pelleted cells were
resuspended in one part PBS and fixed by adding nine parts ice cold 70% ethanol, added
drop-wise while vortexing at a low speed. Fixed cells were stored at -20°C for no more
than one week before analysis. Fixed cells were pelleted by centrifugation at 200 x g for
five minutes and washed twice with PBS. Cells were then resuspended in staining
solution containing 5 µg/mL propidium iodide, 0.1% Triton X-100, and RNaseA in TBS
and incubated at room temperature for 45 minutes. Samples characterizing apoptosis in
H4-APP cells were then analyzed using a BD LSR II flow cytometer. Results were
modeled for cell cycle progression and apoptosis using ModFit LT. Samples involving
caspase inhibitors were analyzed using an AccuriC6 cytometer with CFlow Plus analysis
software.

shRNA Knockdown of Caspases
Four different shRNA clones to both human caspase-3 and caspase-7 in pGFP-VRS vector (TG305638) were obtained from Origene Technologies and transfected into
H4-APP cells using Turbofectin 8.0 transfection reagent (Origene Technologies)
following the manufacturer’s protocol. Since these plasmids allow expression of GFP by
a CMV promoter, the transfection efficiency could be verified by analyzing the cells for
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GFP expression using a Zeiss Observer.A1 inverted microscope with fluorescence
capabilities. Down-regulation of the corresponding caspases was verified by western blot
analysis using caspase-3 and caspase-7 antibodies prior to using these cells for CPT
treatment. An empty vector and a scrambled non-effective shRNA-containing vector
were used as controls in transfection studies.

PS-APP Tissue Processing
Ten month old PS-APP mice were anaesthetized with 0.5 mL of a 1:10 dilution of
SomnaSol in normal saline and transcardially perfused with normal saline. Brains were
harvested and one hemisphere homogenized in RIPA lysis buffer (described above).
After homogenization, proteins were extracted by high speed centrifugation. (20800 x g
for 15 min at 4°C) and the resulting supernatents analyzed by western blot as described
above. The other hemisphere was fixed with 4% paraformaldehyde, and cryoprotected
by incubation in increasing concentrations of sucrose – 10%, 20%, then 30%. Tissue was
transferred into the next highest concentration of sucrose after 24 hours or when the
tissue sank to the bottom of the container. Tissue was then sectioned into 25 µm
sections, and mounted onto Colorfrost Plus slides (Fisher) for immunohistochemical
analysis as described above.

Statistical Analyses
Experiments involving time courses with CPT were analyzed using a two-way
ANOVA (time and treatment). shRNA and inhibitor effects were analyzed with a one-
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way ANOVA when CPT was not present and a two-way ANOVA in the presence of
CPT. All post-hoc analyses were done using the Tukey-Kramer method.

Any

comparisons involving only two conditions were assessed using a student’s t-test. All
statistical analyses were performed using NCSS-PASS.
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Permission for the use and reproduction of this work has been provided by the publisher
in an email transmitted to Dr. Jaya Padmanabhan. The text of this email is reproduced on
the next page.

219

Appendix B: Copyright Permissions (continued)
From: Shankar Pandalai signpost99@gmail.com
To: jayapad jayapad@aol.com
Sent: Thu, Mar 21, 2013 5:19 am
Subject: Permission Granted
RESEARCH SIGNPOST
TRANSWORLD RESEARCH NETWORK
March 21, 2013

Dear Dr. Jaya Padmanabhan,
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License

THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS OF THIS
CREATIVE COMMONS PUBLIC LICENSE ("CCPL" OR "LICENSE"). THE WORK
IS PROTECTED BY COPYRIGHT AND/OR OTHER APPLICABLE LAW. ANY USE
OF THE WORK OTHER THAN AS AUTHORIZED UNDER THIS LICENSE OR
COPYRIGHT LAW IS PROHIBITED.

BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU ACCEPT
AND AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE. THE
LICENSOR

GRANTS

CONSIDERATION

OF

YOU

THE

RIGHTS

YOUR

ACCEPTANCE

CONTAINED
OF

SUCH

HERE

TERMS

IN
AND

CONDITIONS.

1. Definitions
a. "Collective Work" means a work, such as a periodical issue, anthology or
encyclopedia, in which the Work in its entirety in unmodified form, along with a
number of other contributions, constituting separate and independent works in
themselves, are assembled into a collective whole. A work that constitutes a
Collective Work will not be considered a Derivative Work (as defined below) for
the purposes of this License.
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b. "Derivative Work" means a work based upon the Work or upon the Work and
other pre-existing works, such as a translation, musical arrangement,
dramatization, fictionalization, motion picture version, sound recording, art
reproduction, abridgment, condensation, or any other form in which the Work
may be recast, transformed, or adapted, except that a work that constitutes a
Collective Work will not be considered a Derivative Work for the purpose of this
License. For the avoidance of doubt, where the Work is a musical composition or
sound recording, the synchronization of the Work in timed-relation with a moving
image ("synching") will be considered a Derivative Work for the purpose of this
License.
c. "Licensor" means the individual or entity that offers the Work under the terms of
this License.
d. "Original Author" means the individual or entity who created the Work.
e. "Work" means the copyrightable work of authorship offered under the terms of
this License.
f. "You" means an individual or entity exercising rights under this License who has
not previously violated the terms of this License with respect to the Work, or who
has received express permission from the Licensor to exercise rights under this
License despite a previous violation.
2. Fair Use Rights. Nothing in this license is intended to reduce, limit, or restrict any
rights arising from fair use, first sale or other limitations on the exclusive rights of the
copyright owner under copyright law or other applicable laws.
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3. License Grant. Subject to the terms and conditions of this License, Licensor hereby
grants You a worldwide, royalty-free, non-exclusive, perpetual (for the duration of the
applicable copyright) license to exercise the rights in the Work as stated below:
a. to reproduce the Work, to incorporate the Work into one or more Collective
Works, and to reproduce the Work as incorporated in the Collective Works;
b. to create and reproduce Derivative Works;
c. to distribute copies or phonorecords of, display publicly, perform publicly, and
perform publicly by means of a digital audio transmission the Work including as
incorporated in Collective Works;
d. to distribute copies or phonorecords of, display publicly, perform publicly, and
perform publicly by means of a digital audio transmission Derivative Works.
e. For the avoidance of doubt, where the work is a musical composition:
i.

Performance Royalties Under Blanket Licenses. Licensor waives the
exclusive right to collect, whether individually or via a performance rights
society (e.g. ASCAP, BMI, SESAC), royalties for the public performance
or public digital performance (e.g. webcast) of the Work.

ii.

Mechanical Rights and Statutory Royalties. Licensor waives the
exclusive right to collect, whether individually or via a music rights
agency or designated agent (e.g. Harry Fox Agency), royalties for any
phonorecord You create from the Work ("cover version") and distribute,
subject to the compulsory license created by 17 USC Section 115 of the
US Copyright Act (or the equivalent in other jurisdictions).
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f. Webcasting Rights and Statutory Royalties. For the avoidance of doubt, where
the Work is a sound recording, Licensor waives the exclusive right to collect,
whether individually or via a performance-rights society (e.g. SoundExchange),
royalties for the public digital performance (e.g. webcast) of the Work, subject to
the compulsory license created by 17 USC Section 114 of the US Copyright Act
(or the equivalent in other jurisdictions).
The above rights may be exercised in all media and formats whether now known or
hereafter devised. The above rights include the right to make such modifications as are
technically necessary to exercise the rights in other media and formats. All rights not
expressly granted by Licensor are hereby reserved.
4. Restrictions.The license granted in Section 3 above is expressly made subject to and
limited by the following restrictions:
a.

You may distribute, publicly display, publicly perform, or publicly

digitally perform the Work only under the terms of this License, and You must
include a copy of, or the Uniform Resource Identifier for, this License with every
copy or phonorecord of the Work You distribute, publicly display, publicly
perform, or publicly digitally perform. You may not offer or impose any terms on
the Work that alter or restrict the terms of this License or the recipients' exercise
of the rights granted hereunder. You may not sublicense the Work. You must
keep intact all notices that refer to this License and to the disclaimer of
warranties. You may not distribute, publicly display, publicly perform, or publicly
digitally perform the Work with any technological measures that control access or
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use of the Work in a manner inconsistent with the terms of this License
Agreement. The above applies to the Work as incorporated in a Collective Work,
but this does not require the Collective Work apart from the Work itself to be
made subject to the terms of this License. If You create a Collective Work, upon
notice from any Licensor You must, to the extent practicable, remove from the
Collective Work any credit as required by clause 4(b), as requested. If You create
a Derivative Work, upon notice from any Licensor You must, to the extent
practicable, remove from the Derivative Work any credit as required by clause
4(b), as requested.
b. If you distribute, publicly display, publicly perform, or publicly digitally perform
the Work or any Derivative Works or Collective Works, You must keep intact all
copyright notices for the Work and provide, reasonable to the medium or means
You are utilizing: (i) the name of the Original Author (or pseudonym, if
applicable) if supplied, and/or (ii) if the Original Author and/or Licensor
designate another party or parties (e.g. a sponsor institute, publishing entity,
journal) for attribution in Licensor's copyright notice, terms of service or by other
reasonable means, the name of such party or parties; the title of the Work if
supplied; to the extent reasonably practicable, the Uniform Resource Identifier, if
any, that Licensor specifies to be associated with the Work, unless such URI does
not refer to the copyright notice or licensing information for the Work; and in the
case of a Derivative Work, a credit identifying the use of the Work in the
Derivative Work (e.g., "French translation of the Work by Original Author," or
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"Screenplay based on original Work by Original Author"). Such credit may be
implemented in any reasonable manner; provided, however, that in the case of a
Derivative Work or Collective Work, at a minimum such credit will appear where
any other comparable authorship credit appears and in a manner at least as
prominent as such other comparable authorship credit.
5. Representations, Warranties and Disclaimer
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING,
LICENSOR OFFERS THE WORK AS-IS AND MAKES NO REPRESENTATIONS
OR WARRANTIES OF ANY KIND CONCERNING THE WORK, EXPRESS,
IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION,
WARRANTIES OF TITLE, MERCHANTIBILITY, FITNESS FOR A PARTICULAR
PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER
DEFECTS, ACCURACY, OR THE PRESENCE OF ABSENCE OF ERRORS,
WHETHER OR NOT DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW
THE EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY NOT
APPLY TO YOU.
6.

Limitation

on

Liability. EXCEPT

TO

THE

EXTENT

REQUIRED

BY

APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU ON
ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL,
PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF THIS LICENSE OR
THE USE OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES.
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7. Termination
a. This License and the rights granted hereunder will terminate automatically upon
any breach by You of the terms of this License. Individuals or entities who have
received Derivative Works or Collective Works from You under this License,
however, will not have their licenses terminated provided such individuals or
entities remain in full compliance with those licenses. Sections 1, 2, 5, 6, 7, and 8
will survive any termination of this License.
b. Subject to the above terms and conditions, the license granted here is perpetual
(for the duration of the applicable copyright in the Work). Notwithstanding the
above, Licensor reserves the right to release the Work under different license
terms or to stop distributing the Work at any time; provided, however that any
such election will not serve to withdraw this License (or any other license that has
been, or is required to be, granted under the terms of this License), and this
License will continue in full force and effect unless terminated as stated above.

8. Miscellaneous
a. Each time You distribute or publicly digitally perform the Work or a Collective
Work, the Licensor offers to the recipient a license to the Work on the same terms
and conditions as the license granted to You under this License.
b. Each time You distribute or publicly digitally perform a Derivative Work,
Licensor offers to the recipient a license to the original Work on the same terms
and conditions as the license granted to You under this License.
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c. If any provision of this License is invalid or unenforceable under applicable law,
it shall not affect the validity or enforceability of the remainder of the terms of
this License, and without further action by the parties to this agreement, such
provision shall be reformed to the minimum extent necessary to make such
provision valid and enforceable.

d. No term or provision of this License shall be deemed waived and no breach
consented to unless such waiver or consent shall be in writing and signed by the
party to be charged with such waiver or consent.
e. This License constitutes the entire agreement between the parties with respect to
the Work licensed here. There are no understandings, agreements or
representations with respect to the Work not specified here. Licensor shall not be
bound by any additional provisions that may appear in any communication from
You. This License may not be modified without the mutual written agreement of
the Licensor and You.
Creative Commons is not a party to this License, and makes no warranty whatsoever in
connection with the Work. Creative Commons will not be liable to You or any party on
any legal theory for any damages whatsoever, including without limitation any general,
special, incidental or consequential damages arising in connection to this license.
Notwithstanding the foregoing two (2) sentences, if Creative Commons has expressly
identified itself as the Licensor hereunder, it shall have all rights and obligations of
Licensor.
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Except for the limited purpose of indicating to the public that the Work is licensed under
the CCPL, neither party will use the trademark "Creative Commons" or any related
trademark or logo of Creative Commons without the prior written consent of Creative
Commons. Any permitted use will be in compliance with Creative Commons' thencurrent trademark usage guidelines, as may be published on its website or otherwise
made available upon request from time to time.
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